date generated: 2020-10-08

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

##           diabetes       mitoG
## A1CF    -6.9932602  1.51849480
## A3GALT2 -0.4812996  0.04044782
## A4GALT   3.2528398 -0.66706468
## A4GNT    1.2215327  0.29060394
## AAAS     1.7926927 -0.52232889
## AACS    -2.0466443 -0.59825125

Here are some metrics about the input data profile:

Profile metrics
Profile metrics
num_genes_in_profile 15635
duplicated_genes_present 0
num_profile_genes_in_sets 8750
num_profile_genes_not_in_sets 6885
profile_pearson_correl -0.26909
profile_spearman_correl -0.21206

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt

Gene sets metrics
Gene sets metrics
num_genesets 2408
num_genesets_excluded 1006
num_genesets_included 1402

Gene sets by quadrant


Number of significant gene sets (FDR<0.05)= 426

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results


A plot of effect size versus significance


Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

set setSize pMANOVA p.adjustMANOVA s.dist s.diabetes s.mitoG p.diabetes p.mitoG
Folding of actin by CCT/TriC 10 3.94e-05 3.25e-04 0.881 -0.7910 0.3890 1.49e-05 3.34e-02
Establishment of Sister Chromatid Cohesion 11 6.11e-05 4.68e-04 0.838 -0.4880 0.6810 5.03e-03 9.08e-05
Cohesin Loading onto Chromatin 10 1.73e-04 1.13e-03 0.832 -0.5000 0.6650 6.14e-03 2.70e-04
tRNA processing in the mitochondrion 18 1.74e-07 3.29e-06 0.718 0.1160 0.7090 3.95e-01 1.91e-07
ATF6 (ATF6-alpha) activates chaperone genes 10 3.04e-03 1.41e-02 0.677 -0.5660 0.3720 1.95e-03 4.16e-02
Attenuation phase 22 2.93e-06 3.39e-05 0.673 -0.5800 0.3410 2.45e-06 5.65e-03
MyD88 deficiency (TLR2/4) 10 3.85e-03 1.69e-02 0.669 -0.4320 0.5110 1.79e-02 5.18e-03
Classical antibody-mediated complement activation 22 3.07e-06 3.53e-05 0.644 -0.1770 0.6190 1.50e-01 5.07e-07
Formation of tubulin folding intermediates by CCT/TriC 20 3.45e-05 2.91e-04 0.642 -0.5090 0.3900 8.09e-05 2.50e-03
Prefoldin mediated transfer of substrate to CCT/TriC 25 3.93e-06 4.34e-05 0.634 -0.4670 0.4300 5.37e-05 2.00e-04
IRAK4 deficiency (TLR2/4) 11 4.39e-03 1.87e-02 0.628 -0.3710 0.5060 3.30e-02 3.65e-03
Cytosolic iron-sulfur cluster assembly 13 1.97e-03 9.67e-03 0.617 0.5070 -0.3530 1.56e-03 2.77e-02
Glucuronidation 16 6.47e-04 3.53e-03 0.609 0.4480 -0.4130 1.93e-03 4.27e-03
Regulation of TLR by endogenous ligand 15 1.37e-04 9.55e-04 0.605 0.0464 0.6030 7.56e-01 5.23e-05
CD28 dependent Vav1 pathway 12 4.16e-03 1.78e-02 0.602 -0.3380 0.4980 4.27e-02 2.80e-03
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 27 5.89e-06 6.25e-05 0.601 -0.4380 0.4100 8.05e-05 2.23e-04
Role of LAT2/NTAL/LAB on calcium mobilization 29 1.70e-06 2.11e-05 0.589 -0.2440 0.5370 2.30e-02 5.67e-07
Signaling by Hippo 20 1.41e-04 9.72e-04 0.584 -0.2660 0.5200 3.92e-02 5.71e-05
ATF6 (ATF6-alpha) activates chaperones 12 5.54e-03 2.20e-02 0.583 -0.4970 0.3040 2.85e-03 6.79e-02
Scavenging of heme from plasma 29 6.98e-07 1.03e-05 0.574 -0.0735 0.5690 4.94e-01 1.12e-07
CD22 mediated BCR regulation 20 1.18e-04 8.34e-04 0.570 -0.1570 0.5480 2.25e-01 2.22e-05
Pyrimidine salvage 10 1.25e-02 4.29e-02 0.570 0.5330 -0.2000 3.49e-03 2.74e-01
FCGR activation 28 1.93e-05 1.74e-04 0.554 -0.3010 0.4650 5.85e-03 2.08e-05
Elastic fibre formation 37 1.43e-09 6.91e-08 0.549 0.2340 0.4970 1.37e-02 1.70e-07
HSF1 activation 24 1.54e-04 1.05e-03 0.542 -0.4210 0.3420 3.56e-04 3.74e-03
Creation of C4 and C2 activators 26 1.72e-05 1.62e-04 0.542 -0.1120 0.5310 3.24e-01 2.82e-06
eNOS activation 11 1.27e-02 4.32e-02 0.540 -0.1760 0.5100 3.13e-01 3.39e-03
Activation of BAD and translocation to mitochondria 15 3.35e-03 1.52e-02 0.536 -0.2180 0.4900 1.44e-01 1.03e-03
RHO GTPases activate IQGAPs 11 8.83e-03 3.18e-02 0.535 -0.0558 0.5320 7.49e-01 2.23e-03
Apoptosis induced DNA fragmentation 13 8.97e-04 4.74e-03 0.534 0.4140 0.3370 9.81e-03 3.54e-02
Cellular hexose transport 16 2.77e-03 1.30e-02 0.533 0.4720 -0.2470 1.08e-03 8.73e-02
Metabolism of nitric oxide: NOS3 activation and regulation 15 3.51e-03 1.57e-02 0.530 -0.1970 0.4920 1.87e-01 9.60e-04
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 30 2.72e-05 2.40e-04 0.529 -0.3130 0.4260 2.96e-03 5.29e-05
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 12 7.93e-03 2.98e-02 0.528 0.5180 -0.0983 1.87e-03 5.56e-01
Cell-extracellular matrix interactions 16 8.00e-04 4.28e-03 0.526 0.0313 0.5250 8.29e-01 2.74e-04
HSP90 chaperone cycle for steroid hormone receptors (SHR) 37 3.12e-06 3.56e-05 0.522 -0.2960 0.4300 1.84e-03 6.00e-06
EPHB-mediated forward signaling 34 4.22e-06 4.59e-05 0.520 -0.1830 0.4860 6.46e-02 9.30e-07
Josephin domain DUBs 11 1.66e-02 5.35e-02 0.519 -0.4960 0.1520 4.38e-03 3.84e-01
Mitotic Telophase/Cytokinesis 13 1.25e-02 4.29e-02 0.517 -0.2930 0.4270 6.76e-02 7.75e-03
Sema3A PAK dependent Axon repulsion 16 5.00e-03 2.04e-02 0.511 -0.2760 0.4300 5.60e-02 2.88e-03
CTLA4 inhibitory signaling 20 5.00e-04 2.84e-03 0.511 -0.0870 0.5030 5.01e-01 9.78e-05
Defective CFTR causes cystic fibrosis 60 2.63e-09 1.05e-07 0.510 -0.4290 0.2760 8.76e-09 2.21e-04
Formation of the ternary complex, and subsequently, the 43S complex 36 4.74e-08 1.17e-06 0.510 0.1960 0.4700 4.20e-02 1.04e-06
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD 55 1.92e-08 5.61e-07 0.506 -0.4240 0.2750 5.17e-08 4.26e-04
Response of EIF2AK1 (HRI) to heme deficiency 15 7.13e-03 2.71e-02 0.503 -0.2280 0.4490 1.26e-01 2.62e-03
Molecules associated with elastic fibres 27 6.32e-06 6.67e-05 0.502 0.1530 0.4780 1.69e-01 1.73e-05
CDC6 association with the ORC:origin complex 11 8.79e-03 3.18e-02 0.501 0.1090 0.4890 5.30e-01 4.94e-03
Acetylcholine binding and downstream events 11 7.08e-03 2.70e-02 0.499 -0.1960 -0.4590 2.62e-01 8.43e-03
Postsynaptic nicotinic acetylcholine receptors 11 7.08e-03 2.70e-02 0.499 -0.1960 -0.4590 2.62e-01 8.43e-03
AUF1 (hnRNP D0) binds and destabilizes mRNA 54 7.27e-08 1.59e-06 0.495 -0.3830 0.3140 1.12e-06 6.62e-05


Results (complete table)


Click HERE to show results for all gene sets

Complete results
set setSize pMANOVA p.adjustMANOVA s.dist s.diabetes s.mitoG p.diabetes p.mitoG
Folding of actin by CCT/TriC 10 3.94e-05 3.25e-04 0.88100 -7.91e-01 3.89e-01 1.49e-05 3.34e-02
Establishment of Sister Chromatid Cohesion 11 6.11e-05 4.68e-04 0.83800 -4.88e-01 6.81e-01 5.03e-03 9.08e-05
Cohesin Loading onto Chromatin 10 1.73e-04 1.13e-03 0.83200 -5.00e-01 6.65e-01 6.14e-03 2.70e-04
tRNA processing in the mitochondrion 18 1.74e-07 3.29e-06 0.71800 1.16e-01 7.09e-01 3.95e-01 1.91e-07
ATF6 (ATF6-alpha) activates chaperone genes 10 3.04e-03 1.41e-02 0.67700 -5.66e-01 3.72e-01 1.95e-03 4.16e-02
Attenuation phase 22 2.93e-06 3.39e-05 0.67300 -5.80e-01 3.41e-01 2.45e-06 5.65e-03
MyD88 deficiency (TLR2/4) 10 3.85e-03 1.69e-02 0.66900 -4.32e-01 5.11e-01 1.79e-02 5.18e-03
Classical antibody-mediated complement activation 22 3.07e-06 3.53e-05 0.64400 -1.77e-01 6.19e-01 1.50e-01 5.07e-07
Formation of tubulin folding intermediates by CCT/TriC 20 3.45e-05 2.91e-04 0.64200 -5.09e-01 3.90e-01 8.09e-05 2.50e-03
Prefoldin mediated transfer of substrate to CCT/TriC 25 3.93e-06 4.34e-05 0.63400 -4.67e-01 4.30e-01 5.37e-05 2.00e-04
IRAK4 deficiency (TLR2/4) 11 4.39e-03 1.87e-02 0.62800 -3.71e-01 5.06e-01 3.30e-02 3.65e-03
Cytosolic iron-sulfur cluster assembly 13 1.97e-03 9.67e-03 0.61700 5.07e-01 -3.53e-01 1.56e-03 2.77e-02
Glucuronidation 16 6.47e-04 3.53e-03 0.60900 4.48e-01 -4.13e-01 1.93e-03 4.27e-03
Regulation of TLR by endogenous ligand 15 1.37e-04 9.55e-04 0.60500 4.64e-02 6.03e-01 7.56e-01 5.23e-05
CD28 dependent Vav1 pathway 12 4.16e-03 1.78e-02 0.60200 -3.38e-01 4.98e-01 4.27e-02 2.80e-03
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 27 5.89e-06 6.25e-05 0.60100 -4.38e-01 4.10e-01 8.05e-05 2.23e-04
Role of LAT2/NTAL/LAB on calcium mobilization 29 1.70e-06 2.11e-05 0.58900 -2.44e-01 5.37e-01 2.30e-02 5.67e-07
Signaling by Hippo 20 1.41e-04 9.72e-04 0.58400 -2.66e-01 5.20e-01 3.92e-02 5.71e-05
ATF6 (ATF6-alpha) activates chaperones 12 5.54e-03 2.20e-02 0.58300 -4.97e-01 3.04e-01 2.85e-03 6.79e-02
Scavenging of heme from plasma 29 6.98e-07 1.03e-05 0.57400 -7.35e-02 5.69e-01 4.94e-01 1.12e-07
CD22 mediated BCR regulation 20 1.18e-04 8.34e-04 0.57000 -1.57e-01 5.48e-01 2.25e-01 2.22e-05
Pyrimidine salvage 10 1.25e-02 4.29e-02 0.57000 5.33e-01 -2.00e-01 3.49e-03 2.74e-01
FCGR activation 28 1.93e-05 1.74e-04 0.55400 -3.01e-01 4.65e-01 5.85e-03 2.08e-05
Elastic fibre formation 37 1.43e-09 6.91e-08 0.54900 2.34e-01 4.97e-01 1.37e-02 1.70e-07
HSF1 activation 24 1.54e-04 1.05e-03 0.54200 -4.21e-01 3.42e-01 3.56e-04 3.74e-03
Creation of C4 and C2 activators 26 1.72e-05 1.62e-04 0.54200 -1.12e-01 5.31e-01 3.24e-01 2.82e-06
eNOS activation 11 1.27e-02 4.32e-02 0.54000 -1.76e-01 5.10e-01 3.13e-01 3.39e-03
Activation of BAD and translocation to mitochondria 15 3.35e-03 1.52e-02 0.53600 -2.18e-01 4.90e-01 1.44e-01 1.03e-03
RHO GTPases activate IQGAPs 11 8.83e-03 3.18e-02 0.53500 -5.58e-02 5.32e-01 7.49e-01 2.23e-03
Apoptosis induced DNA fragmentation 13 8.97e-04 4.74e-03 0.53400 4.14e-01 3.37e-01 9.81e-03 3.54e-02
Cellular hexose transport 16 2.77e-03 1.30e-02 0.53300 4.72e-01 -2.47e-01 1.08e-03 8.73e-02
Metabolism of nitric oxide: NOS3 activation and regulation 15 3.51e-03 1.57e-02 0.53000 -1.97e-01 4.92e-01 1.87e-01 9.60e-04
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 30 2.72e-05 2.40e-04 0.52900 -3.13e-01 4.26e-01 2.96e-03 5.29e-05
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 12 7.93e-03 2.98e-02 0.52800 5.18e-01 -9.83e-02 1.87e-03 5.56e-01
Cell-extracellular matrix interactions 16 8.00e-04 4.28e-03 0.52600 3.13e-02 5.25e-01 8.29e-01 2.74e-04
HSP90 chaperone cycle for steroid hormone receptors (SHR) 37 3.12e-06 3.56e-05 0.52200 -2.96e-01 4.30e-01 1.84e-03 6.00e-06
EPHB-mediated forward signaling 34 4.22e-06 4.59e-05 0.52000 -1.83e-01 4.86e-01 6.46e-02 9.30e-07
Josephin domain DUBs 11 1.66e-02 5.35e-02 0.51900 -4.96e-01 1.52e-01 4.38e-03 3.84e-01
Mitotic Telophase/Cytokinesis 13 1.25e-02 4.29e-02 0.51700 -2.93e-01 4.27e-01 6.76e-02 7.75e-03
Sema3A PAK dependent Axon repulsion 16 5.00e-03 2.04e-02 0.51100 -2.76e-01 4.30e-01 5.60e-02 2.88e-03
CTLA4 inhibitory signaling 20 5.00e-04 2.84e-03 0.51100 -8.70e-02 5.03e-01 5.01e-01 9.78e-05
Defective CFTR causes cystic fibrosis 60 2.63e-09 1.05e-07 0.51000 -4.29e-01 2.76e-01 8.76e-09 2.21e-04
Formation of the ternary complex, and subsequently, the 43S complex 36 4.74e-08 1.17e-06 0.51000 1.96e-01 4.70e-01 4.20e-02 1.04e-06
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD 55 1.92e-08 5.61e-07 0.50600 -4.24e-01 2.75e-01 5.17e-08 4.26e-04
Response of EIF2AK1 (HRI) to heme deficiency 15 7.13e-03 2.71e-02 0.50300 -2.28e-01 4.49e-01 1.26e-01 2.62e-03
Molecules associated with elastic fibres 27 6.32e-06 6.67e-05 0.50200 1.53e-01 4.78e-01 1.69e-01 1.73e-05
CDC6 association with the ORC:origin complex 11 8.79e-03 3.18e-02 0.50100 1.09e-01 4.89e-01 5.30e-01 4.94e-03
Acetylcholine binding and downstream events 11 7.08e-03 2.70e-02 0.49900 -1.96e-01 -4.59e-01 2.62e-01 8.43e-03
Postsynaptic nicotinic acetylcholine receptors 11 7.08e-03 2.70e-02 0.49900 -1.96e-01 -4.59e-01 2.62e-01 8.43e-03
AUF1 (hnRNP D0) binds and destabilizes mRNA 54 7.27e-08 1.59e-06 0.49500 -3.83e-01 3.14e-01 1.12e-06 6.62e-05
Cross-presentation of soluble exogenous antigens (endosomes) 48 4.51e-07 6.95e-06 0.49400 -3.91e-01 3.03e-01 2.82e-06 2.83e-04
Negative regulation of NOTCH4 signaling 52 1.64e-07 3.15e-06 0.49300 -3.49e-01 3.48e-01 1.31e-05 1.40e-05
Gluconeogenesis 30 4.13e-06 4.53e-05 0.49300 4.82e-01 1.01e-01 4.87e-06 3.37e-01
Translesion synthesis by POLK 17 4.04e-04 2.38e-03 0.49200 3.16e-01 3.77e-01 2.39e-02 7.12e-03
Translesion synthesis by REV1 16 6.41e-04 3.51e-03 0.49200 3.40e-01 3.55e-01 1.86e-02 1.39e-02
Glutamate and glutamine metabolism 13 3.99e-03 1.74e-02 0.48800 4.60e-01 1.65e-01 4.10e-03 3.03e-01
Binding and Uptake of Ligands by Scavenger Receptors 54 4.40e-09 1.58e-07 0.48600 -4.27e-02 4.84e-01 5.88e-01 7.54e-10
MET activates RAP1 and RAC1 11 4.07e-02 1.07e-01 0.48300 -3.00e-01 3.79e-01 8.53e-02 2.94e-02
Activation of RAC1 12 2.92e-02 8.37e-02 0.47900 -2.39e-01 4.15e-01 1.51e-01 1.28e-02
Olfactory Signaling Pathway 209 2.09e-38 2.93e-35 0.47700 -2.16e-01 -4.25e-01 7.91e-08 3.03e-26
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 44 1.52e-06 1.94e-05 0.47700 -1.75e-01 4.43e-01 4.50e-02 3.60e-07
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 35 2.06e-05 1.85e-04 0.47600 -4.49e-01 1.59e-01 4.28e-06 1.04e-01
Cargo concentration in the ER 29 2.32e-04 1.47e-03 0.47400 -4.12e-01 2.34e-01 1.21e-04 2.89e-02
Bicarbonate transporters 10 5.12e-02 1.26e-01 0.47100 4.37e-01 -1.77e-01 1.67e-02 3.34e-01
Miscellaneous substrates 10 3.11e-02 8.63e-02 0.47000 4.70e-01 -1.28e-05 1.00e-02 1.00e+00
GPVI-mediated activation cascade 32 1.70e-04 1.13e-03 0.46800 -3.17e-01 3.44e-01 1.89e-03 7.51e-04
CD28 co-stimulation 33 1.38e-04 9.60e-04 0.46600 -3.02e-01 3.55e-01 2.67e-03 4.20e-04
Citric acid cycle (TCA cycle) 22 1.63e-04 1.10e-03 0.46600 2.01e-01 4.20e-01 1.03e-01 6.42e-04
Regulation of activated PAK-2p34 by proteasome mediated degradation 49 1.79e-06 2.20e-05 0.46500 -3.72e-01 2.80e-01 6.78e-06 7.01e-04
Regulation of Apoptosis 52 8.17e-07 1.18e-05 0.46400 -3.78e-01 2.69e-01 2.41e-06 8.05e-04
Frs2-mediated activation 12 3.51e-02 9.42e-02 0.46400 -2.13e-01 4.12e-01 2.02e-01 1.35e-02
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 12 2.44e-02 7.21e-02 0.46200 4.54e-01 -8.54e-02 6.45e-03 6.09e-01
AMER1 mutants destabilize the destruction complex 14 4.72e-03 1.95e-02 0.46200 1.68e-01 4.30e-01 2.78e-01 5.32e-03
APC truncation mutants have impaired AXIN binding 14 4.72e-03 1.95e-02 0.46200 1.68e-01 4.30e-01 2.78e-01 5.32e-03
AXIN missense mutants destabilize the destruction complex 14 4.72e-03 1.95e-02 0.46200 1.68e-01 4.30e-01 2.78e-01 5.32e-03
AXIN mutants destabilize the destruction complex, activating WNT signaling 14 4.72e-03 1.95e-02 0.46200 1.68e-01 4.30e-01 2.78e-01 5.32e-03
Truncations of AMER1 destabilize the destruction complex 14 4.72e-03 1.95e-02 0.46200 1.68e-01 4.30e-01 2.78e-01 5.32e-03
truncated APC mutants destabilize the destruction complex 14 4.72e-03 1.95e-02 0.46200 1.68e-01 4.30e-01 2.78e-01 5.32e-03
Calnexin/calreticulin cycle 26 6.05e-04 3.35e-03 0.45900 -4.30e-01 1.61e-01 1.46e-04 1.57e-01
Regulation of KIT signaling 16 1.57e-02 5.14e-02 0.45800 -3.20e-01 3.28e-01 2.65e-02 2.32e-02
Regulation of RUNX3 expression and activity 53 1.05e-06 1.43e-05 0.45800 -3.45e-01 3.02e-01 1.41e-05 1.46e-04
FCERI mediated Ca+2 mobilization 44 3.15e-06 3.56e-05 0.45700 -1.35e-01 4.36e-01 1.23e-01 5.46e-07
Vif-mediated degradation of APOBEC3G 52 1.47e-06 1.92e-05 0.45700 -3.48e-01 2.96e-01 1.45e-05 2.21e-04
rRNA processing in the mitochondrion 22 4.47e-04 2.58e-03 0.45600 8.29e-02 4.48e-01 5.01e-01 2.74e-04
Amino acid transport across the plasma membrane 31 3.89e-04 2.32e-03 0.45300 3.10e-01 -3.30e-01 2.86e-03 1.46e-03
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation 31 1.71e-04 1.13e-03 0.45200 -1.40e-01 4.29e-01 1.77e-01 3.51e-05
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 54 1.21e-06 1.62e-05 0.45000 -3.54e-01 2.79e-01 7.03e-06 3.88e-04
Hedgehog ligand biogenesis 64 6.79e-08 1.53e-06 0.45000 -3.88e-01 2.28e-01 8.27e-08 1.61e-03
FCERI mediated MAPK activation 45 2.48e-06 2.92e-05 0.44900 -1.01e-01 4.38e-01 2.39e-01 3.78e-07
Prolonged ERK activation events 14 2.97e-02 8.38e-02 0.44900 -2.75e-01 3.55e-01 7.53e-02 2.15e-02
Hh mutants abrogate ligand secretion 58 4.04e-07 6.36e-06 0.44800 -3.77e-01 2.43e-01 7.04e-07 1.37e-03
Syndecan interactions 19 9.74e-04 5.11e-03 0.44700 1.89e-01 4.05e-01 1.54e-01 2.22e-03
Ribosomal scanning and start codon recognition 43 3.35e-07 5.68e-06 0.44700 1.17e-01 4.31e-01 1.85e-01 9.86e-07
Translation initiation complex formation 43 3.40e-07 5.68e-06 0.44600 1.19e-01 4.30e-01 1.77e-01 1.06e-06
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 44 2.16e-07 3.94e-06 0.44600 1.30e-01 4.27e-01 1.37e-01 9.62e-07
Protein ubiquitination 65 9.55e-08 2.03e-06 0.44600 -2.60e-01 3.62e-01 2.88e-04 4.47e-07
Vpu mediated degradation of CD4 51 3.49e-06 3.89e-05 0.44400 -3.55e-01 2.67e-01 1.15e-05 9.65e-04
Mismatch Repair 13 2.88e-02 8.28e-02 0.44200 4.26e-01 -1.17e-01 7.84e-03 4.67e-01
Na+/Cl- dependent neurotransmitter transporters 15 1.16e-02 4.03e-02 0.44000 2.23e-02 -4.39e-01 8.81e-01 3.23e-03
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) 11 5.53e-02 1.32e-01 0.44000 -4.15e-01 1.45e-01 1.72e-02 4.06e-01
Translesion synthesis by POLI 17 2.01e-03 9.80e-03 0.43900 3.37e-01 2.81e-01 1.62e-02 4.47e-02
Suppression of phagosomal maturation 13 4.46e-02 1.14e-01 0.43800 -2.73e-01 3.43e-01 8.79e-02 3.24e-02
Interleukin-6 signaling 10 8.98e-02 1.92e-01 0.43700 -2.43e-01 3.63e-01 1.84e-01 4.66e-02
Regulation of signaling by CBL 18 1.35e-02 4.53e-02 0.43600 -2.52e-01 3.57e-01 6.46e-02 8.81e-03
Incretin synthesis, secretion, and inactivation 12 4.25e-02 1.10e-01 0.43600 -4.17e-01 1.28e-01 1.24e-02 4.42e-01
HSF1-dependent transactivation 31 5.15e-04 2.91e-03 0.43500 -3.84e-01 2.05e-01 2.19e-04 4.86e-02
Regulation of actin dynamics for phagocytic cup formation 76 1.57e-09 7.15e-08 0.43400 -9.74e-02 4.22e-01 1.43e-01 1.93e-10
Formation of ATP by chemiosmotic coupling 16 3.96e-03 1.74e-02 0.43200 3.79e-01 2.08e-01 8.71e-03 1.49e-01
Smooth Muscle Contraction 29 3.83e-04 2.30e-03 0.43100 -7.26e-02 4.25e-01 4.99e-01 7.40e-05
NIK-->noncanonical NF-kB signaling 58 1.68e-06 2.11e-05 0.42900 -3.37e-01 2.66e-01 8.99e-06 4.61e-04
Degradation of GLI1 by the proteasome 58 1.52e-06 1.94e-05 0.42900 -3.52e-01 2.45e-01 3.48e-06 1.27e-03
Nephrin family interactions 21 2.25e-03 1.09e-02 0.42800 8.36e-03 4.28e-01 9.47e-01 6.80e-04
Diseases associated with N-glycosylation of proteins 16 4.00e-03 1.74e-02 0.42800 -3.51e-01 -2.46e-01 1.52e-02 8.89e-02
MET activates RAS signaling 11 5.93e-02 1.39e-01 0.42800 -1.11e-01 4.13e-01 5.24e-01 1.76e-02
Misspliced GSK3beta mutants stabilize beta-catenin 15 8.87e-03 3.18e-02 0.42800 1.01e-01 4.16e-01 4.98e-01 5.33e-03
S33 mutants of beta-catenin aren't phosphorylated 15 8.87e-03 3.18e-02 0.42800 1.01e-01 4.16e-01 4.98e-01 5.33e-03
S37 mutants of beta-catenin aren't phosphorylated 15 8.87e-03 3.18e-02 0.42800 1.01e-01 4.16e-01 4.98e-01 5.33e-03
S45 mutants of beta-catenin aren't phosphorylated 15 8.87e-03 3.18e-02 0.42800 1.01e-01 4.16e-01 4.98e-01 5.33e-03
T41 mutants of beta-catenin aren't phosphorylated 15 8.87e-03 3.18e-02 0.42800 1.01e-01 4.16e-01 4.98e-01 5.33e-03
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex 15 8.87e-03 3.18e-02 0.42800 1.01e-01 4.16e-01 4.98e-01 5.33e-03
Degradation of GLI2 by the proteasome 58 1.94e-06 2.35e-05 0.42600 -3.46e-01 2.49e-01 5.35e-06 1.05e-03
Caspase-mediated cleavage of cytoskeletal proteins 12 1.92e-02 5.98e-02 0.42500 1.77e-01 3.87e-01 2.89e-01 2.04e-02
Processing and activation of SUMO 10 9.43e-02 1.98e-01 0.42500 -1.87e-01 3.82e-01 3.07e-01 3.65e-02
Common Pathway of Fibrin Clot Formation 16 7.47e-03 2.83e-02 0.42400 8.61e-02 4.15e-01 5.51e-01 4.03e-03
CLEC7A (Dectin-1) induces NFAT activation 11 3.55e-02 9.47e-02 0.42400 7.91e-02 4.16e-01 6.50e-01 1.69e-02
Formation of the cornified envelope 26 2.57e-03 1.22e-02 0.42200 3.70e-01 -2.03e-01 1.10e-03 7.28e-02
E3 ubiquitin ligases ubiquitinate target proteins 45 4.23e-05 3.45e-04 0.42200 -2.39e-01 3.48e-01 5.51e-03 5.46e-05
Regulation of IFNG signaling 13 4.71e-02 1.18e-01 0.42200 -1.72e-01 3.85e-01 2.82e-01 1.62e-02
GLI3 is processed to GLI3R by the proteasome 58 2.66e-06 3.11e-05 0.42200 -3.35e-01 2.55e-01 1.01e-05 7.70e-04
Formation of a pool of free 40S subunits 67 1.80e-10 1.10e-08 0.42100 2.61e-01 3.30e-01 2.19e-04 2.97e-06
Regulation of PTEN stability and activity 68 3.60e-07 5.95e-06 0.42100 -2.90e-01 3.04e-01 3.48e-05 1.45e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 51 1.28e-05 1.23e-04 0.42000 -3.41e-01 2.45e-01 2.47e-05 2.50e-03
p53-Independent DNA Damage Response 51 1.28e-05 1.23e-04 0.42000 -3.41e-01 2.45e-01 2.47e-05 2.50e-03
p53-Independent G1/S DNA damage checkpoint 51 1.28e-05 1.23e-04 0.42000 -3.41e-01 2.45e-01 2.47e-05 2.50e-03
Ubiquitin-dependent degradation of Cyclin D 51 1.40e-05 1.34e-04 0.42000 -3.32e-01 2.56e-01 4.04e-05 1.57e-03
CD28 dependent PI3K/Akt signaling 22 8.60e-03 3.15e-02 0.41800 -2.98e-01 2.94e-01 1.56e-02 1.71e-02
Regulation of ornithine decarboxylase (ODC) 50 1.73e-05 1.62e-04 0.41800 -3.45e-01 2.35e-01 2.45e-05 4.01e-03
Acetylcholine Neurotransmitter Release Cycle 11 8.60e-02 1.87e-01 0.41700 2.10e-01 -3.61e-01 2.27e-01 3.84e-02
Unwinding of DNA 12 1.90e-02 5.93e-02 0.41700 2.66e-01 3.21e-01 1.10e-01 5.39e-02
RORA activates gene expression 18 2.14e-02 6.46e-02 0.41600 -2.99e-01 2.89e-01 2.81e-02 3.40e-02
Degradation of AXIN 54 9.93e-06 1.00e-04 0.41500 -3.17e-01 2.68e-01 5.61e-05 6.66e-04
Elevation of cytosolic Ca2+ levels 15 9.91e-03 3.51e-02 0.41400 3.87e-01 1.49e-01 9.51e-03 3.19e-01
Activation of NF-kappaB in B cells 66 8.09e-07 1.18e-05 0.41400 -3.19e-01 2.65e-01 7.64e-06 2.02e-04
FCERI mediated NF-kB activation 91 4.57e-09 1.60e-07 0.41300 -2.58e-01 3.22e-01 2.16e-05 1.10e-07
Regulation of localization of FOXO transcription factors 12 4.56e-02 1.16e-01 0.41100 -2.69e-02 4.10e-01 8.72e-01 1.40e-02
Peptide chain elongation 55 2.51e-08 6.75e-07 0.41000 3.17e-01 2.60e-01 4.79e-05 8.52e-04
Autodegradation of the E3 ubiquitin ligase COP1 50 2.89e-05 2.53e-04 0.40900 -3.32e-01 2.39e-01 4.99e-05 3.49e-03
Dectin-1 mediated noncanonical NF-kB signaling 61 3.24e-06 3.64e-05 0.40900 -3.19e-01 2.56e-01 1.68e-05 5.56e-04
Platelet sensitization by LDL 17 6.21e-03 2.42e-02 0.40800 1.46e-01 3.81e-01 2.97e-01 6.47e-03
Lysosphingolipid and LPA receptors 13 4.81e-02 1.20e-01 0.40700 3.94e-01 -1.03e-01 1.39e-02 5.19e-01
Viral mRNA Translation 56 2.25e-08 6.45e-07 0.40700 3.11e-01 2.63e-01 5.77e-05 6.53e-04
Signaling by the B Cell Receptor (BCR) 123 8.95e-12 7.37e-10 0.40600 -2.27e-01 3.37e-01 1.34e-05 1.17e-10
Activation of PPARGC1A (PGC-1alpha) by phosphorylation 10 9.13e-02 1.94e-01 0.40600 3.99e-01 -7.38e-02 2.87e-02 6.86e-01
Eicosanoids 10 8.37e-02 1.83e-01 0.40600 4.04e-01 -3.81e-02 2.70e-02 8.35e-01
PECAM1 interactions 12 4.87e-02 1.22e-01 0.40500 -2.03e-02 4.04e-01 9.03e-01 1.53e-02
Advanced glycosylation endproduct receptor signaling 11 8.06e-02 1.78e-01 0.40400 -1.07e-01 3.90e-01 5.38e-01 2.51e-02
Other semaphorin interactions 19 1.97e-02 6.08e-02 0.40400 -2.19e-01 3.40e-01 9.88e-02 1.03e-02
Pentose phosphate pathway 14 1.37e-02 4.59e-02 0.40400 2.27e-01 3.34e-01 1.42e-01 3.04e-02
Regulation of RAS by GAPs 67 1.54e-06 1.94e-05 0.40200 -2.85e-01 2.85e-01 5.67e-05 5.63e-05
SCF-beta-TrCP mediated degradation of Emi1 54 1.79e-05 1.66e-04 0.40200 -3.26e-01 2.37e-01 3.52e-05 2.65e-03
Tie2 Signaling 18 2.21e-02 6.63e-02 0.40100 -1.68e-01 3.64e-01 2.18e-01 7.46e-03
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane 11 8.52e-02 1.86e-01 0.40100 3.85e-01 -1.10e-01 2.69e-02 5.28e-01
ER-Phagosome pathway 78 1.58e-07 3.07e-06 0.40000 -3.32e-01 2.23e-01 4.14e-07 6.64e-04
Signaling by NOTCH4 79 1.44e-07 2.93e-06 0.39900 -2.26e-01 3.28e-01 5.17e-04 4.53e-07
Trafficking and processing of endosomal TLR 11 1.12e-01 2.25e-01 0.39900 -2.33e-01 3.23e-01 1.81e-01 6.32e-02
FCGR3A-mediated phagocytosis 74 5.10e-08 1.19e-06 0.39800 -8.08e-02 3.90e-01 2.30e-01 6.83e-09
Leishmania phagocytosis 74 5.10e-08 1.19e-06 0.39800 -8.08e-02 3.90e-01 2.30e-01 6.83e-09
Parasite infection 74 5.10e-08 1.19e-06 0.39800 -8.08e-02 3.90e-01 2.30e-01 6.83e-09
VEGFR2 mediated vascular permeability 27 3.19e-03 1.47e-02 0.39700 -1.38e-01 3.72e-01 2.16e-01 8.16e-04
Interleukin-12 signaling 37 4.36e-04 2.54e-03 0.39600 -1.53e-01 3.66e-01 1.06e-01 1.19e-04
Potential therapeutics for SARS 78 1.54e-07 3.04e-06 0.39600 -1.94e-01 3.46e-01 3.12e-03 1.32e-07
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) 12 9.60e-02 2.00e-01 0.39500 -3.15e-01 2.39e-01 5.88e-02 1.52e-01
Antigen processing-Cross presentation 91 2.30e-08 6.45e-07 0.39400 -3.16e-01 2.36e-01 1.96e-07 1.03e-04
HuR (ELAVL1) binds and stabilizes mRNA 10 1.40e-01 2.64e-01 0.39300 -2.06e-01 3.34e-01 2.58e-01 6.72e-02
Glutathione synthesis and recycling 12 5.49e-02 1.32e-01 0.39200 -3.92e-01 -4.66e-03 1.89e-02 9.78e-01
Activation of the AP-1 family of transcription factors 10 1.26e-01 2.45e-01 0.39000 -1.33e-01 3.67e-01 4.68e-01 4.43e-02
Cap-dependent Translation Initiation 85 5.33e-11 3.40e-09 0.39000 1.73e-01 3.50e-01 5.89e-03 2.50e-08
Eukaryotic Translation Initiation 85 5.33e-11 3.40e-09 0.39000 1.73e-01 3.50e-01 5.89e-03 2.50e-08
GTP hydrolysis and joining of the 60S ribosomal subunit 78 3.66e-10 1.97e-08 0.39000 1.75e-01 3.49e-01 7.75e-03 1.00e-07
Serotonin Neurotransmitter Release Cycle 15 4.41e-02 1.13e-01 0.38900 1.20e-01 -3.70e-01 4.20e-01 1.31e-02
Killing mechanisms 11 1.22e-01 2.39e-01 0.38900 2.14e-01 -3.25e-01 2.18e-01 6.23e-02
WNT5:FZD7-mediated leishmania damping 11 1.22e-01 2.39e-01 0.38900 2.14e-01 -3.25e-01 2.18e-01 6.23e-02
Receptor-type tyrosine-protein phosphatases 17 3.98e-02 1.05e-01 0.38900 3.16e-01 -2.26e-01 2.40e-02 1.06e-01
RHO GTPases Activate WASPs and WAVEs 36 2.84e-04 1.77e-03 0.38700 -3.19e-02 3.86e-01 7.41e-01 6.16e-05
Scavenging by Class A Receptors 16 1.95e-02 6.04e-02 0.38600 4.68e-02 3.84e-01 7.46e-01 7.91e-03
L13a-mediated translational silencing of Ceruloplasmin expression 77 7.06e-10 3.66e-08 0.38600 1.82e-01 3.40e-01 5.86e-03 2.50e-07
Downstream signaling events of B Cell Receptor (BCR) 80 4.41e-07 6.87e-06 0.38500 -2.60e-01 2.84e-01 5.79e-05 1.14e-05
Interleukin-10 signaling 31 3.40e-03 1.53e-02 0.38500 -2.48e-01 2.94e-01 1.67e-02 4.68e-03
DCC mediated attractive signaling 13 9.10e-02 1.94e-01 0.38400 -3.05e-01 2.34e-01 5.68e-02 1.45e-01
FOXO-mediated transcription of cell cycle genes 15 1.90e-02 5.93e-02 0.38400 3.58e-01 1.39e-01 1.65e-02 3.51e-01
Regulation of mRNA stability by proteins that bind AU-rich elements 87 1.41e-07 2.91e-06 0.38400 -2.73e-01 2.70e-01 1.11e-05 1.37e-05
Apoptotic execution phase 49 2.16e-06 2.56e-05 0.38200 1.66e-01 3.44e-01 4.51e-02 3.10e-05
Synaptic adhesion-like molecules 21 2.28e-02 6.80e-02 0.38100 2.92e-01 -2.44e-01 2.04e-02 5.29e-02
Norepinephrine Neurotransmitter Release Cycle 15 5.58e-02 1.33e-01 0.38000 1.49e-01 -3.50e-01 3.18e-01 1.89e-02
Downregulation of SMAD2/3:SMAD4 transcriptional activity 23 1.60e-02 5.22e-02 0.38000 -2.97e-01 2.38e-01 1.38e-02 4.82e-02
Keratinization 39 5.80e-04 3.25e-03 0.38000 3.48e-01 -1.53e-01 1.71e-04 9.74e-02
PCNA-Dependent Long Patch Base Excision Repair 20 4.26e-03 1.82e-02 0.37900 2.93e-01 2.42e-01 2.35e-02 6.15e-02
RHO GTPases Activate ROCKs 19 1.13e-02 3.94e-02 0.37900 4.52e-02 3.76e-01 7.33e-01 4.57e-03
Eukaryotic Translation Elongation 58 1.52e-07 3.04e-06 0.37800 2.82e-01 2.52e-01 2.08e-04 9.11e-04
Fc epsilon receptor (FCERI) signaling 143 6.39e-12 5.60e-10 0.37800 -1.98e-01 3.22e-01 4.42e-05 3.24e-11
Cristae formation 29 4.15e-04 2.42e-03 0.37600 2.56e-01 2.75e-01 1.71e-02 1.03e-02
Infection with Mycobacterium tuberculosis 26 8.34e-03 3.09e-02 0.37500 -1.65e-01 3.37e-01 1.46e-01 2.91e-03
Platelet calcium homeostasis 26 1.09e-03 5.63e-03 0.37300 3.03e-01 2.18e-01 7.54e-03 5.43e-02
CDT1 association with the CDC6:ORC:origin complex 58 4.79e-05 3.82e-04 0.37300 -2.49e-01 2.78e-01 1.07e-03 2.58e-04
MET receptor recycling 10 1.28e-01 2.46e-01 0.37200 -3.69e-01 4.85e-02 4.33e-02 7.91e-01
Response of Mtb to phagocytosis 22 2.13e-02 6.45e-02 0.37200 -2.02e-01 3.12e-01 1.02e-01 1.12e-02
RHO GTPases activate PAKs 21 1.65e-02 5.35e-02 0.37100 -8.60e-02 3.61e-01 4.95e-01 4.18e-03
Metalloprotease DUBs 20 3.04e-02 8.50e-02 0.36900 -1.82e-01 3.21e-01 1.60e-01 1.30e-02
Endogenous sterols 19 9.64e-03 3.43e-02 0.36900 1.36e-01 3.43e-01 3.05e-01 9.70e-03
Interleukin-12 family signaling 46 2.55e-04 1.61e-03 0.36800 -1.46e-01 3.38e-01 8.70e-02 7.21e-05
Eukaryotic Translation Termination 60 2.07e-07 3.82e-06 0.36800 2.69e-01 2.51e-01 3.20e-04 7.76e-04
InlB-mediated entry of Listeria monocytogenes into host cell 14 9.23e-02 1.95e-01 0.36700 -3.05e-01 2.05e-01 4.81e-02 1.85e-01
ABC transporters in lipid homeostasis 15 5.45e-02 1.31e-01 0.36700 3.60e-01 -7.27e-02 1.59e-02 6.26e-01
IRF3-mediated induction of type I IFN 13 1.04e-01 2.13e-01 0.36700 -3.23e-01 1.73e-01 4.35e-02 2.79e-01
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 64 2.44e-05 2.17e-04 0.36700 -2.57e-01 2.62e-01 3.76e-04 2.98e-04
Selenocysteine synthesis 60 2.60e-07 4.62e-06 0.36600 2.92e-01 2.20e-01 9.03e-05 3.16e-03
YAP1- and WWTR1 (TAZ)-stimulated gene expression 12 1.36e-01 2.59e-01 0.36600 -2.42e-01 2.75e-01 1.47e-01 9.90e-02
COPI-independent Golgi-to-ER retrograde traffic 33 2.69e-03 1.28e-02 0.36600 -1.34e-01 3.40e-01 1.84e-01 7.18e-04
RUNX3 regulates NOTCH signaling 14 3.70e-02 9.83e-02 0.36500 1.12e-01 3.48e-01 4.70e-01 2.42e-02
Response of EIF2AK4 (GCN2) to amino acid deficiency 68 3.40e-08 8.67e-07 0.36500 2.38e-01 2.77e-01 6.94e-04 7.69e-05
Downstream TCR signaling 88 4.66e-07 7.10e-06 0.36500 -2.92e-01 2.19e-01 2.21e-06 3.98e-04
Reduction of cytosolic Ca++ levels 11 6.57e-02 1.52e-01 0.36400 1.88e-01 3.12e-01 2.81e-01 7.28e-02
BBSome-mediated cargo-targeting to cilium 21 2.18e-02 6.55e-02 0.36400 -3.46e-01 1.13e-01 5.99e-03 3.71e-01
Chaperone Mediated Autophagy 16 7.25e-02 1.65e-01 0.36400 -2.44e-01 2.70e-01 9.16e-02 6.12e-02
Stabilization of p53 54 1.41e-04 9.71e-04 0.36400 -2.82e-01 2.30e-01 3.42e-04 3.44e-03
Constitutive Signaling by Overexpressed ERBB2 11 1.28e-01 2.46e-01 0.36400 -8.72e-02 3.53e-01 6.17e-01 4.25e-02
Signaling by SCF-KIT 42 1.01e-03 5.24e-03 0.36400 -2.27e-01 2.84e-01 1.10e-02 1.44e-03
Signal regulatory protein family interactions 12 7.02e-02 1.61e-01 0.36400 -3.59e-01 -5.83e-02 3.14e-02 7.26e-01
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex 13 5.77e-02 1.36e-01 0.36400 5.00e-02 3.60e-01 7.55e-01 2.46e-02
The role of GTSE1 in G2/M progression after G2 checkpoint 59 6.68e-05 5.00e-04 0.36300 -2.72e-01 2.40e-01 2.96e-04 1.44e-03
Regulation of pyruvate dehydrogenase (PDH) complex 15 5.75e-02 1.36e-01 0.36200 -6.57e-02 3.56e-01 6.60e-01 1.69e-02
Constitutive Signaling by EGFRvIII 15 8.70e-02 1.88e-01 0.36100 -2.90e-01 2.15e-01 5.21e-02 1.49e-01
Signaling by EGFRvIII in Cancer 15 8.70e-02 1.88e-01 0.36100 -2.90e-01 2.15e-01 5.21e-02 1.49e-01
Fatty acids 11 1.47e-01 2.73e-01 0.36000 3.35e-01 -1.31e-01 5.42e-02 4.52e-01
Translesion Synthesis by POLH 18 1.91e-02 5.95e-02 0.36000 7.20e-02 3.52e-01 5.97e-01 9.64e-03
NOTCH4 Activation and Transmission of Signal to the Nucleus 10 2.02e-01 3.41e-01 0.35900 -2.43e-01 2.64e-01 1.83e-01 1.48e-01
Beta-catenin phosphorylation cascade 17 1.90e-02 5.93e-02 0.35900 1.42e-01 3.29e-01 3.10e-01 1.87e-02
Synthesis of very long-chain fatty acyl-CoAs 19 2.05e-02 6.29e-02 0.35800 1.32e-02 3.58e-01 9.20e-01 6.88e-03
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 24 2.96e-03 1.38e-02 0.35800 2.80e-01 2.23e-01 1.75e-02 5.87e-02
TCR signaling 109 2.92e-08 7.58e-07 0.35800 -2.85e-01 2.16e-01 2.73e-07 9.70e-05
Formation of Senescence-Associated Heterochromatin Foci (SAHF) 16 3.69e-02 9.80e-02 0.35700 3.56e-01 2.65e-02 1.37e-02 8.54e-01
Erythropoietin activates RAS 14 8.33e-02 1.82e-01 0.35600 -9.51e-02 3.43e-01 5.38e-01 2.61e-02
NOTCH4 Intracellular Domain Regulates Transcription 18 1.77e-02 5.62e-02 0.35600 1.11e-01 3.38e-01 4.15e-01 1.29e-02
G-protein beta:gamma signalling 30 6.44e-03 2.49e-02 0.35600 -1.40e-01 3.27e-01 1.85e-01 1.92e-03
Negative regulation of MET activity 20 4.43e-02 1.14e-01 0.35500 -2.42e-01 2.59e-01 6.06e-02 4.48e-02
Recognition of DNA damage by PCNA-containing replication complex 29 1.32e-03 6.70e-03 0.35400 1.48e-01 3.22e-01 1.68e-01 2.68e-03
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon 16 7.63e-02 1.71e-01 0.35300 -3.10e-01 1.68e-01 3.16e-02 2.45e-01
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 19 5.23e-02 1.28e-01 0.35300 -2.80e-01 2.15e-01 3.47e-02 1.05e-01
Signaling by Ligand-Responsive EGFR Variants in Cancer 19 5.23e-02 1.28e-01 0.35300 -2.80e-01 2.15e-01 3.47e-02 1.05e-01
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs 10 9.42e-02 1.98e-01 0.35200 -2.55e-01 -2.43e-01 1.63e-01 1.83e-01
Organic cation/anion/zwitterion transport 13 5.08e-02 1.26e-01 0.35200 -1.68e-01 -3.10e-01 2.95e-01 5.33e-02
Interleukin-35 Signalling 11 1.85e-01 3.21e-01 0.35200 -2.62e-01 2.35e-01 1.32e-01 1.78e-01
DARPP-32 events 23 5.26e-03 2.12e-02 0.35100 1.71e-01 3.06e-01 1.55e-01 1.10e-02
Signaling by Leptin 10 1.25e-01 2.45e-01 0.35000 3.44e-01 6.60e-02 5.96e-02 7.18e-01
Interleukin-3, Interleukin-5 and GM-CSF signaling 39 2.63e-03 1.25e-02 0.34900 -2.82e-01 2.05e-01 2.28e-03 2.68e-02
Assembly of the pre-replicative complex 67 3.78e-05 3.14e-04 0.34800 -2.01e-01 2.84e-01 4.37e-03 5.74e-05
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 62 6.74e-07 1.00e-05 0.34800 2.15e-01 2.74e-01 3.36e-03 1.94e-04
Fcgamma receptor (FCGR) dependent phagocytosis 100 8.78e-08 1.89e-06 0.34800 -1.24e-01 3.25e-01 3.17e-02 1.96e-08
Signaling by PDGFR in disease 19 5.29e-02 1.29e-01 0.34800 -1.76e-01 3.00e-01 1.85e-01 2.35e-02
RAF activation 33 2.79e-03 1.31e-02 0.34700 -4.74e-02 3.44e-01 6.37e-01 6.26e-04
Base-Excision Repair, AP Site Formation 24 2.73e-02 7.93e-02 0.34700 2.73e-01 -2.14e-01 2.05e-02 6.94e-02
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest 13 1.26e-01 2.45e-01 0.34700 3.17e-01 -1.39e-01 4.76e-02 3.85e-01
STING mediated induction of host immune responses 16 7.58e-02 1.71e-01 0.34500 -3.24e-01 1.19e-01 2.48e-02 4.12e-01
ER Quality Control Compartment (ERQC) 21 3.56e-02 9.50e-02 0.34400 -3.20e-01 1.25e-01 1.11e-02 3.21e-01
Apoptotic cleavage of cellular proteins 35 5.92e-04 3.30e-03 0.34300 1.33e-01 3.16e-01 1.74e-01 1.21e-03
Metabolism of polyamines 58 1.99e-04 1.29e-03 0.34200 -2.82e-01 1.94e-01 2.05e-04 1.08e-02
Keratan sulfate degradation 10 1.47e-01 2.73e-01 0.34200 3.77e-02 3.40e-01 8.36e-01 6.30e-02
p75NTR recruits signalling complexes 13 1.49e-01 2.75e-01 0.34100 -2.81e-01 1.94e-01 7.97e-02 2.26e-01
Aspartate and asparagine metabolism 11 9.62e-02 2.00e-01 0.34100 1.49e-01 3.07e-01 3.93e-01 7.81e-02
CLEC7A (Dectin-1) signaling 97 9.51e-07 1.34e-05 0.34000 -2.23e-01 2.57e-01 1.54e-04 1.19e-05
Cytosolic tRNA aminoacylation 24 3.00e-02 8.41e-02 0.34000 -1.82e-01 2.87e-01 1.23e-01 1.50e-02
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 103 3.99e-07 6.35e-06 0.34000 -2.69e-01 2.08e-01 2.51e-06 2.73e-04
Orc1 removal from chromatin 69 4.77e-05 3.82e-04 0.33900 -1.96e-01 2.77e-01 4.91e-03 6.91e-05
FCGR3A-mediated IL10 synthesis 52 3.70e-04 2.23e-03 0.33900 -1.33e-01 3.11e-01 9.77e-02 1.03e-04
Synthesis of PIPs at the early endosome membrane 16 1.04e-01 2.13e-01 0.33800 -2.19e-01 2.58e-01 1.30e-01 7.42e-02
Signalling to ERKs 32 9.69e-03 3.44e-02 0.33800 -1.78e-01 2.87e-01 8.13e-02 4.96e-03
Autodegradation of Cdh1 by Cdh1:APC/C 62 1.64e-04 1.10e-03 0.33700 -2.47e-01 2.30e-01 7.69e-04 1.75e-03
Translocation of SLC2A4 (GLUT4) to the plasma membrane 51 1.82e-04 1.18e-03 0.33700 -4.17e-02 3.35e-01 6.07e-01 3.56e-05
Glycogen breakdown (glycogenolysis) 14 5.93e-02 1.39e-01 0.33700 1.12e-01 3.18e-01 4.70e-01 3.95e-02
Free fatty acids regulate insulin secretion 10 2.48e-01 3.94e-01 0.33600 -2.40e-01 2.34e-01 1.88e-01 2.00e-01
Digestion and absorption 13 7.67e-02 1.72e-01 0.33600 3.21e-01 9.75e-02 4.50e-02 5.43e-01
Receptor Mediated Mitophagy 11 2.08e-01 3.47e-01 0.33500 -1.80e-01 2.83e-01 3.02e-01 1.04e-01
G beta:gamma signalling through PI3Kgamma 23 2.92e-02 8.37e-02 0.33500 -1.07e-01 3.18e-01 3.75e-01 8.36e-03
Listeria monocytogenes entry into host cells 19 7.00e-02 1.61e-01 0.33500 -2.65e-01 2.05e-01 4.53e-02 1.23e-01
Activation of BH3-only proteins 29 8.37e-03 3.09e-02 0.33500 -4.95e-02 3.31e-01 6.44e-01 2.02e-03
Signaling by PDGFRA extracellular domain mutants 12 1.21e-01 2.38e-01 0.33500 2.31e-03 3.35e-01 9.89e-01 4.48e-02
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants 12 1.21e-01 2.38e-01 0.33500 2.31e-03 3.35e-01 9.89e-01 4.48e-02
SCF(Skp2)-mediated degradation of p27/p21 58 3.38e-04 2.05e-03 0.33400 -2.30e-01 2.42e-01 2.45e-03 1.42e-03
Cytochrome c-mediated apoptotic response 11 1.28e-01 2.46e-01 0.33300 5.83e-02 3.28e-01 7.38e-01 5.96e-02
Regulation of RUNX2 expression and activity 70 6.64e-05 5.00e-04 0.33300 -2.59e-01 2.10e-01 1.84e-04 2.43e-03
Phosphorylation of CD3 and TCR zeta chains 16 6.68e-02 1.54e-01 0.33300 -3.32e-01 2.15e-02 2.14e-02 8.81e-01
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 16 3.49e-02 9.38e-02 0.33200 2.45e-01 2.25e-01 9.04e-02 1.20e-01
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects 17 2.97e-02 8.38e-02 0.33100 2.70e-01 1.92e-01 5.38e-02 1.70e-01
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) 17 2.97e-02 8.38e-02 0.33100 2.70e-01 1.92e-01 5.38e-02 1.70e-01
Integrin cell surface interactions 58 3.79e-05 3.14e-04 0.33100 1.71e-02 3.31e-01 8.22e-01 1.32e-05
LGI-ADAM interactions 12 1.92e-01 3.29e-01 0.33100 1.92e-01 -2.70e-01 2.51e-01 1.05e-01
Gastrin-CREB signalling pathway via PKC and MAPK 17 7.70e-02 1.72e-01 0.33100 -9.92e-02 3.16e-01 4.79e-01 2.43e-02
Role of phospholipids in phagocytosis 40 4.49e-03 1.91e-02 0.33000 -2.14e-01 2.52e-01 1.92e-02 5.92e-03
Regulation of innate immune responses to cytosolic DNA 15 9.32e-02 1.96e-01 0.33000 -3.25e-01 5.68e-02 2.95e-02 7.04e-01
Costimulation by the CD28 family 61 2.93e-04 1.79e-03 0.32800 -2.12e-01 2.51e-01 4.28e-03 7.03e-04
SRP-dependent cotranslational protein targeting to membrane 79 9.05e-07 1.29e-05 0.32800 3.60e-02 3.26e-01 5.81e-01 5.45e-07
Diseases associated with the TLR signaling cascade 22 5.35e-02 1.30e-01 0.32800 -2.11e-01 2.50e-01 8.62e-02 4.22e-02
Diseases of Immune System 22 5.35e-02 1.30e-01 0.32800 -2.11e-01 2.50e-01 8.62e-02 4.22e-02
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest 18 5.78e-02 1.37e-01 0.32700 3.24e-01 -4.24e-02 1.73e-02 7.55e-01
Cellular response to hypoxia 73 6.17e-05 4.70e-04 0.32700 -2.59e-01 1.99e-01 1.28e-04 3.34e-03
Downregulation of TGF-beta receptor signaling 26 2.45e-02 7.22e-02 0.32600 -1.17e-01 3.04e-01 3.01e-01 7.33e-03
Presynaptic depolarization and calcium channel opening 11 2.08e-01 3.46e-01 0.32500 1.12e-01 -3.05e-01 5.20e-01 8.00e-02
Purine salvage 12 1.79e-01 3.12e-01 0.32500 -3.07e-01 1.07e-01 6.60e-02 5.23e-01
TICAM1-dependent activation of IRF3/IRF7 12 1.75e-01 3.08e-01 0.32400 -3.10e-01 9.42e-02 6.30e-02 5.72e-01
CREB1 phosphorylation through the activation of Adenylate Cyclase 11 1.68e-01 3.02e-01 0.32200 -3.61e-03 3.22e-01 9.83e-01 6.43e-02
RHO GTPases activate PKNs 43 7.37e-04 3.97e-03 0.32200 2.62e-02 3.21e-01 7.66e-01 2.75e-04
Spry regulation of FGF signaling 16 1.05e-01 2.14e-01 0.32200 -1.06e-01 3.04e-01 4.62e-01 3.55e-02
Uptake and function of anthrax toxins 10 1.78e-01 3.12e-01 0.32100 3.17e-01 5.11e-02 8.26e-02 7.80e-01
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases 14 1.45e-01 2.69e-01 0.32100 -1.18e-01 2.98e-01 4.45e-01 5.32e-02
Assembly of active LPL and LIPC lipase complexes 16 1.25e-01 2.45e-01 0.32000 2.70e-01 -1.72e-01 6.16e-02 2.35e-01
Signaling by KIT in disease 20 5.71e-02 1.36e-01 0.32000 -8.29e-02 3.09e-01 5.21e-01 1.69e-02
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants 20 5.71e-02 1.36e-01 0.32000 -8.29e-02 3.09e-01 5.21e-01 1.69e-02
Class C/3 (Metabotropic glutamate/pheromone receptors) 12 1.96e-01 3.33e-01 0.32000 1.26e-01 -2.94e-01 4.51e-01 7.81e-02
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) 81 3.38e-07 5.68e-06 0.31900 1.31e-01 2.91e-01 4.24e-02 6.16e-06
Nonsense-Mediated Decay (NMD) 81 3.38e-07 5.68e-06 0.31900 1.31e-01 2.91e-01 4.24e-02 6.16e-06
IKK complex recruitment mediated by RIP1 20 6.79e-02 1.56e-01 0.31900 -1.27e-01 2.92e-01 3.25e-01 2.38e-02
Formation of Fibrin Clot (Clotting Cascade) 28 6.34e-03 2.46e-02 0.31700 1.21e-01 2.93e-01 2.69e-01 7.35e-03
Cell surface interactions at the vascular wall 132 3.12e-09 1.22e-07 0.31500 -3.27e-02 3.14e-01 5.17e-01 4.94e-10
Transport of inorganic cations/anions and amino acids/oligopeptides 97 6.76e-06 6.97e-05 0.31500 2.00e-01 -2.43e-01 6.68e-04 3.49e-05
BMAL1:CLOCK,NPAS2 activates circadian gene expression 26 3.52e-02 9.42e-02 0.31400 -1.38e-01 2.82e-01 2.23e-01 1.28e-02
Signaling by FGFR3 fusions in cancer 10 2.76e-01 4.23e-01 0.31400 -1.39e-01 2.82e-01 4.47e-01 1.23e-01
APC/C:Cdc20 mediated degradation of Securin 66 3.29e-04 2.01e-03 0.31400 -2.27e-01 2.17e-01 1.42e-03 2.35e-03
mitochondrial fatty acid beta-oxidation of saturated fatty acids 10 2.94e-01 4.43e-01 0.31400 -2.47e-01 1.94e-01 1.77e-01 2.89e-01
Degradation of DVL 56 1.09e-03 5.63e-03 0.31300 -2.50e-01 1.88e-01 1.24e-03 1.48e-02
ABC transporter disorders 73 8.44e-05 6.13e-04 0.31300 -2.85e-01 1.29e-01 2.61e-05 5.68e-02
PD-1 signaling 16 7.99e-02 1.77e-01 0.31200 -3.11e-01 -2.66e-02 3.15e-02 8.54e-01
TICAM1, RIP1-mediated IKK complex recruitment 17 1.10e-01 2.22e-01 0.31000 -1.09e-01 2.90e-01 4.35e-01 3.82e-02
G alpha (s) signalling events 298 1.03e-23 4.83e-21 0.31000 -1.68e-01 -2.61e-01 6.21e-07 1.09e-14
MAPK6/MAPK4 signaling 85 4.15e-05 3.40e-04 0.31000 -2.02e-01 2.35e-01 1.33e-03 1.76e-04
Influenza Viral RNA Transcription and Replication 103 8.50e-09 2.84e-07 0.31000 2.48e-01 1.85e-01 1.35e-05 1.17e-03
Phase 0 - rapid depolarisation 24 4.70e-02 1.18e-01 0.31000 2.85e-01 -1.22e-01 1.58e-02 3.01e-01
Transcriptional regulation by RUNX3 93 1.28e-05 1.23e-04 0.30900 -1.59e-01 2.65e-01 8.24e-03 1.02e-05
RUNX1 regulates transcription of genes involved in differentiation of HSCs 77 1.25e-04 8.77e-04 0.30800 -2.13e-01 2.22e-01 1.21e-03 7.73e-04
GAB1 signalosome 14 1.36e-01 2.59e-01 0.30700 -3.06e-01 2.80e-02 4.75e-02 8.56e-01
Pausing and recovery of Tat-mediated HIV elongation 30 4.67e-03 1.95e-02 0.30700 2.00e-01 2.33e-01 5.81e-02 2.72e-02
Tat-mediated HIV elongation arrest and recovery 30 4.67e-03 1.95e-02 0.30700 2.00e-01 2.33e-01 5.81e-02 2.72e-02
SARS-CoV Infections 139 7.13e-08 1.59e-06 0.30700 -1.66e-01 2.58e-01 7.62e-04 1.50e-07
Intrinsic Pathway for Apoptosis 48 7.29e-04 3.94e-03 0.30700 1.60e-02 3.06e-01 8.48e-01 2.43e-04
Endosomal Sorting Complex Required For Transport (ESCRT) 30 1.46e-02 4.84e-02 0.30500 -2.70e-02 3.04e-01 7.98e-01 3.93e-03
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism 11 1.46e-01 2.72e-01 0.30500 2.56e-01 1.66e-01 1.42e-01 3.39e-01
Degradation of beta-catenin by the destruction complex 84 6.09e-05 4.68e-04 0.30500 -1.83e-01 2.43e-01 3.70e-03 1.16e-04
Signal transduction by L1 21 5.14e-02 1.26e-01 0.30500 -2.07e-02 3.04e-01 8.69e-01 1.59e-02
Cleavage of the damaged pyrimidine 22 7.87e-02 1.75e-01 0.30300 2.48e-01 -1.75e-01 4.40e-02 1.56e-01
Depyrimidination 22 7.87e-02 1.75e-01 0.30300 2.48e-01 -1.75e-01 4.40e-02 1.56e-01
Recognition and association of DNA glycosylase with site containing an affected pyrimidine 22 7.87e-02 1.75e-01 0.30300 2.48e-01 -1.75e-01 4.40e-02 1.56e-01
Cyclin E associated events during G1/S transition 81 8.14e-05 5.94e-04 0.30300 -1.60e-01 2.57e-01 1.27e-02 6.33e-05
MECP2 regulates neuronal receptors and channels 15 1.07e-01 2.17e-01 0.30300 2.68e-02 3.01e-01 8.57e-01 4.33e-02
Glucose metabolism 85 1.09e-06 1.47e-05 0.30300 2.87e-01 9.66e-02 4.92e-06 1.24e-01
Resolution of Abasic Sites (AP sites) 37 5.09e-03 2.07e-02 0.30200 3.02e-01 3.33e-04 1.50e-03 9.97e-01
Formation of Incision Complex in GG-NER 42 3.29e-03 1.50e-02 0.30200 -3.24e-02 3.00e-01 7.17e-01 7.74e-04
GRB2:SOS provides linkage to MAPK signaling for Integrins 15 8.83e-02 1.90e-01 0.30100 1.03e-01 2.83e-01 4.89e-01 5.78e-02
Interaction between L1 and Ankyrins 25 3.09e-02 8.61e-02 0.29900 2.99e-01 -4.88e-03 9.73e-03 9.66e-01
DAP12 signaling 29 4.02e-02 1.06e-01 0.29900 -1.90e-01 2.31e-01 7.69e-02 3.15e-02
Early Phase of HIV Life Cycle 14 1.65e-01 2.99e-01 0.29900 -5.86e-02 2.93e-01 7.04e-01 5.78e-02
DNA strand elongation 31 6.32e-03 2.45e-02 0.29800 2.66e-01 1.35e-01 1.04e-02 1.92e-01
C-type lectin receptors (CLRs) 127 9.77e-07 1.36e-05 0.29800 -2.08e-01 2.13e-01 5.08e-05 3.52e-05
Disassembly of the destruction complex and recruitment of AXIN to the membrane 28 9.98e-03 3.52e-02 0.29800 2.56e-01 1.51e-01 1.89e-02 1.66e-01
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding 39 1.33e-02 4.48e-02 0.29700 -1.69e-01 2.44e-01 6.77e-02 8.36e-03
rRNA processing 176 9.46e-12 7.37e-10 0.29600 4.33e-02 2.92e-01 3.22e-01 2.31e-11
GRB2 events in EGFR signaling 10 3.13e-01 4.59e-01 0.29300 -1.03e-01 2.74e-01 5.71e-01 1.33e-01
Chemokine receptors bind chemokines 39 1.48e-02 4.88e-02 0.29300 -2.42e-01 1.66e-01 8.97e-03 7.35e-02
Recycling pathway of L1 27 3.74e-02 9.91e-02 0.29200 -6.44e-02 2.85e-01 5.62e-01 1.04e-02
Apoptosis 164 4.27e-09 1.57e-07 0.29200 -8.27e-02 2.80e-01 6.80e-02 6.17e-10
MAPK targets/ Nuclear events mediated by MAP kinases 30 2.98e-02 8.38e-02 0.29200 -8.77e-02 2.78e-01 4.06e-01 8.38e-03
Processive synthesis on the C-strand of the telomere 18 8.13e-02 1.79e-01 0.29200 2.90e-01 3.15e-02 3.33e-02 8.17e-01
Semaphorin interactions 64 6.38e-04 3.51e-03 0.29100 -9.58e-02 2.75e-01 1.85e-01 1.45e-04
Initial triggering of complement 33 2.10e-02 6.38e-02 0.29100 -8.30e-02 2.79e-01 4.09e-01 5.63e-03
HIV elongation arrest and recovery 32 6.11e-03 2.39e-02 0.29000 1.81e-01 2.27e-01 7.71e-02 2.62e-02
Pausing and recovery of HIV elongation 32 6.11e-03 2.39e-02 0.29000 1.81e-01 2.27e-01 7.71e-02 2.62e-02
Apoptotic factor-mediated response 14 1.07e-01 2.16e-01 0.29000 1.93e-01 2.16e-01 2.10e-01 1.61e-01
Hedgehog 'on' state 83 1.69e-04 1.13e-03 0.29000 -2.33e-01 1.72e-01 2.44e-04 6.69e-03
DNA Replication Pre-Initiation 83 1.50e-04 1.02e-03 0.28900 -1.52e-01 2.46e-01 1.64e-02 1.07e-04
TGF-beta receptor signaling activates SMADs 32 2.98e-02 8.38e-02 0.28900 -1.21e-01 2.62e-01 2.36e-01 1.02e-02
Signaling by EGFR in Cancer 22 1.04e-01 2.13e-01 0.28800 -2.15e-01 1.92e-01 8.10e-02 1.18e-01
Major pathway of rRNA processing in the nucleolus and cytosol 145 2.19e-09 9.05e-08 0.28700 5.02e-02 2.82e-01 2.98e-01 4.49e-09
Interleukin receptor SHC signaling 22 9.22e-02 1.95e-01 0.28600 -2.62e-01 1.16e-01 3.36e-02 3.45e-01
E2F mediated regulation of DNA replication 22 3.32e-02 8.97e-02 0.28600 1.74e-01 2.27e-01 1.58e-01 6.51e-02
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 70 8.69e-04 4.61e-03 0.28600 -2.03e-01 2.02e-01 3.37e-03 3.57e-03
Transcriptional regulation of pluripotent stem cells 16 8.62e-02 1.87e-01 0.28500 2.35e-01 1.62e-01 1.04e-01 2.61e-01
EPHA-mediated growth cone collapse 15 1.46e-01 2.71e-01 0.28500 3.05e-03 2.85e-01 9.84e-01 5.57e-02
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 13 1.94e-01 3.31e-01 0.28500 -6.03e-03 2.85e-01 9.70e-01 7.53e-02
G beta:gamma signalling through CDC42 18 9.68e-02 2.01e-01 0.28500 1.29e-02 2.85e-01 9.24e-01 3.66e-02
Asymmetric localization of PCP proteins 63 1.83e-03 8.99e-03 0.28500 -2.15e-01 1.87e-01 3.20e-03 1.05e-02
Blood group systems biosynthesis 12 3.00e-01 4.49e-01 0.28400 -1.78e-01 2.21e-01 2.86e-01 1.84e-01
Lewis blood group biosynthesis 12 3.00e-01 4.49e-01 0.28400 -1.78e-01 2.21e-01 2.86e-01 1.84e-01
p130Cas linkage to MAPK signaling for integrins 15 1.05e-01 2.14e-01 0.28400 1.49e-01 2.42e-01 3.18e-01 1.05e-01
Dual Incision in GG-NER 40 2.25e-03 1.09e-02 0.28400 1.78e-01 2.21e-01 5.13e-02 1.56e-02
Regulation of expression of SLITs and ROBOs 134 1.34e-07 2.81e-06 0.28200 -3.36e-02 2.80e-01 5.03e-01 2.14e-08
Golgi Associated Vesicle Biogenesis 54 4.82e-03 1.98e-02 0.28200 -1.73e-01 2.22e-01 2.79e-02 4.71e-03
RNA Polymerase I Promoter Opening 12 1.70e-01 3.04e-01 0.28200 1.45e-01 2.42e-01 3.85e-01 1.47e-01
Influenza Infection 119 2.42e-08 6.64e-07 0.28200 1.51e-01 2.38e-01 4.50e-03 7.67e-06
Leading Strand Synthesis 13 1.90e-01 3.27e-01 0.28100 2.81e-01 1.82e-02 7.95e-02 9.09e-01
Polymerase switching 13 1.90e-01 3.27e-01 0.28100 2.81e-01 1.82e-02 7.95e-02 9.09e-01
Signaling by ROBO receptors 177 1.58e-09 7.15e-08 0.28100 -4.72e-02 2.77e-01 2.80e-01 2.01e-10
Post-chaperonin tubulin folding pathway 17 1.30e-01 2.49e-01 0.28100 -2.22e-02 2.81e-01 8.74e-01 4.53e-02
Rap1 signalling 15 2.18e-01 3.56e-01 0.28100 -1.39e-01 2.44e-01 3.51e-01 1.01e-01
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models 20 5.23e-02 1.28e-01 0.28100 2.39e-01 1.48e-01 6.40e-02 2.53e-01
Neurodegenerative Diseases 20 5.23e-02 1.28e-01 0.28100 2.39e-01 1.48e-01 6.40e-02 2.53e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation 14 2.31e-01 3.73e-01 0.28100 -1.10e-01 2.58e-01 4.74e-01 9.46e-02
Laminin interactions 23 3.31e-02 8.95e-02 0.28100 2.29e-01 1.62e-01 5.75e-02 1.78e-01
CD209 (DC-SIGN) signaling 19 1.53e-01 2.80e-01 0.28000 -1.60e-01 2.30e-01 2.26e-01 8.27e-02
UCH proteinases 87 2.13e-04 1.37e-03 0.28000 -2.20e-01 1.73e-01 4.01e-04 5.19e-03
Signaling by ERBB2 48 9.64e-03 3.43e-02 0.28000 -2.04e-01 1.91e-01 1.43e-02 2.20e-02
Deadenylation of mRNA 22 1.14e-01 2.28e-01 0.28000 -2.33e-01 1.54e-01 5.83e-02 2.10e-01
Golgi Cisternae Pericentriolar Stack Reorganization 13 2.45e-01 3.91e-01 0.28000 -8.23e-02 2.67e-01 6.08e-01 9.53e-02
VEGFA-VEGFR2 Pathway 93 6.73e-05 5.00e-04 0.27900 -1.10e-01 2.57e-01 6.78e-02 1.86e-05
Regulation of HSF1-mediated heat shock response 77 4.07e-04 2.39e-03 0.27900 -1.20e-01 2.52e-01 6.92e-02 1.37e-04
RNA Polymerase II Pre-transcription Events 79 2.19e-04 1.40e-03 0.27900 -8.30e-02 2.66e-01 2.02e-01 4.44e-05
Platelet homeostasis 79 1.03e-05 1.03e-04 0.27800 1.60e-01 2.28e-01 1.40e-02 4.65e-04
Signaling by VEGF 101 3.08e-05 2.63e-04 0.27800 -1.06e-01 2.57e-01 6.65e-02 7.95e-06
Mitochondrial tRNA aminoacylation 21 4.58e-02 1.16e-01 0.27800 -1.84e-01 -2.09e-01 1.45e-01 9.79e-02
Miscellaneous transport and binding events 23 1.03e-01 2.13e-01 0.27800 -2.40e-01 1.41e-01 4.67e-02 2.43e-01
Signaling by FGFR4 in disease 11 3.50e-01 4.94e-01 0.27800 -1.83e-01 2.09e-01 2.93e-01 2.31e-01
CDK-mediated phosphorylation and removal of Cdc6 70 1.30e-03 6.63e-03 0.27800 -2.00e-01 1.92e-01 3.79e-03 5.45e-03
Activation of ATR in response to replication stress 37 4.64e-03 1.95e-02 0.27800 2.22e-01 1.66e-01 1.93e-02 8.08e-02
Synthesis of Leukotrienes (LT) and Eoxins (EX) 18 8.88e-02 1.90e-01 0.27700 2.65e-01 8.07e-02 5.17e-02 5.54e-01
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 103 5.36e-07 8.07e-06 0.27700 1.27e-01 2.46e-01 2.62e-02 1.64e-05
Fertilization 15 1.95e-01 3.32e-01 0.27700 6.13e-02 -2.70e-01 6.81e-01 7.05e-02
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain 19 8.90e-02 1.90e-01 0.27600 4.09e-02 2.73e-01 7.58e-01 3.91e-02
SHC1 events in EGFR signaling 11 3.19e-01 4.62e-01 0.27600 -9.27e-02 2.60e-01 5.95e-01 1.35e-01
Interleukin-1 signaling 96 9.53e-05 6.82e-04 0.27500 -1.39e-01 2.37e-01 1.84e-02 5.88e-05
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint 71 1.37e-03 6.90e-03 0.27500 -1.96e-01 1.92e-01 4.37e-03 5.06e-03
Signaling by RAF1 mutants 38 1.65e-02 5.35e-02 0.27500 -5.65e-02 2.69e-01 5.47e-01 4.17e-03
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 120 5.69e-08 1.31e-06 0.27400 2.38e-01 1.37e-01 6.91e-06 9.66e-03
Cyclin A:Cdk2-associated events at S phase entry 83 3.58e-04 2.16e-03 0.27400 -1.41e-01 2.35e-01 2.68e-02 2.11e-04
Glycogen synthesis 15 1.49e-01 2.75e-01 0.27400 5.05e-02 2.69e-01 7.35e-01 7.10e-02
Sealing of the nuclear envelope (NE) by ESCRT-III 23 8.65e-02 1.87e-01 0.27400 -6.23e-02 2.66e-01 6.05e-01 2.70e-02
TICAM1,TRAF6-dependent induction of TAK1 complex 11 3.03e-01 4.53e-01 0.27200 -4.33e-02 2.69e-01 8.04e-01 1.23e-01
Programmed Cell Death 175 1.23e-08 3.74e-07 0.27200 -6.16e-02 2.65e-01 1.61e-01 1.59e-09
Post-translational protein phosphorylation 90 5.27e-06 5.64e-05 0.27200 1.22e-01 2.43e-01 4.51e-02 7.00e-05
rRNA processing in the nucleus and cytosol 154 7.37e-09 2.52e-07 0.27200 3.75e-02 2.69e-01 4.23e-01 8.49e-09
Cellular response to heat stress 93 1.61e-04 1.09e-03 0.27100 -1.35e-01 2.35e-01 2.45e-02 8.91e-05
TNFR2 non-canonical NF-kB pathway 90 2.85e-04 1.77e-03 0.27100 -2.08e-01 1.74e-01 6.57e-04 4.45e-03
Plasma lipoprotein remodeling 27 5.63e-02 1.34e-01 0.27100 2.67e-01 -4.67e-02 1.65e-02 6.75e-01
Membrane binding and targetting of GAG proteins 14 2.18e-01 3.56e-01 0.27100 -3.30e-02 2.69e-01 8.31e-01 8.19e-02
Synthesis And Processing Of GAG, GAGPOL Polyproteins 14 2.18e-01 3.56e-01 0.27100 -3.30e-02 2.69e-01 8.31e-01 8.19e-02
Constitutive Signaling by NOTCH1 HD Domain Mutants 15 2.52e-01 3.97e-01 0.27000 -2.24e-01 1.52e-01 1.34e-01 3.10e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer 15 2.52e-01 3.97e-01 0.27000 -2.24e-01 1.52e-01 1.34e-01 3.10e-01
Interleukin-27 signaling 10 4.01e-01 5.42e-01 0.27000 -1.57e-01 2.20e-01 3.91e-01 2.29e-01
Extra-nuclear estrogen signaling 67 9.35e-04 4.93e-03 0.27000 -5.52e-02 2.64e-01 4.35e-01 1.88e-04
Regulation of Complement cascade 52 5.48e-03 2.19e-02 0.26900 -7.84e-02 2.58e-01 3.28e-01 1.31e-03
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion 14 2.64e-01 4.09e-01 0.26800 -1.10e-01 2.45e-01 4.76e-01 1.13e-01
EPH-Ephrin signaling 89 4.54e-05 3.66e-04 0.26800 5.55e-04 2.68e-01 9.93e-01 1.25e-05
Cleavage of the damaged purine 17 2.19e-01 3.56e-01 0.26800 2.13e-01 -1.62e-01 1.28e-01 2.48e-01
Depurination 17 2.19e-01 3.56e-01 0.26800 2.13e-01 -1.62e-01 1.28e-01 2.48e-01
Recognition and association of DNA glycosylase with site containing an affected purine 17 2.19e-01 3.56e-01 0.26800 2.13e-01 -1.62e-01 1.28e-01 2.48e-01
ADP signalling through P2Y purinoceptor 12 19 1.21e-01 2.38e-01 0.26700 -3.23e-03 2.67e-01 9.81e-01 4.40e-02
Methylation 12 2.94e-01 4.44e-01 0.26700 -2.61e-01 5.44e-02 1.18e-01 7.44e-01
Non-integrin membrane-ECM interactions 41 4.09e-03 1.76e-02 0.26700 1.63e-01 2.11e-01 7.03e-02 1.97e-02
Respiratory electron transport 99 2.09e-06 2.50e-05 0.26600 2.21e-01 1.48e-01 1.44e-04 1.12e-02
Lagging Strand Synthesis 19 1.15e-01 2.30e-01 0.26600 2.65e-01 1.76e-02 4.56e-02 8.95e-01
Pyruvate metabolism 28 7.57e-02 1.71e-01 0.26500 -1.15e-01 2.39e-01 2.91e-01 2.85e-02
IRAK2 mediated activation of TAK1 complex 10 3.60e-01 5.04e-01 0.26500 -4.84e-02 2.61e-01 7.91e-01 1.53e-01
p38MAPK events 13 2.60e-01 4.07e-01 0.26500 -3.64e-02 2.62e-01 8.20e-01 1.02e-01
Pyruvate metabolism and Citric Acid (TCA) cycle 52 3.41e-03 1.53e-02 0.26400 1.41e-03 2.64e-01 9.86e-01 1.00e-03
Branched-chain amino acid catabolism 21 1.51e-01 2.78e-01 0.26300 -2.34e-01 1.20e-01 6.29e-02 3.40e-01
Translation 256 4.93e-11 3.40e-09 0.26300 -8.73e-02 2.48e-01 1.65e-02 9.09e-12
DNA Damage/Telomere Stress Induced Senescence 39 1.27e-02 4.33e-02 0.26300 2.62e-01 2.22e-02 4.71e-03 8.10e-01
Gap-filling DNA repair synthesis and ligation in GG-NER 24 4.36e-02 1.13e-01 0.26200 1.73e-01 1.97e-01 1.41e-01 9.54e-02
Dissolution of Fibrin Clot 12 2.60e-01 4.07e-01 0.26200 2.52e-02 2.61e-01 8.80e-01 1.18e-01
Activated NOTCH1 Transmits Signal to the Nucleus 29 7.30e-02 1.66e-01 0.26200 -2.38e-01 1.09e-01 2.66e-02 3.08e-01
Glucagon-type ligand receptors 23 7.97e-02 1.77e-01 0.26200 1.42e-02 2.61e-01 9.06e-01 3.00e-02
Signaling by Activin 12 2.80e-01 4.27e-01 0.26200 2.62e-01 -7.84e-03 1.17e-01 9.62e-01
Switching of origins to a post-replicative state 88 4.52e-04 2.59e-03 0.26100 -1.28e-01 2.28e-01 3.87e-02 2.17e-04
Glycolysis 66 2.92e-04 1.79e-03 0.26000 2.34e-01 1.14e-01 1.02e-03 1.11e-01
Transcription of E2F targets under negative control by DREAM complex 19 1.41e-01 2.65e-01 0.26000 -1.58e-02 2.59e-01 9.05e-01 5.06e-02
The role of Nef in HIV-1 replication and disease pathogenesis 27 1.02e-01 2.10e-01 0.25900 -1.44e-01 2.16e-01 1.97e-01 5.24e-02
Degradation of cysteine and homocysteine 13 3.38e-01 4.82e-01 0.25900 1.99e-01 -1.65e-01 2.13e-01 3.02e-01
Transcription of the HIV genome 68 1.34e-03 6.79e-03 0.25900 -4.48e-02 2.55e-01 5.23e-01 2.78e-04
Phase 2 - plateau phase 12 3.70e-01 5.13e-01 0.25800 2.04e-01 -1.57e-01 2.21e-01 3.45e-01
ECM proteoglycans 47 3.01e-03 1.40e-02 0.25700 2.14e-01 1.42e-01 1.11e-02 9.30e-02
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 72 2.89e-03 1.35e-02 0.25700 -1.71e-01 1.91e-01 1.19e-02 5.13e-03
trans-Golgi Network Vesicle Budding 70 3.42e-03 1.53e-02 0.25600 -1.74e-01 1.88e-01 1.19e-02 6.44e-03
Polymerase switching on the C-strand of the telomere 25 1.28e-01 2.46e-01 0.25600 2.08e-01 -1.50e-01 7.19e-02 1.94e-01
NOTCH2 intracellular domain regulates transcription 11 2.54e-01 3.99e-01 0.25600 1.94e-01 1.67e-01 2.64e-01 3.38e-01
Platelet degranulation 118 5.21e-06 5.61e-05 0.25600 4.45e-03 2.56e-01 9.34e-01 1.57e-06
Activation of the pre-replicative complex 32 1.88e-02 5.92e-02 0.25600 1.62e-01 1.98e-01 1.12e-01 5.26e-02
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 16 1.65e-01 2.99e-01 0.25600 6.22e-02 2.48e-01 6.67e-01 8.61e-02
Zinc transporters 16 2.03e-01 3.41e-01 0.25600 -2.55e-01 1.58e-02 7.73e-02 9.13e-01
Base Excision Repair 51 6.55e-03 2.52e-02 0.25500 2.55e-01 -2.10e-02 1.67e-03 7.96e-01
Synthesis of PE 13 3.33e-01 4.77e-01 0.25500 2.27e-01 -1.17e-01 1.57e-01 4.65e-01
Anti-inflammatory response favouring Leishmania parasite infection 125 1.81e-05 1.66e-04 0.25500 -8.98e-02 2.39e-01 8.33e-02 4.05e-06
Leishmania parasite growth and survival 125 1.81e-05 1.66e-04 0.25500 -8.98e-02 2.39e-01 8.33e-02 4.05e-06
EGR2 and SOX10-mediated initiation of Schwann cell myelination 25 7.58e-02 1.71e-01 0.25500 8.64e-03 2.55e-01 9.40e-01 2.76e-02
Signaling by high-kinase activity BRAF mutants 33 4.67e-02 1.18e-01 0.25500 -5.30e-02 2.49e-01 5.98e-01 1.33e-02
Budding and maturation of HIV virion 26 7.50e-02 1.70e-01 0.25500 -1.15e-02 2.54e-01 9.19e-01 2.49e-02
Prostacyclin signalling through prostacyclin receptor 17 1.99e-01 3.36e-01 0.25400 -3.93e-02 2.51e-01 7.79e-01 7.27e-02
SIRT1 negatively regulates rRNA expression 17 1.28e-01 2.46e-01 0.25400 2.15e-01 1.37e-01 1.26e-01 3.29e-01
Fatty acyl-CoA biosynthesis 29 8.05e-02 1.78e-01 0.25400 -9.18e-02 2.37e-01 3.92e-01 2.71e-02
Vitamin D (calciferol) metabolism 11 3.42e-01 4.86e-01 0.25400 2.53e-01 -1.97e-02 1.47e-01 9.10e-01
Paradoxical activation of RAF signaling by kinase inactive BRAF 41 2.54e-02 7.41e-02 0.25400 -6.84e-02 2.44e-01 4.49e-01 6.86e-03
Signaling by RAS mutants 41 2.54e-02 7.41e-02 0.25400 -6.84e-02 2.44e-01 4.49e-01 6.86e-03
Signaling by moderate kinase activity BRAF mutants 41 2.54e-02 7.41e-02 0.25400 -6.84e-02 2.44e-01 4.49e-01 6.86e-03
Signaling downstream of RAS mutants 41 2.54e-02 7.41e-02 0.25400 -6.84e-02 2.44e-01 4.49e-01 6.86e-03
Voltage gated Potassium channels 35 3.12e-02 8.64e-02 0.25300 9.22e-03 -2.53e-01 9.25e-01 9.56e-03
APC/C:Cdc20 mediated degradation of mitotic proteins 73 3.10e-03 1.43e-02 0.25300 -1.70e-01 1.88e-01 1.21e-02 5.56e-03
Signaling by EGFR 46 2.27e-02 6.79e-02 0.25300 -2.21e-01 1.24e-01 9.56e-03 1.46e-01
Condensation of Prometaphase Chromosomes 11 2.64e-01 4.09e-01 0.25300 1.63e-01 1.93e-01 3.49e-01 2.68e-01
HIV Infection 222 1.07e-08 3.42e-07 0.25200 -1.06e-01 2.29e-01 6.37e-03 4.51e-09
p53-Dependent G1 DNA Damage Response 62 7.81e-03 2.94e-02 0.25200 -1.74e-01 1.82e-01 1.78e-02 1.32e-02
p53-Dependent G1/S DNA damage checkpoint 62 7.81e-03 2.94e-02 0.25200 -1.74e-01 1.82e-01 1.78e-02 1.32e-02
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells 14 1.86e-01 3.21e-01 0.25200 1.63e-01 1.92e-01 2.90e-01 2.15e-01
Signaling by BMP 23 8.97e-02 1.92e-01 0.25100 3.42e-02 2.49e-01 7.77e-01 3.86e-02
Ketone body metabolism 10 4.51e-01 5.87e-01 0.25100 -2.08e-01 1.41e-01 2.55e-01 4.40e-01
TRAF6-mediated induction of TAK1 complex within TLR4 complex 15 2.79e-01 4.27e-01 0.25100 -8.86e-02 2.35e-01 5.53e-01 1.15e-01
O-glycosylation of TSR domain-containing proteins 37 1.20e-02 4.13e-02 0.25100 1.73e-01 1.82e-01 6.87e-02 5.58e-02
Selenoamino acid metabolism 83 5.28e-05 4.16e-04 0.25100 1.55e-01 1.97e-01 1.44e-02 1.94e-03
Complex I biogenesis 55 1.48e-03 7.42e-03 0.25100 1.99e-01 1.53e-01 1.08e-02 5.04e-02
Pregnenolone biosynthesis 11 2.96e-01 4.46e-01 0.25000 -7.74e-02 -2.38e-01 6.57e-01 1.71e-01
Transcriptional Regulation by E2F6 34 5.38e-02 1.30e-01 0.25000 -7.56e-02 2.38e-01 4.46e-01 1.62e-02
Retrograde neurotrophin signalling 14 3.00e-01 4.50e-01 0.25000 -7.51e-02 2.38e-01 6.27e-01 1.23e-01
Interleukin-2 signaling 11 2.84e-01 4.32e-01 0.25000 -2.23e-01 -1.13e-01 2.01e-01 5.18e-01
Interleukin-2 family signaling 36 3.42e-02 9.21e-02 0.24900 -2.48e-01 2.24e-02 9.93e-03 8.16e-01
Host Interactions of HIV factors 126 6.12e-05 4.68e-04 0.24900 -1.52e-01 1.97e-01 3.21e-03 1.31e-04
Sialic acid metabolism 28 7.57e-02 1.71e-01 0.24900 -3.14e-02 2.47e-01 7.73e-01 2.36e-02
Response to elevated platelet cytosolic Ca2+ 123 8.33e-06 8.53e-05 0.24900 -1.02e-02 2.49e-01 8.45e-01 1.90e-06
Activation of the phototransduction cascade 10 4.02e-01 5.42e-01 0.24900 3.82e-02 -2.46e-01 8.34e-01 1.78e-01
Translation of structural proteins 28 1.11e-01 2.24e-01 0.24900 -2.10e-01 1.34e-01 5.46e-02 2.20e-01
S Phase 158 9.88e-07 1.36e-05 0.24900 -5.55e-02 2.43e-01 2.30e-01 1.46e-07
PCP/CE pathway 89 1.13e-03 5.83e-03 0.24800 -1.90e-01 1.60e-01 1.94e-03 9.29e-03
Defective B3GALTL causes Peters-plus syndrome (PpS) 36 1.49e-02 4.90e-02 0.24800 1.69e-01 1.81e-01 7.87e-02 5.98e-02
Signaling by TGF-beta Receptor Complex 73 3.25e-03 1.48e-02 0.24800 -1.21e-01 2.16e-01 7.44e-02 1.42e-03
Intrinsic Pathway of Fibrin Clot Formation 16 1.56e-01 2.85e-01 0.24700 1.70e-01 1.80e-01 2.39e-01 2.14e-01
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins 74 4.03e-03 1.74e-02 0.24600 -1.67e-01 1.81e-01 1.31e-02 7.28e-03
p75NTR signals via NF-kB 16 3.02e-01 4.51e-01 0.24600 -1.62e-01 1.85e-01 2.62e-01 2.00e-01
Formation of RNA Pol II elongation complex 57 6.12e-03 2.39e-02 0.24600 -3.17e-02 2.44e-01 6.79e-01 1.47e-03
RNA Polymerase II Transcription Elongation 57 6.12e-03 2.39e-02 0.24600 -3.17e-02 2.44e-01 6.79e-01 1.47e-03
Defects in vitamin and cofactor metabolism 21 1.21e-01 2.38e-01 0.24500 -2.42e-01 -3.96e-02 5.52e-02 7.54e-01
Signalling to RAS 19 2.12e-01 3.51e-01 0.24500 -8.11e-02 2.31e-01 5.41e-01 8.14e-02
Alpha-protein kinase 1 signaling pathway 11 3.27e-01 4.69e-01 0.24500 4.76e-02 2.40e-01 7.85e-01 1.68e-01
ER to Golgi Anterograde Transport 126 7.20e-05 5.31e-04 0.24500 -1.27e-01 2.09e-01 1.38e-02 5.18e-05
Processing of Intronless Pre-mRNAs 17 2.11e-01 3.49e-01 0.24500 -2.44e-01 1.40e-02 8.13e-02 9.20e-01
Triglyceride catabolism 18 1.31e-01 2.51e-01 0.24400 1.53e-01 1.90e-01 2.61e-01 1.62e-01
Triglyceride biosynthesis 12 4.14e-01 5.54e-01 0.24400 1.82e-01 -1.62e-01 2.76e-01 3.30e-01
Carnitine metabolism 12 3.18e-01 4.62e-01 0.24300 2.43e-01 1.56e-02 1.45e-01 9.26e-01
Keratan sulfate biosynthesis 24 7.59e-02 1.71e-01 0.24300 1.03e-01 2.20e-01 3.83e-01 6.24e-02
Ion transport by P-type ATPases 46 1.55e-02 5.08e-02 0.24300 -9.99e-03 2.42e-01 9.07e-01 4.45e-03
COPII-mediated vesicle transport 63 1.05e-02 3.68e-02 0.24200 -1.65e-01 1.77e-01 2.35e-02 1.51e-02
Translocation of ZAP-70 to Immunological synapse 13 2.62e-01 4.08e-01 0.24200 -2.31e-01 -7.21e-02 1.49e-01 6.53e-01
VEGFR2 mediated cell proliferation 19 2.54e-01 3.99e-01 0.24200 -1.67e-01 1.74e-01 2.07e-01 1.88e-01
DAP12 interactions 34 8.62e-02 1.87e-01 0.24100 -1.79e-01 1.63e-01 7.16e-02 1.01e-01
RUNX2 regulates osteoblast differentiation 22 1.18e-01 2.36e-01 0.24100 3.60e-02 2.39e-01 7.70e-01 5.28e-02
Pyrimidine catabolism 12 2.70e-01 4.16e-01 0.24100 2.01e-01 1.34e-01 2.29e-01 4.23e-01
Regulation of APC/C activators between G1/S and early anaphase 78 3.78e-03 1.67e-02 0.24100 -1.73e-01 1.68e-01 8.43e-03 1.03e-02
Caspase activation via Death Receptors in the presence of ligand 13 3.93e-01 5.36e-01 0.24100 -1.81e-01 1.59e-01 2.58e-01 3.22e-01
Signaling by ERBB2 ECD mutants 16 3.18e-01 4.62e-01 0.24100 -1.72e-01 1.68e-01 2.33e-01 2.44e-01
The citric acid (TCA) cycle and respiratory electron transport 168 1.10e-08 3.43e-07 0.24100 1.62e-01 1.78e-01 2.88e-04 7.32e-05
Processive synthesis on the lagging strand 14 3.40e-01 4.84e-01 0.24100 2.22e-01 -9.29e-02 1.50e-01 5.47e-01
Signaling by Erythropoietin 25 1.64e-01 2.98e-01 0.24100 -1.44e-01 1.93e-01 2.12e-01 9.58e-02
RHO GTPases Activate NADPH Oxidases 21 1.77e-01 3.11e-01 0.24000 -2.35e-01 5.19e-02 6.25e-02 6.81e-01
G1/S Transition 128 2.93e-05 2.55e-04 0.24000 -5.43e-02 2.34e-01 2.89e-01 4.92e-06
Telomere C-strand (Lagging Strand) Synthesis 33 7.21e-02 1.65e-01 0.24000 2.30e-01 -6.98e-02 2.24e-02 4.88e-01
Toll-like Receptor Cascades 138 1.08e-05 1.06e-04 0.24000 -4.42e-02 2.36e-01 3.71e-01 1.74e-06
G1/S DNA Damage Checkpoints 64 1.07e-02 3.75e-02 0.24000 -1.70e-01 1.69e-01 1.84e-02 1.96e-02
Removal of the Flap Intermediate from the C-strand 16 2.38e-01 3.81e-01 0.23900 2.39e-01 -4.04e-04 9.74e-02 9.98e-01
Glycogen metabolism 26 8.26e-02 1.81e-01 0.23900 3.86e-02 2.36e-01 7.33e-01 3.71e-02
Sema4D induced cell migration and growth-cone collapse 20 1.19e-01 2.36e-01 0.23900 2.05e-01 1.24e-01 1.13e-01 3.38e-01
Infectious disease 693 4.47e-24 3.13e-21 0.23900 -5.48e-02 2.32e-01 1.46e-02 3.51e-25
Signaling by PDGF 50 1.81e-02 5.72e-02 0.23800 -5.72e-02 2.31e-01 4.84e-01 4.65e-03
G beta:gamma signalling through BTK 16 2.50e-01 3.96e-01 0.23800 -1.59e-02 2.38e-01 9.12e-01 9.96e-02
Mitochondrial Fatty Acid Beta-Oxidation 34 6.68e-02 1.54e-01 0.23800 -6.09e-02 2.30e-01 5.39e-01 2.02e-02
Sema4D in semaphorin signaling 24 7.89e-02 1.75e-01 0.23700 1.35e-01 1.95e-01 2.53e-01 9.77e-02
Circadian Clock 67 4.88e-03 2.00e-02 0.23700 -5.48e-02 2.31e-01 4.38e-01 1.11e-03
Signaling by Hedgehog 133 7.99e-05 5.87e-04 0.23500 -2.07e-01 1.12e-01 3.83e-05 2.61e-02
Cholesterol biosynthesis 24 1.92e-01 3.29e-01 0.23400 1.92e-01 -1.33e-01 1.03e-01 2.59e-01
PTEN Regulation 139 8.95e-05 6.47e-04 0.23400 -1.61e-01 1.70e-01 1.08e-03 5.59e-04
Downregulation of ERBB2:ERBB3 signaling 13 4.02e-01 5.42e-01 0.23400 -1.16e-01 2.03e-01 4.69e-01 2.05e-01
FGFR2 ligand binding and activation 10 5.05e-01 6.22e-01 0.23200 1.94e-01 -1.28e-01 2.88e-01 4.83e-01
SHC1 events in ERBB4 signaling 12 3.87e-01 5.31e-01 0.23200 -3.70e-02 2.29e-01 8.24e-01 1.69e-01
Insulin processing 25 1.74e-01 3.08e-01 0.23200 -1.06e-01 2.07e-01 3.58e-01 7.38e-02
Ion homeostasis 43 1.79e-02 5.65e-02 0.23100 7.00e-02 2.20e-01 4.27e-01 1.26e-02
Activated NTRK2 signals through FRS2 and FRS3 11 4.68e-01 5.95e-01 0.23000 -1.04e-01 2.06e-01 5.51e-01 2.38e-01
Disorders of Developmental Biology 13 3.94e-01 5.36e-01 0.23000 -7.95e-02 2.16e-01 6.20e-01 1.78e-01
Disorders of Nervous System Development 13 3.94e-01 5.36e-01 0.23000 -7.95e-02 2.16e-01 6.20e-01 1.78e-01
Loss of function of MECP2 in Rett syndrome 13 3.94e-01 5.36e-01 0.23000 -7.95e-02 2.16e-01 6.20e-01 1.78e-01
Pervasive developmental disorders 13 3.94e-01 5.36e-01 0.23000 -7.95e-02 2.16e-01 6.20e-01 1.78e-01
rRNA modification in the nucleus and cytosol 55 1.99e-02 6.15e-02 0.23000 -8.10e-02 2.15e-01 2.99e-01 5.78e-03
Aggrephagy 20 2.70e-01 4.16e-01 0.23000 -1.54e-01 1.70e-01 2.32e-01 1.88e-01
COPI-mediated anterograde transport 77 4.84e-03 1.98e-02 0.23000 -9.55e-02 2.09e-01 1.48e-01 1.54e-03
NRIF signals cell death from the nucleus 16 3.51e-01 4.94e-01 0.23000 -1.45e-01 1.78e-01 3.16e-01 2.18e-01
DNA Damage Bypass 46 1.31e-02 4.42e-02 0.22900 8.26e-02 2.14e-01 3.33e-01 1.20e-02
Signaling by NODAL 16 2.84e-01 4.32e-01 0.22900 2.28e-01 -2.34e-02 1.15e-01 8.71e-01
Hedgehog 'off' state 98 1.50e-03 7.48e-03 0.22900 -1.96e-01 1.18e-01 8.11e-04 4.37e-02
HIV Transcription Initiation 46 3.19e-02 8.70e-02 0.22900 -4.61e-02 2.24e-01 5.89e-01 8.65e-03
RNA Polymerase II HIV Promoter Escape 46 3.19e-02 8.70e-02 0.22900 -4.61e-02 2.24e-01 5.89e-01 8.65e-03
RNA Polymerase II Promoter Escape 46 3.19e-02 8.70e-02 0.22900 -4.61e-02 2.24e-01 5.89e-01 8.65e-03
RNA Polymerase II Transcription Initiation 46 3.19e-02 8.70e-02 0.22900 -4.61e-02 2.24e-01 5.89e-01 8.65e-03
RNA Polymerase II Transcription Initiation And Promoter Clearance 46 3.19e-02 8.70e-02 0.22900 -4.61e-02 2.24e-01 5.89e-01 8.65e-03
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening 46 3.19e-02 8.70e-02 0.22900 -4.61e-02 2.24e-01 5.89e-01 8.65e-03
Asparagine N-linked glycosylation 265 4.38e-08 1.10e-06 0.22800 -1.80e-01 1.40e-01 4.83e-07 8.72e-05
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 44 5.64e-02 1.35e-01 0.22800 -1.30e-01 1.88e-01 1.37e-01 3.13e-02
SLC-mediated transmembrane transport 217 9.57e-07 1.34e-05 0.22800 1.44e-01 -1.77e-01 2.56e-04 7.60e-06
NF-kB is activated and signals survival 13 4.33e-01 5.70e-01 0.22800 -1.73e-01 1.48e-01 2.80e-01 3.55e-01
PERK regulates gene expression 30 1.37e-01 2.60e-01 0.22800 -1.18e-01 1.95e-01 2.64e-01 6.45e-02
Regulation of TP53 Expression and Degradation 34 5.83e-02 1.37e-01 0.22700 1.82e-02 2.26e-01 8.55e-01 2.23e-02
Estrogen-dependent nuclear events downstream of ESR-membrane signaling 21 2.16e-01 3.55e-01 0.22700 -5.38e-02 2.20e-01 6.70e-01 8.03e-02
CRMPs in Sema3A signaling 16 3.61e-01 5.05e-01 0.22700 -1.48e-01 1.71e-01 3.05e-01 2.36e-01
RAF-independent MAPK1/3 activation 22 1.81e-01 3.16e-01 0.22600 -1.62e-02 2.25e-01 8.95e-01 6.73e-02
Interleukin-4 and Interleukin-13 signaling 95 4.98e-04 2.84e-03 0.22600 4.07e-03 2.26e-01 9.45e-01 1.47e-04
Signaling by WNT in cancer 33 4.14e-02 1.08e-01 0.22600 1.68e-01 1.50e-01 9.47e-02 1.35e-01
Extracellular matrix organization 252 2.09e-10 1.22e-08 0.22500 6.98e-02 2.14e-01 5.70e-02 4.94e-09
Mitochondrial translation 94 2.05e-03 9.97e-03 0.22500 -1.01e-01 2.02e-01 9.15e-02 7.38e-04
Signaling by FGFR2 IIIa TM 19 1.69e-01 3.04e-01 0.22500 1.04e-01 2.00e-01 4.35e-01 1.31e-01
AKT phosphorylates targets in the cytosol 14 3.08e-01 4.55e-01 0.22500 3.34e-02 2.22e-01 8.29e-01 1.50e-01
VLDLR internalisation and degradation 12 4.61e-01 5.93e-01 0.22500 -1.94e-01 1.12e-01 2.44e-01 5.00e-01
Signaling by TGFB family members 96 1.01e-03 5.25e-03 0.22400 -4.65e-02 2.19e-01 4.31e-01 2.04e-04
Synthesis of PIPs at the plasma membrane 52 2.31e-02 6.85e-02 0.22400 -4.33e-02 2.20e-01 5.90e-01 6.05e-03
Leishmania infection 204 3.73e-07 6.08e-06 0.22400 -3.74e-02 2.21e-01 3.59e-01 5.45e-08
TP53 Regulates Transcription of Cell Cycle Genes 46 1.43e-02 4.73e-02 0.22400 1.99e-01 1.04e-01 1.98e-02 2.23e-01
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation 10 5.11e-01 6.26e-01 0.22400 -2.08e-01 8.36e-02 2.55e-01 6.47e-01
Mitotic G1 phase and G1/S transition 145 3.02e-05 2.60e-04 0.22400 -4.32e-02 2.20e-01 3.70e-01 5.07e-06
G-protein activation 24 1.39e-01 2.62e-01 0.22400 2.49e-02 2.22e-01 8.33e-01 5.93e-02
Mitochondrial translation initiation 88 2.33e-03 1.12e-02 0.22300 -6.38e-02 2.14e-01 3.02e-01 5.24e-04
TP53 Regulates Transcription of Caspase Activators and Caspases 11 3.67e-01 5.10e-01 0.22300 -2.00e-01 -9.94e-02 2.52e-01 5.68e-01
Processing of Capped Intronless Pre-mRNA 25 1.01e-01 2.09e-01 0.22300 -1.96e-01 -1.07e-01 9.07e-02 3.56e-01
Cyclin A/B1/B2 associated events during G2/M transition 24 1.34e-01 2.56e-01 0.22300 2.19e-01 4.17e-02 6.37e-02 7.24e-01
Opioid Signalling 84 5.73e-04 3.22e-03 0.22300 8.36e-02 2.06e-01 1.86e-01 1.09e-03
Intra-Golgi traffic 41 4.41e-02 1.13e-01 0.22300 -1.00e-02 2.22e-01 9.12e-01 1.38e-02
Polo-like kinase mediated events 16 3.57e-01 5.01e-01 0.22300 1.98e-01 -1.01e-01 1.70e-01 4.84e-01
Transport to the Golgi and subsequent modification 153 6.74e-05 5.00e-04 0.22200 -1.06e-01 1.95e-01 2.38e-02 3.35e-05
Mitochondrial translation termination 88 2.76e-03 1.30e-02 0.22100 -6.83e-02 2.10e-01 2.69e-01 6.48e-04
Separation of Sister Chromatids 166 2.96e-05 2.56e-04 0.22100 -1.03e-01 1.96e-01 2.21e-02 1.38e-05
MAP2K and MAPK activation 37 7.48e-02 1.70e-01 0.22100 -4.50e-02 2.16e-01 6.36e-01 2.28e-02
Regulation of TP53 Degradation 33 6.46e-02 1.50e-01 0.22100 4.71e-02 2.16e-01 6.40e-01 3.22e-02
Zinc influx into cells by the SLC39 gene family 10 4.10e-01 5.50e-01 0.22000 -1.96e-01 -1.00e-01 2.83e-01 5.83e-01
RAB geranylgeranylation 59 1.05e-02 3.68e-02 0.22000 1.22e-02 2.19e-01 8.71e-01 3.59e-03
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain 13 4.40e-01 5.78e-01 0.22000 -1.98e-01 9.57e-02 2.17e-01 5.50e-01
Adaptive Immune System 663 3.43e-17 6.01e-15 0.21900 -1.41e-01 1.67e-01 6.49e-10 2.84e-13
Removal of the Flap Intermediate 13 4.44e-01 5.82e-01 0.21900 1.95e-01 -9.87e-02 2.22e-01 5.38e-01
Formation of HIV-1 elongation complex containing HIV-1 Tat 42 2.95e-02 8.38e-02 0.21800 6.94e-02 2.07e-01 4.37e-01 2.06e-02
HIV Transcription Elongation 42 2.95e-02 8.38e-02 0.21800 6.94e-02 2.07e-01 4.37e-01 2.06e-02
Tat-mediated elongation of the HIV-1 transcript 42 2.95e-02 8.38e-02 0.21800 6.94e-02 2.07e-01 4.37e-01 2.06e-02
TRP channels 20 3.11e-01 4.59e-01 0.21700 1.59e-01 -1.48e-01 2.18e-01 2.52e-01
Clathrin-mediated endocytosis 133 1.24e-04 8.72e-04 0.21700 -4.15e-02 2.13e-01 4.09e-01 2.22e-05
Diseases of programmed cell death 26 1.05e-01 2.14e-01 0.21700 1.92e-01 1.01e-01 9.02e-02 3.72e-01
Global Genome Nucleotide Excision Repair (GG-NER) 82 1.62e-03 8.07e-03 0.21700 3.40e-02 2.14e-01 5.95e-01 8.05e-04
Iron uptake and transport 56 3.09e-02 8.61e-02 0.21700 -8.73e-02 1.99e-01 2.59e-01 1.02e-02
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion 38 3.38e-02 9.11e-02 0.21700 1.59e-01 1.47e-01 9.01e-02 1.16e-01
Downstream signal transduction 29 1.77e-01 3.11e-01 0.21700 -1.11e-01 1.86e-01 3.02e-01 8.30e-02
PI-3K cascade:FGFR4 12 4.29e-01 5.67e-01 0.21600 -2.15e-01 1.93e-02 1.97e-01 9.08e-01
Synthesis of glycosylphosphatidylinositol (GPI) 17 2.91e-01 4.41e-01 0.21600 3.86e-03 -2.16e-01 9.78e-01 1.23e-01
Aberrant regulation of mitotic cell cycle due to RB1 defects 35 5.10e-02 1.26e-01 0.21600 1.94e-01 9.49e-02 4.76e-02 3.31e-01
Diseases of mitotic cell cycle 35 5.10e-02 1.26e-01 0.21600 1.94e-01 9.49e-02 4.76e-02 3.31e-01
Mitochondrial translation elongation 88 3.58e-03 1.59e-02 0.21500 -6.11e-02 2.06e-01 3.22e-01 8.26e-04
PLC beta mediated events 50 1.72e-02 5.51e-02 0.21500 6.49e-02 2.05e-01 4.28e-01 1.22e-02
Late endosomal microautophagy 29 1.17e-01 2.33e-01 0.21500 1.07e-02 2.15e-01 9.21e-01 4.54e-02
HCMV Late Events 63 4.56e-03 1.93e-02 0.21500 1.86e-01 1.08e-01 1.08e-02 1.38e-01
Vesicle-mediated transport 622 2.63e-17 5.27e-15 0.21500 -6.29e-02 2.05e-01 7.76e-03 3.39e-18
G-protein mediated events 51 1.67e-02 5.35e-02 0.21500 6.03e-02 2.06e-01 4.57e-01 1.10e-02
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 19 3.37e-01 4.81e-01 0.21400 -1.72e-01 1.28e-01 1.95e-01 3.35e-01
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) 13 3.76e-01 5.18e-01 0.21400 2.53e-02 2.12e-01 8.74e-01 1.85e-01
Transport of vitamins, nucleosides, and related molecules 34 1.45e-01 2.69e-01 0.21400 1.68e-01 -1.32e-01 8.95e-02 1.84e-01
Mitophagy 27 2.18e-01 3.56e-01 0.21400 -1.43e-01 1.59e-01 1.99e-01 1.54e-01
Phase 4 - resting membrane potential 11 4.28e-01 5.67e-01 0.21300 -2.10e-01 -4.07e-02 2.29e-01 8.15e-01
EPH-ephrin mediated repulsion of cells 47 2.86e-02 8.24e-02 0.21300 3.11e-02 2.11e-01 7.12e-01 1.23e-02
Dopamine Neurotransmitter Release Cycle 20 3.12e-01 4.59e-01 0.21300 1.07e-01 -1.85e-01 4.09e-01 1.53e-01
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters 20 2.68e-01 4.13e-01 0.21300 -3.79e-02 2.10e-01 7.70e-01 1.05e-01
Platelet activation, signaling and aggregation 242 3.93e-07 6.34e-06 0.21200 -6.71e-02 2.02e-01 7.26e-02 7.04e-08
Formation of HIV elongation complex in the absence of HIV Tat 44 3.10e-02 8.61e-02 0.21200 6.12e-02 2.03e-01 4.83e-01 1.96e-02
Signal amplification 29 1.63e-01 2.97e-01 0.21200 -6.03e-02 2.04e-01 5.74e-01 5.78e-02
Oncogenic MAPK signaling 77 6.97e-03 2.67e-02 0.21200 -4.28e-02 2.08e-01 5.17e-01 1.62e-03
EGFR downregulation 27 2.13e-01 3.52e-01 0.21200 -1.82e-01 1.09e-01 1.02e-01 3.27e-01
Basigin interactions 24 1.52e-01 2.79e-01 0.21200 2.02e-01 6.25e-02 8.65e-02 5.96e-01
Synthesis, secretion, and deacylation of Ghrelin 13 4.87e-01 6.09e-01 0.21100 -1.60e-01 1.39e-01 3.19e-01 3.87e-01
tRNA Aminoacylation 42 6.27e-02 1.46e-01 0.21100 -2.09e-01 2.89e-02 1.89e-02 7.46e-01
Inwardly rectifying K+ channels 28 1.98e-01 3.35e-01 0.21100 -9.53e-02 1.88e-01 3.83e-01 8.47e-02
HIV Life Cycle 145 6.69e-05 5.00e-04 0.21100 -2.10e-02 2.10e-01 6.63e-01 1.32e-05
Downregulation of ERBB2 signaling 27 2.27e-01 3.66e-01 0.21100 -1.58e-01 1.40e-01 1.57e-01 2.08e-01
Platelet Adhesion to exposed collagen 12 4.99e-01 6.18e-01 0.21100 -1.89e-01 9.31e-02 2.57e-01 5.76e-01
Downstream signaling of activated FGFR1 23 2.64e-01 4.09e-01 0.21100 -1.89e-01 9.32e-02 1.17e-01 4.39e-01
Toll Like Receptor 4 (TLR4) Cascade 117 5.94e-04 3.30e-03 0.21100 -4.11e-02 2.06e-01 4.43e-01 1.16e-04
Negative regulation of MAPK pathway 42 5.02e-02 1.25e-01 0.21100 1.29e-02 2.10e-01 8.85e-01 1.85e-02
Cargo recognition for clathrin-mediated endocytosis 95 3.84e-03 1.69e-02 0.21000 -8.25e-02 1.94e-01 1.65e-01 1.12e-03
Complement cascade 59 2.43e-02 7.19e-02 0.21000 -4.46e-02 2.05e-01 5.53e-01 6.40e-03
Biotin transport and metabolism 11 4.01e-01 5.42e-01 0.21000 -1.73e-01 -1.20e-01 3.22e-01 4.91e-01
Biosynthesis of DHA-derived SPMs 13 3.62e-01 5.05e-01 0.21000 6.86e-02 1.98e-01 6.69e-01 2.15e-01
SHC1 events in ERBB2 signaling 20 3.36e-01 4.80e-01 0.21000 -1.41e-01 1.55e-01 2.74e-01 2.29e-01
Vasopressin regulates renal water homeostasis via Aquaporins 39 3.87e-02 1.02e-01 0.21000 1.31e-01 1.64e-01 1.56e-01 7.68e-02
Synthesis of DNA 116 7.91e-04 4.25e-03 0.20900 -5.10e-02 2.03e-01 3.44e-01 1.59e-04
G2/M Checkpoints 133 4.50e-04 2.59e-03 0.20900 -8.08e-02 1.93e-01 1.08e-01 1.23e-04
HDR through MMEJ (alt-NHEJ) 10 5.50e-01 6.61e-01 0.20900 -6.67e-02 1.98e-01 7.15e-01 2.78e-01
Biosynthesis of specialized proresolving mediators (SPMs) 15 3.21e-01 4.63e-01 0.20800 6.02e-02 1.99e-01 6.87e-01 1.82e-01
Dual incision in TC-NER 64 5.98e-03 2.36e-02 0.20800 1.04e-01 1.80e-01 1.49e-01 1.30e-02
ESR-mediated signaling 160 4.48e-05 3.63e-04 0.20800 -3.34e-02 2.05e-01 4.67e-01 7.84e-06
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane 21 3.07e-01 4.55e-01 0.20700 -1.87e-01 9.06e-02 1.39e-01 4.72e-01
MET promotes cell motility 29 1.73e-01 3.08e-01 0.20700 -5.08e-02 2.01e-01 6.36e-01 6.12e-02
Cargo trafficking to the periciliary membrane 47 5.01e-02 1.25e-01 0.20700 -2.06e-01 2.54e-02 1.48e-02 7.64e-01
Extension of Telomeres 49 5.71e-02 1.36e-01 0.20700 1.96e-01 -6.67e-02 1.77e-02 4.20e-01
TAK1 activates NFkB by phosphorylation and activation of IKKs complex 24 1.52e-01 2.79e-01 0.20700 9.60e-02 1.83e-01 4.16e-01 1.21e-01
Senescence-Associated Secretory Phenotype (SASP) 55 1.67e-02 5.35e-02 0.20600 1.97e-01 5.98e-02 1.14e-02 4.43e-01
Purine ribonucleoside monophosphate biosynthesis 10 4.55e-01 5.88e-01 0.20600 9.95e-02 1.81e-01 5.86e-01 3.23e-01
Metal ion SLC transporters 24 2.80e-01 4.27e-01 0.20500 -1.68e-01 1.18e-01 1.54e-01 3.16e-01
APC/C-mediated degradation of cell cycle proteins 85 1.16e-02 4.03e-02 0.20500 -1.22e-01 1.65e-01 5.12e-02 8.72e-03
Regulation of mitotic cell cycle 85 1.16e-02 4.03e-02 0.20500 -1.22e-01 1.65e-01 5.12e-02 8.72e-03
Signaling by Interleukins 381 7.80e-10 3.90e-08 0.20500 -7.69e-02 1.90e-01 1.03e-02 2.09e-10
Mucopolysaccharidoses 11 4.91e-01 6.12e-01 0.20500 -2.05e-01 8.86e-03 2.40e-01 9.59e-01
Generation of second messenger molecules 27 2.07e-01 3.46e-01 0.20400 -1.97e-01 5.35e-02 7.63e-02 6.31e-01
Transcriptional regulation by RUNX2 114 2.20e-03 1.07e-02 0.20400 -9.11e-02 1.82e-01 9.31e-02 7.91e-04
MyD88-independent TLR4 cascade 91 4.03e-03 1.74e-02 0.20400 -3.11e-02 2.01e-01 6.08e-01 9.15e-04
TRIF(TICAM1)-mediated TLR4 signaling 91 4.03e-03 1.74e-02 0.20400 -3.11e-02 2.01e-01 6.08e-01 9.15e-04
Signaling by FGFR4 33 1.82e-01 3.17e-01 0.20300 -1.20e-01 1.64e-01 2.32e-01 1.04e-01
DNA Replication 123 6.83e-04 3.71e-03 0.20300 -3.73e-02 1.99e-01 4.75e-01 1.35e-04
Telomere Maintenance 71 1.16e-02 4.03e-02 0.20300 2.03e-01 -1.21e-02 3.19e-03 8.60e-01
MAP kinase activation 60 2.14e-02 6.46e-02 0.20300 -1.69e-03 2.03e-01 9.82e-01 6.65e-03
SUMOylation of transcription cofactors 42 9.90e-02 2.05e-01 0.20200 -1.89e-01 7.14e-02 3.40e-02 4.23e-01
Dermatan sulfate biosynthesis 11 4.30e-01 5.68e-01 0.20200 1.67e-01 1.14e-01 3.38e-01 5.13e-01
Telomere C-strand synthesis initiation 13 4.84e-01 6.06e-01 0.20200 6.47e-02 -1.91e-01 6.86e-01 2.32e-01
Metabolism of steroid hormones 23 1.70e-01 3.05e-01 0.20200 -1.61e-01 -1.22e-01 1.82e-01 3.10e-01
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes 28 1.15e-01 2.30e-01 0.20200 1.52e-01 1.33e-01 1.64e-01 2.25e-01
Interleukin-1 family signaling 126 1.44e-03 7.24e-03 0.20200 -9.93e-02 1.76e-01 5.46e-02 6.68e-04
IRE1alpha activates chaperones 50 5.86e-02 1.38e-01 0.20200 -1.94e-01 5.30e-02 1.74e-02 5.17e-01
Heme degradation 12 4.02e-01 5.42e-01 0.20100 1.09e-01 1.70e-01 5.14e-01 3.09e-01
Activation of G protein gated Potassium channels 24 2.64e-01 4.09e-01 0.20100 -6.38e-02 1.91e-01 5.89e-01 1.06e-01
G protein gated Potassium channels 24 2.64e-01 4.09e-01 0.20100 -6.38e-02 1.91e-01 5.89e-01 1.06e-01
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits 24 2.64e-01 4.09e-01 0.20100 -6.38e-02 1.91e-01 5.89e-01 1.06e-01
Diseases of signal transduction by growth factor receptors and second messengers 362 9.24e-09 3.01e-07 0.20100 -9.65e-02 1.77e-01 1.67e-03 8.66e-09
Nervous system development 494 2.15e-13 2.52e-11 0.20100 -1.98e-02 2.00e-01 4.53e-01 3.27e-14
Thromboxane signalling through TP receptor 21 3.07e-01 4.55e-01 0.20100 -5.59e-02 1.93e-01 6.58e-01 1.26e-01
XBP1(S) activates chaperone genes 48 6.79e-02 1.56e-01 0.20100 -1.93e-01 5.43e-02 2.07e-02 5.15e-01
Metabolism of RNA 629 2.03e-14 2.85e-12 0.20100 -9.31e-02 1.78e-01 7.40e-05 3.92e-14
Hyaluronan metabolism 16 4.52e-01 5.87e-01 0.20000 1.36e-01 -1.47e-01 3.47e-01 3.08e-01
Myogenesis 23 2.52e-01 3.98e-01 0.20000 -2.19e-02 1.99e-01 8.56e-01 9.88e-02
Mitochondrial calcium ion transport 22 2.48e-01 3.94e-01 0.20000 4.74e-03 2.00e-01 9.69e-01 1.05e-01
Viral Messenger RNA Synthesis 44 4.38e-02 1.13e-01 0.20000 1.87e-01 6.97e-02 3.19e-02 4.24e-01
Negative regulation of the PI3K/AKT network 94 5.20e-03 2.11e-02 0.20000 -4.89e-02 1.94e-01 4.13e-01 1.19e-03
Metabolism of Angiotensinogen to Angiotensins 13 4.69e-01 5.95e-01 0.20000 1.97e-01 -3.22e-02 2.19e-01 8.41e-01
Initiation of Nuclear Envelope (NE) Reformation 19 2.65e-01 4.09e-01 0.20000 1.91e-01 5.89e-02 1.50e-01 6.57e-01
PI-3K cascade:FGFR1 13 4.81e-01 6.05e-01 0.19900 -1.94e-01 4.46e-02 2.26e-01 7.81e-01
MET activates PTK2 signaling 18 2.91e-01 4.41e-01 0.19900 5.01e-02 1.93e-01 7.13e-01 1.57e-01
Negative regulators of DDX58/IFIH1 signaling 32 2.09e-01 3.47e-01 0.19900 -1.26e-01 1.53e-01 2.17e-01 1.33e-01
Signaling by FGFR3 34 1.79e-01 3.12e-01 0.19900 -9.67e-02 1.74e-01 3.29e-01 8.01e-02
ERK/MAPK targets 21 2.61e-01 4.08e-01 0.19800 1.72e-02 1.98e-01 8.92e-01 1.17e-01
Pre-NOTCH Processing in Golgi 17 3.85e-01 5.29e-01 0.19800 -4.21e-02 1.94e-01 7.64e-01 1.67e-01
Late Phase of HIV Life Cycle 132 3.94e-04 2.33e-03 0.19800 -1.25e-02 1.97e-01 8.04e-01 9.07e-05
Diseases associated with O-glycosylation of proteins 58 1.64e-02 5.35e-02 0.19700 1.80e-01 8.22e-02 1.81e-02 2.79e-01
Unfolded Protein Response (UPR) 89 1.26e-02 4.32e-02 0.19700 -1.66e-01 1.06e-01 6.73e-03 8.34e-02
Axon guidance 472 1.93e-12 2.08e-10 0.19700 -1.71e-02 1.96e-01 5.25e-01 3.19e-13
Ub-specific processing proteases 164 3.94e-04 2.33e-03 0.19700 -1.28e-01 1.50e-01 4.73e-03 9.32e-04
Mitotic Metaphase and Anaphase 221 9.70e-06 9.85e-05 0.19700 -6.54e-02 1.86e-01 9.48e-02 1.97e-06
PIWI-interacting RNA (piRNA) biogenesis 22 2.47e-01 3.93e-01 0.19700 1.96e-01 2.02e-02 1.12e-01 8.70e-01
Mitotic Anaphase 220 1.05e-05 1.04e-04 0.19700 -6.45e-02 1.86e-01 1.00e-01 2.09e-06
FOXO-mediated transcription 61 1.62e-02 5.27e-02 0.19700 5.65e-02 1.88e-01 4.46e-01 1.09e-02
Negative regulation of FGFR1 signaling 24 3.04e-01 4.54e-01 0.19700 -9.73e-02 1.71e-01 4.10e-01 1.47e-01
ERKs are inactivated 12 4.97e-01 6.17e-01 0.19700 -1.75e-02 1.96e-01 9.16e-01 2.40e-01
RHO GTPase Effectors 246 3.36e-07 5.68e-06 0.19700 6.60e-03 1.96e-01 8.59e-01 1.19e-07
Assembly of collagen fibrils and other multimeric structures 44 6.43e-02 1.49e-01 0.19600 1.56e-02 1.96e-01 8.58e-01 2.48e-02
Synthesis of bile acids and bile salts 27 1.48e-01 2.74e-01 0.19600 9.17e-02 1.73e-01 4.10e-01 1.20e-01
HDACs deacetylate histones 40 1.10e-01 2.22e-01 0.19600 -3.70e-02 1.92e-01 6.85e-01 3.57e-02
mRNA 3'-end processing 54 6.09e-02 1.42e-01 0.19600 -1.84e-01 6.57e-02 1.93e-02 4.04e-01
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known 36 1.68e-01 3.02e-01 0.19500 -1.75e-01 8.72e-02 6.97e-02 3.65e-01
Signaling by BRAF and RAF fusions 60 4.04e-02 1.06e-01 0.19500 -4.92e-02 1.89e-01 5.10e-01 1.14e-02
VxPx cargo-targeting to cilium 18 3.53e-01 4.97e-01 0.19500 -1.95e-01 1.54e-02 1.53e-01 9.10e-01
Processing of SMDT1 15 4.28e-01 5.67e-01 0.19500 -2.35e-02 1.94e-01 8.75e-01 1.94e-01
Intra-Golgi and retrograde Golgi-to-ER traffic 175 2.22e-04 1.42e-03 0.19500 -9.93e-02 1.68e-01 2.37e-02 1.32e-04
Signaling by ERBB2 in Cancer 24 3.26e-01 4.69e-01 0.19400 -1.29e-01 1.46e-01 2.76e-01 2.17e-01
Negative regulation of FGFR4 signaling 23 3.36e-01 4.80e-01 0.19400 -1.04e-01 1.63e-01 3.87e-01 1.76e-01
Abortive elongation of HIV-1 transcript in the absence of Tat 23 1.95e-01 3.32e-01 0.19300 1.35e-01 1.38e-01 2.61e-01 2.52e-01
AKT phosphorylates targets in the nucleus 10 5.04e-01 6.22e-01 0.19300 8.58e-02 1.73e-01 6.38e-01 3.43e-01
Signaling by NOTCH 179 2.91e-04 1.79e-03 0.19300 -1.32e-01 1.40e-01 2.36e-03 1.21e-03
ADP signalling through P2Y purinoceptor 1 22 2.97e-01 4.47e-01 0.19300 -2.34e-02 1.91e-01 8.50e-01 1.21e-01
RAB GEFs exchange GTP for GDP on RABs 86 1.36e-02 4.55e-02 0.19200 -6.61e-02 1.81e-01 2.90e-01 3.78e-03
RNA Pol II CTD phosphorylation and interaction with CE 27 1.61e-01 2.94e-01 0.19200 8.24e-02 1.74e-01 4.59e-01 1.18e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection 27 1.61e-01 2.94e-01 0.19200 8.24e-02 1.74e-01 4.59e-01 1.18e-01
Chylomicron assembly 10 4.95e-01 6.15e-01 0.19200 1.44e-01 1.28e-01 4.31e-01 4.84e-01
Translation of Replicase and Assembly of the Replication Transcription Complex 11 4.61e-01 5.93e-01 0.19200 1.37e-01 1.35e-01 4.32e-01 4.38e-01
Adherens junctions interactions 25 3.13e-01 4.59e-01 0.19200 -1.06e-01 1.60e-01 3.58e-01 1.67e-01
Transcription-Coupled Nucleotide Excision Repair (TC-NER) 77 5.90e-03 2.34e-02 0.19200 7.93e-02 1.75e-01 2.29e-01 8.12e-03
Beta-catenin independent WNT signaling 141 1.72e-03 8.48e-03 0.19100 -1.19e-01 1.50e-01 1.52e-02 2.14e-03
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression 25 3.12e-01 4.59e-01 0.19100 -9.56e-02 1.65e-01 4.08e-01 1.53e-01
Synthesis of PIPs at the late endosome membrane 11 5.86e-01 6.88e-01 0.19100 -1.76e-01 7.34e-02 3.12e-01 6.73e-01
mRNA Splicing - Major Pathway 172 4.41e-04 2.55e-03 0.19100 -1.16e-01 1.51e-01 8.81e-03 6.26e-04
Ethanol oxidation 11 6.01e-01 7.00e-01 0.19000 -9.50e-02 1.65e-01 5.85e-01 3.44e-01
Thrombin signalling through proteinase activated receptors (PARs) 29 2.45e-01 3.91e-01 0.19000 -6.96e-02 1.77e-01 5.17e-01 9.90e-02
Toll Like Receptor 3 (TLR3) Cascade 88 8.35e-03 3.09e-02 0.19000 -1.55e-02 1.89e-01 8.02e-01 2.17e-03
TP53 Regulates Transcription of Cell Death Genes 36 1.85e-01 3.21e-01 0.19000 -1.69e-01 8.58e-02 7.87e-02 3.73e-01
Mitochondrial iron-sulfur cluster biogenesis 11 5.14e-01 6.28e-01 0.19000 1.87e-01 3.25e-02 2.83e-01 8.52e-01
Hemostasis 547 1.75e-13 2.22e-11 0.19000 -7.04e-03 1.89e-01 7.79e-01 4.52e-14
Signaling by ERBB4 52 9.28e-02 1.96e-01 0.19000 -9.73e-02 1.63e-01 2.25e-01 4.26e-02
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway 14 5.32e-01 6.46e-01 0.18900 -1.58e-01 1.03e-01 3.05e-01 5.05e-01
Neutrophil degranulation 416 2.06e-09 8.77e-08 0.18900 -5.58e-02 1.80e-01 5.19e-02 3.10e-10
Innate Immune System 893 2.85e-18 6.66e-16 0.18900 -6.99e-02 1.75e-01 4.43e-04 1.05e-18
Assembly Of The HIV Virion 16 3.83e-01 5.27e-01 0.18900 3.24e-02 1.86e-01 8.23e-01 1.98e-01
tRNA modification in the nucleus and cytosol 43 9.12e-02 1.94e-01 0.18900 -7.46e-06 -1.89e-01 1.00e+00 3.24e-02
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 87 1.19e-02 4.10e-02 0.18800 -3.57e-02 1.85e-01 5.65e-01 2.91e-03
PIP3 activates AKT signaling 248 1.84e-05 1.67e-04 0.18800 -1.04e-01 1.57e-01 5.07e-03 2.19e-05
Detoxification of Reactive Oxygen Species 33 2.37e-01 3.81e-01 0.18800 -1.28e-01 1.38e-01 2.03e-01 1.72e-01
Nucleotide Excision Repair 108 1.27e-03 6.51e-03 0.18800 5.64e-02 1.79e-01 3.12e-01 1.31e-03
Inhibition of DNA recombination at telomere 28 1.71e-01 3.05e-01 0.18700 1.74e-01 6.98e-02 1.11e-01 5.23e-01
Insulin receptor recycling 24 2.54e-01 4.00e-01 0.18700 1.68e-02 1.86e-01 8.87e-01 1.14e-01
Signaling by MET 66 4.60e-02 1.16e-01 0.18700 -7.02e-02 1.73e-01 3.24e-01 1.49e-02
MyD88:MAL(TIRAP) cascade initiated on plasma membrane 89 8.21e-03 3.05e-02 0.18700 -4.18e-03 1.87e-01 9.46e-01 2.35e-03
Toll Like Receptor 2 (TLR2) Cascade 89 8.21e-03 3.05e-02 0.18700 -4.18e-03 1.87e-01 9.46e-01 2.35e-03
Toll Like Receptor TLR1:TLR2 Cascade 89 8.21e-03 3.05e-02 0.18700 -4.18e-03 1.87e-01 9.46e-01 2.35e-03
Toll Like Receptor TLR6:TLR2 Cascade 89 8.21e-03 3.05e-02 0.18700 -4.18e-03 1.87e-01 9.46e-01 2.35e-03
Membrane Trafficking 570 5.56e-12 5.20e-10 0.18600 -6.42e-02 1.75e-01 9.14e-03 1.15e-12
Aflatoxin activation and detoxification 14 4.37e-01 5.75e-01 0.18600 -4.11e-02 -1.81e-01 7.90e-01 2.40e-01
Ephrin signaling 18 3.19e-01 4.62e-01 0.18500 8.75e-02 1.63e-01 5.21e-01 2.30e-01
Integrin signaling 27 2.07e-01 3.46e-01 0.18500 3.77e-02 1.81e-01 7.34e-01 1.03e-01
G0 and Early G1 26 1.91e-01 3.29e-01 0.18500 9.09e-02 1.61e-01 4.23e-01 1.54e-01
NOD1/2 Signaling Pathway 29 2.24e-01 3.63e-01 0.18500 -1.84e-02 1.84e-01 8.64e-01 8.59e-02
Deubiquitination 236 5.21e-05 4.13e-04 0.18500 -1.15e-01 1.44e-01 2.33e-03 1.42e-04
Signaling by FGFR1 41 1.79e-01 3.12e-01 0.18400 -1.30e-01 1.30e-01 1.49e-01 1.49e-01
Nucleobase biosynthesis 13 4.77e-01 6.02e-01 0.18400 1.81e-01 3.18e-02 2.58e-01 8.43e-01
NOTCH3 Intracellular Domain Regulates Transcription 24 2.43e-01 3.89e-01 0.18400 5.03e-02 1.77e-01 6.70e-01 1.34e-01
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 16 5.13e-01 6.27e-01 0.18400 -1.30e-01 1.30e-01 3.68e-01 3.69e-01
WNT5A-dependent internalization of FZD4 15 4.84e-01 6.06e-01 0.18300 -3.68e-02 1.80e-01 8.05e-01 2.28e-01
Adrenaline,noradrenaline inhibits insulin secretion 26 2.20e-01 3.58e-01 0.18300 1.77e-01 4.75e-02 1.19e-01 6.75e-01
G beta:gamma signalling through PLC beta 18 4.01e-01 5.42e-01 0.18300 -1.54e-02 1.82e-01 9.10e-01 1.80e-01
Nuclear Pore Complex (NPC) Disassembly 36 1.27e-01 2.46e-01 0.18300 1.78e-01 4.06e-02 6.40e-02 6.74e-01
Ovarian tumor domain proteases 37 1.51e-01 2.78e-01 0.18300 -1.04e-02 1.83e-01 9.13e-01 5.48e-02
Signaling by cytosolic FGFR1 fusion mutants 18 4.28e-01 5.67e-01 0.18300 -4.44e-02 1.77e-01 7.45e-01 1.93e-01
RNA Polymerase III Transcription Termination 21 3.58e-01 5.02e-01 0.18300 1.80e-01 -2.89e-02 1.53e-01 8.19e-01
RNA Polymerase III Chain Elongation 16 4.73e-01 5.97e-01 0.18200 1.77e-01 -4.25e-02 2.21e-01 7.68e-01
Gap-filling DNA repair synthesis and ligation in TC-NER 63 2.10e-02 6.38e-02 0.18200 9.25e-02 1.56e-01 2.04e-01 3.18e-02
Competing endogenous RNAs (ceRNAs) regulate PTEN translation 10 6.26e-01 7.19e-01 0.18200 4.23e-02 -1.77e-01 8.17e-01 3.33e-01
Condensation of Prophase Chromosomes 22 2.66e-01 4.11e-01 0.18100 1.63e-01 7.90e-02 1.85e-01 5.21e-01
PKA-mediated phosphorylation of CREB 19 3.16e-01 4.62e-01 0.18100 8.34e-02 1.61e-01 5.29e-01 2.24e-01
Antiviral mechanism by IFN-stimulated genes 76 4.46e-02 1.14e-01 0.18100 -1.10e-01 1.44e-01 9.84e-02 2.95e-02
Nitric oxide stimulates guanylate cyclase 19 3.06e-01 4.55e-01 0.18100 1.35e-01 1.21e-01 3.09e-01 3.62e-01
Toll Like Receptor 7/8 (TLR7/8) Cascade 85 1.28e-02 4.34e-02 0.18100 3.52e-04 1.81e-01 9.96e-01 3.94e-03
Beta-oxidation of very long chain fatty acids 11 6.40e-01 7.29e-01 0.18100 1.22e-01 -1.34e-01 4.84e-01 4.43e-01
RHO GTPases activate CIT 19 3.24e-01 4.66e-01 0.18000 7.72e-02 1.63e-01 5.60e-01 2.19e-01
FOXO-mediated transcription of cell death genes 15 4.87e-01 6.09e-01 0.18000 2.45e-02 -1.78e-01 8.69e-01 2.32e-01
NOTCH2 Activation and Transmission of Signal to the Nucleus 22 3.09e-01 4.57e-01 0.18000 -1.79e-01 -2.19e-02 1.47e-01 8.59e-01
Signaling by NTRK1 (TRKA) 106 5.44e-03 2.18e-02 0.18000 -9.88e-03 1.79e-01 8.61e-01 1.43e-03
Protein-protein interactions at synapses 80 4.15e-02 1.08e-01 0.18000 1.20e-01 -1.34e-01 6.37e-02 3.89e-02
Ca-dependent events 35 1.24e-01 2.43e-01 0.18000 8.70e-02 1.57e-01 3.73e-01 1.08e-01
Termination of O-glycan biosynthesis 16 4.22e-01 5.62e-01 0.17900 1.77e-01 2.91e-02 2.20e-01 8.40e-01
NGF-stimulated transcription 33 1.38e-01 2.61e-01 0.17900 1.53e-01 9.45e-02 1.30e-01 3.48e-01
Interactions of Vpr with host cellular proteins 36 1.20e-01 2.38e-01 0.17900 1.60e-01 7.97e-02 9.57e-02 4.08e-01
SUMOylation of immune response proteins 11 6.30e-01 7.21e-01 0.17900 1.61e-01 -7.79e-02 3.54e-01 6.55e-01
TNFs bind their physiological receptors 20 4.31e-01 5.69e-01 0.17900 1.62e-01 -7.70e-02 2.11e-01 5.51e-01
PINK1-PRKN Mediated Mitophagy 20 4.52e-01 5.87e-01 0.17900 -1.14e-01 1.38e-01 3.77e-01 2.86e-01
ERBB2 Activates PTK6 Signaling 11 5.13e-01 6.27e-01 0.17900 -1.15e-01 -1.37e-01 5.09e-01 4.31e-01
mRNA Capping 29 2.23e-01 3.62e-01 0.17900 1.40e-02 1.78e-01 8.96e-01 9.70e-02
Retrograde transport at the Trans-Golgi-Network 45 1.21e-01 2.38e-01 0.17800 -2.56e-02 1.77e-01 7.67e-01 4.04e-02
TRAF6 mediated NF-kB activation 21 3.45e-01 4.89e-01 0.17800 1.78e-01 8.33e-03 1.58e-01 9.47e-01
Toll Like Receptor 9 (TLR9) Cascade 88 1.43e-02 4.73e-02 0.17800 -9.50e-03 1.78e-01 8.78e-01 4.01e-03
Amyloid fiber formation 50 4.99e-02 1.24e-01 0.17800 1.29e-01 1.22e-01 1.15e-01 1.35e-01
Depolymerisation of the Nuclear Lamina 15 4.55e-01 5.88e-01 0.17700 1.75e-01 2.82e-02 2.41e-01 8.50e-01
Transcriptional regulation of granulopoiesis 38 1.13e-01 2.28e-01 0.17700 8.06e-02 1.57e-01 3.90e-01 9.38e-02
Positive epigenetic regulation of rRNA expression 52 1.27e-01 2.46e-01 0.17600 -8.92e-02 1.52e-01 2.66e-01 5.76e-02
activated TAK1 mediates p38 MAPK activation 17 3.69e-01 5.12e-01 0.17600 1.17e-01 1.31e-01 4.03e-01 3.50e-01
Gap junction trafficking and regulation 23 3.07e-01 4.55e-01 0.17600 2.56e-02 1.74e-01 8.32e-01 1.49e-01
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 83 1.73e-02 5.54e-02 0.17500 8.35e-03 1.75e-01 8.95e-01 5.92e-03
Erythrocytes take up carbon dioxide and release oxygen 10 5.67e-01 6.74e-01 0.17500 1.53e-01 8.57e-02 4.04e-01 6.39e-01
O2/CO2 exchange in erythrocytes 10 5.67e-01 6.74e-01 0.17500 1.53e-01 8.57e-02 4.04e-01 6.39e-01
MyD88 dependent cascade initiated on endosome 84 1.84e-02 5.79e-02 0.17400 6.27e-04 1.74e-01 9.92e-01 5.77e-03
Transcriptional regulation by small RNAs 56 6.26e-02 1.46e-01 0.17400 1.73e-01 1.85e-02 2.52e-02 8.11e-01
TRAF3-dependent IRF activation pathway 12 5.51e-01 6.62e-01 0.17300 -1.72e-01 -2.23e-02 3.03e-01 8.94e-01
RNA Polymerase II Transcription Termination 62 5.97e-02 1.40e-01 0.17300 -1.72e-01 1.03e-02 1.90e-02 8.89e-01
Regulation of IFNA signaling 24 3.16e-01 4.61e-01 0.17300 -1.19e-02 -1.72e-01 9.20e-01 1.44e-01
Cytochrome P450 - arranged by substrate type 46 7.98e-02 1.77e-01 0.17200 1.50e-01 8.49e-02 7.86e-02 3.19e-01
Golgi-to-ER retrograde transport 112 1.67e-02 5.35e-02 0.17200 -1.13e-01 1.30e-01 3.90e-02 1.76e-02
ABC-family proteins mediated transport 97 2.84e-02 8.21e-02 0.17200 -1.34e-01 1.08e-01 2.23e-02 6.70e-02
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template 37 1.26e-01 2.45e-01 0.17200 1.07e-01 1.35e-01 2.62e-01 1.55e-01
ZBP1(DAI) mediated induction of type I IFNs 21 4.64e-01 5.95e-01 0.17200 -1.20e-01 1.23e-01 3.39e-01 3.30e-01
Triglyceride metabolism 30 2.12e-01 3.51e-01 0.17200 1.65e-01 4.93e-02 1.19e-01 6.40e-01
MyD88 cascade initiated on plasma membrane 77 2.08e-02 6.36e-02 0.17200 3.72e-02 1.68e-01 5.73e-01 1.10e-02
Toll Like Receptor 10 (TLR10) Cascade 77 2.08e-02 6.36e-02 0.17200 3.72e-02 1.68e-01 5.73e-01 1.10e-02
Toll Like Receptor 5 (TLR5) Cascade 77 2.08e-02 6.36e-02 0.17200 3.72e-02 1.68e-01 5.73e-01 1.10e-02
Regulation of TP53 Activity through Acetylation 29 3.13e-01 4.59e-01 0.17200 -5.69e-02 1.62e-01 5.96e-01 1.31e-01
Nuclear Events (kinase and transcription factor activation) 54 5.24e-02 1.28e-01 0.17200 8.64e-02 1.48e-01 2.72e-01 5.95e-02
Chaperonin-mediated protein folding 87 3.26e-02 8.85e-02 0.17100 -6.16e-02 1.60e-01 3.21e-01 1.00e-02
Signaling by FGFR1 in disease 31 2.71e-01 4.16e-01 0.17100 -3.46e-02 1.68e-01 7.39e-01 1.06e-01
Keratan sulfate/keratin metabolism 29 2.17e-01 3.55e-01 0.17100 6.45e-02 1.59e-01 5.48e-01 1.39e-01
Activation of GABAB receptors 37 2.14e-01 3.53e-01 0.17100 -3.81e-02 1.67e-01 6.88e-01 7.92e-02
GABA B receptor activation 37 2.14e-01 3.53e-01 0.17100 -3.81e-02 1.67e-01 6.88e-01 7.92e-02
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 16 4.62e-01 5.93e-01 0.17100 2.18e-02 1.69e-01 8.80e-01 2.41e-01
Resolution of Sister Chromatid Cohesion 103 8.60e-03 3.15e-02 0.17100 5.94e-03 1.71e-01 9.17e-01 2.79e-03
Aberrant regulation of mitotic exit in cancer due to RB1 defects 19 3.84e-01 5.27e-01 0.17100 1.65e-01 4.31e-02 2.13e-01 7.45e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 14 5.32e-01 6.46e-01 0.17100 -4.76e-03 1.70e-01 9.75e-01 2.69e-01
Defective EXT2 causes exostoses 2 14 5.32e-01 6.46e-01 0.17100 -4.76e-03 1.70e-01 9.75e-01 2.69e-01
DNA methylation 13 5.35e-01 6.48e-01 0.17000 1.69e-01 2.21e-02 2.91e-01 8.90e-01
Ca2+ pathway 59 5.16e-02 1.27e-01 0.17000 4.61e-02 1.64e-01 5.40e-01 2.98e-02
Cytosolic sulfonation of small molecules 21 3.95e-01 5.37e-01 0.17000 9.25e-03 -1.70e-01 9.42e-01 1.78e-01
Arachidonic acid metabolism 45 8.51e-02 1.86e-01 0.17000 1.17e-01 1.23e-01 1.74e-01 1.54e-01
Diseases associated with visual transduction 10 5.81e-01 6.84e-01 0.17000 -1.37e-01 -1.00e-01 4.53e-01 5.84e-01
Diseases of the neuronal system 10 5.81e-01 6.84e-01 0.17000 -1.37e-01 -1.00e-01 4.53e-01 5.84e-01
Retinoid cycle disease events 10 5.81e-01 6.84e-01 0.17000 -1.37e-01 -1.00e-01 4.53e-01 5.84e-01
Meiotic recombination 34 1.78e-01 3.12e-01 0.16900 1.60e-01 5.57e-02 1.07e-01 5.75e-01
Nuclear Envelope (NE) Reassembly 67 4.20e-02 1.09e-01 0.16900 2.35e-02 1.67e-01 7.40e-01 1.78e-02
HS-GAG degradation 21 3.55e-01 4.99e-01 0.16900 -1.64e-01 -4.12e-02 1.93e-01 7.44e-01
RUNX2 regulates bone development 29 2.08e-01 3.46e-01 0.16900 1.15e-01 1.24e-01 2.85e-01 2.48e-01
Bile acid and bile salt metabolism 33 1.74e-01 3.08e-01 0.16900 8.76e-02 1.44e-01 3.84e-01 1.52e-01
Centrosome maturation 81 1.28e-02 4.33e-02 0.16900 1.15e-01 1.24e-01 7.43e-02 5.48e-02
Recruitment of mitotic centrosome proteins and complexes 81 1.28e-02 4.33e-02 0.16900 1.15e-01 1.24e-01 7.43e-02 5.48e-02
Glutamate Neurotransmitter Release Cycle 19 5.03e-01 6.21e-01 0.16800 8.45e-02 -1.45e-01 5.24e-01 2.73e-01
HCMV Infection 90 8.78e-03 3.18e-02 0.16800 9.06e-02 1.42e-01 1.38e-01 2.04e-02
Intracellular signaling by second messengers 286 3.22e-05 2.74e-04 0.16800 -7.54e-02 1.50e-01 2.87e-02 1.30e-05
DNA Damage Recognition in GG-NER 38 1.85e-01 3.21e-01 0.16800 3.44e-03 1.68e-01 9.71e-01 7.38e-02
TRAF6 mediated IRF7 activation 26 3.01e-01 4.51e-01 0.16700 -1.94e-02 -1.66e-01 8.64e-01 1.42e-01
Caspase activation via extrinsic apoptotic signalling pathway 22 4.66e-01 5.95e-01 0.16700 -1.23e-01 1.14e-01 3.19e-01 3.56e-01
Cellular responses to external stimuli 470 1.78e-09 7.78e-08 0.16700 2.38e-03 1.67e-01 9.30e-01 6.23e-10
Cyclin D associated events in G1 46 9.54e-02 1.99e-01 0.16700 7.38e-02 1.50e-01 3.87e-01 7.86e-02
G1 Phase 46 9.54e-02 1.99e-01 0.16700 7.38e-02 1.50e-01 3.87e-01 7.86e-02
Lysosome Vesicle Biogenesis 34 2.61e-01 4.08e-01 0.16700 -1.62e-01 3.93e-02 1.02e-01 6.92e-01
FGFR2 mutant receptor activation 24 3.12e-01 4.59e-01 0.16700 1.60e-01 4.65e-02 1.75e-01 6.93e-01
MAPK1/MAPK3 signaling 255 1.73e-04 1.13e-03 0.16700 -1.06e-01 1.29e-01 3.66e-03 4.18e-04
Cellular responses to stress 465 3.24e-09 1.23e-07 0.16700 -2.36e-03 1.66e-01 9.31e-01 8.88e-10
Signaling by Nuclear Receptors 228 9.20e-05 6.61e-04 0.16600 -1.97e-02 1.65e-01 6.08e-01 1.77e-05
Interferon gamma signaling 69 4.48e-02 1.14e-01 0.16600 -1.66e-01 -1.54e-02 1.74e-02 8.25e-01
Nuclear Envelope Breakdown 53 8.76e-02 1.89e-01 0.16600 1.64e-01 2.65e-02 3.93e-02 7.39e-01
SARS-CoV-2 Infection 63 1.16e-01 2.32e-01 0.16600 -1.02e-01 1.31e-01 1.62e-01 7.28e-02
mRNA Splicing 180 2.28e-03 1.10e-02 0.16600 -1.03e-01 1.30e-01 1.73e-02 2.74e-03
TP53 Regulates Transcription of DNA Repair Genes 60 4.45e-02 1.14e-01 0.16500 1.22e-01 1.11e-01 1.02e-01 1.36e-01
Dectin-2 family 18 4.53e-01 5.87e-01 0.16500 -1.65e-01 -1.02e-02 2.26e-01 9.40e-01
MAPK family signaling cascades 291 5.33e-05 4.17e-04 0.16500 -9.31e-02 1.37e-01 6.45e-03 6.36e-05
AURKA Activation by TPX2 72 2.47e-02 7.27e-02 0.16500 1.03e-01 1.29e-01 1.31e-01 5.86e-02
Aquaporin-mediated transport 44 1.04e-01 2.13e-01 0.16500 1.19e-01 1.14e-01 1.73e-01 1.90e-01
Signaling by NTRK3 (TRKC) 17 4.61e-01 5.93e-01 0.16500 1.62e-01 2.81e-02 2.47e-01 8.41e-01
ISG15 antiviral mechanism 68 9.16e-02 1.94e-01 0.16400 -7.21e-02 1.48e-01 3.04e-01 3.54e-02
Negative regulation of FGFR2 signaling 25 3.64e-01 5.08e-01 0.16400 -1.72e-02 1.63e-01 8.82e-01 1.58e-01
Class I MHC mediated antigen processing & presentation 341 1.52e-05 1.44e-04 0.16400 -1.20e-01 1.11e-01 1.39e-04 4.44e-04
Unblocking of NMDA receptors, glutamate binding and activation 20 5.09e-01 6.25e-01 0.16400 1.35e-01 -9.20e-02 2.95e-01 4.76e-01
RAF/MAP kinase cascade 250 2.77e-04 1.73e-03 0.16400 -1.05e-01 1.26e-01 4.47e-03 6.30e-04
Notch-HLH transcription pathway 27 2.60e-01 4.07e-01 0.16300 1.38e-01 8.79e-02 2.16e-01 4.29e-01
SARS-CoV-1 Infection 46 1.82e-01 3.17e-01 0.16300 -4.52e-02 1.57e-01 5.96e-01 6.58e-02
Interleukin-20 family signaling 16 5.84e-01 6.87e-01 0.16300 8.93e-02 -1.37e-01 5.36e-01 3.44e-01
Formation of TC-NER Pre-Incision Complex 53 1.15e-01 2.30e-01 0.16300 -8.04e-03 1.63e-01 9.19e-01 4.03e-02
Gap junction trafficking 21 3.94e-01 5.36e-01 0.16300 2.53e-02 1.61e-01 8.41e-01 2.02e-01
SUMOylation of ubiquitinylation proteins 38 1.79e-01 3.12e-01 0.16300 1.58e-01 3.66e-02 9.10e-02 6.96e-01
PKA activation 17 4.29e-01 5.67e-01 0.16300 1.32e-01 9.45e-02 3.45e-01 5.00e-01
Loss of Nlp from mitotic centrosomes 69 3.27e-02 8.85e-02 0.16200 9.70e-02 1.30e-01 1.64e-01 6.17e-02
Loss of proteins required for interphase microtubule organization from the centrosome 69 3.27e-02 8.85e-02 0.16200 9.70e-02 1.30e-01 1.64e-01 6.17e-02
Activation of SMO 17 4.28e-01 5.67e-01 0.16200 -1.25e-01 -1.04e-01 3.73e-01 4.59e-01
FRS-mediated FGFR1 signaling 15 6.14e-01 7.10e-01 0.16200 -1.14e-01 1.15e-01 4.45e-01 4.39e-01
Termination of translesion DNA synthesis 31 2.24e-01 3.63e-01 0.16200 1.44e-01 7.34e-02 1.64e-01 4.80e-01
ADORA2B mediated anti-inflammatory cytokines production 78 5.40e-02 1.30e-01 0.16100 -3.17e-02 1.58e-01 6.29e-01 1.57e-02
HDR through Single Strand Annealing (SSA) 37 1.75e-01 3.08e-01 0.16100 1.48e-01 6.42e-02 1.19e-01 4.99e-01
Cell Cycle Checkpoints 249 5.47e-05 4.26e-04 0.16100 -7.59e-03 1.61e-01 8.37e-01 1.25e-05
Recruitment of NuMA to mitotic centrosomes 80 2.01e-02 6.20e-02 0.16100 1.26e-01 1.00e-01 5.17e-02 1.22e-01
mRNA decay by 5' to 3' exoribonuclease 15 5.07e-01 6.22e-01 0.16100 4.77e-02 1.53e-01 7.49e-01 3.04e-01
FRS-mediated FGFR4 signaling 14 6.38e-01 7.27e-01 0.16100 -1.27e-01 9.88e-02 4.12e-01 5.22e-01
NOTCH1 Intracellular Domain Regulates Transcription 47 1.41e-01 2.65e-01 0.16100 1.27e-02 1.60e-01 8.80e-01 5.78e-02
Signaling by ERBB2 KD Mutants 23 4.82e-01 6.06e-01 0.16000 -1.16e-01 1.11e-01 3.35e-01 3.59e-01
Metabolism of folate and pterines 17 5.52e-01 6.62e-01 0.16000 1.51e-01 -5.26e-02 2.80e-01 7.07e-01
Chromosome Maintenance 95 2.28e-02 6.80e-02 0.16000 1.60e-01 -2.78e-03 7.01e-03 9.63e-01
FLT3 Signaling 264 2.62e-04 1.64e-03 0.16000 -1.07e-01 1.19e-01 2.82e-03 8.91e-04
Assembly and cell surface presentation of NMDA receptors 24 4.68e-01 5.95e-01 0.16000 1.20e-01 -1.05e-01 3.09e-01 3.71e-01
ROS and RNS production in phagocytes 35 2.76e-01 4.23e-01 0.16000 -3.02e-02 1.57e-01 7.58e-01 1.08e-01
Interconversion of nucleotide di- and triphosphates 27 3.23e-01 4.65e-01 0.16000 1.59e-01 1.79e-02 1.54e-01 8.72e-01
Cytosolic sensors of pathogen-associated DNA 61 1.43e-01 2.67e-01 0.16000 -1.31e-01 9.14e-02 7.76e-02 2.17e-01
Regulation of RUNX1 Expression and Activity 17 4.71e-01 5.96e-01 0.15900 -4.37e-02 -1.53e-01 7.55e-01 2.74e-01
RA biosynthesis pathway 19 4.71e-01 5.96e-01 0.15800 -1.58e-01 -2.11e-03 2.32e-01 9.87e-01
G alpha (z) signalling events 44 2.06e-01 3.46e-01 0.15800 -3.31e-02 1.55e-01 7.04e-01 7.56e-02
Homologous DNA Pairing and Strand Exchange 42 1.63e-01 2.97e-01 0.15800 1.54e-01 3.86e-02 8.52e-02 6.65e-01
SUMOylation of SUMOylation proteins 35 1.95e-01 3.32e-01 0.15800 1.34e-01 8.41e-02 1.71e-01 3.89e-01
RIP-mediated NFkB activation via ZBP1 17 5.79e-01 6.83e-01 0.15800 -7.65e-02 1.38e-01 5.85e-01 3.24e-01
Signaling by WNT 264 1.79e-04 1.17e-03 0.15700 -5.64e-02 1.47e-01 1.15e-01 4.30e-05
Regulation of FZD by ubiquitination 18 4.67e-01 5.95e-01 0.15700 1.52e-01 3.73e-02 2.64e-01 7.84e-01
Presynaptic phase of homologous DNA pairing and strand exchange 39 1.67e-01 3.02e-01 0.15700 1.32e-01 8.49e-02 1.55e-01 3.59e-01
RNA polymerase II transcribes snRNA genes 71 7.15e-02 1.64e-01 0.15600 -1.10e-02 1.56e-01 8.73e-01 2.30e-02
Glyoxylate metabolism and glycine degradation 28 3.60e-01 5.04e-01 0.15600 1.55e-01 -1.82e-02 1.55e-01 8.68e-01
The NLRP3 inflammasome 15 6.26e-01 7.19e-01 0.15600 -8.06e-02 1.34e-01 5.89e-01 3.69e-01
Negative regulation of FGFR3 signaling 23 4.49e-01 5.87e-01 0.15600 -3.45e-02 1.52e-01 7.74e-01 2.06e-01
Oncogene Induced Senescence 32 2.80e-01 4.27e-01 0.15600 1.56e-01 1.46e-02 1.28e-01 8.86e-01
Amine ligand-binding receptors 16 5.40e-01 6.51e-01 0.15600 -4.18e-03 -1.56e-01 9.77e-01 2.81e-01
Glutathione conjugation 30 2.52e-01 3.97e-01 0.15600 1.20e-01 9.89e-02 2.54e-01 3.49e-01
Signaling by NOTCH1 71 1.14e-01 2.28e-01 0.15600 -8.49e-02 1.31e-01 2.16e-01 5.70e-02
RAS processing 19 5.37e-01 6.49e-01 0.15500 -5.30e-02 1.46e-01 6.89e-01 2.70e-01
Class I peroxisomal membrane protein import 20 4.17e-01 5.57e-01 0.15500 1.42e-01 6.26e-02 2.71e-01 6.28e-01
TP53 Regulates Metabolic Genes 84 2.88e-02 8.28e-02 0.15500 4.70e-02 1.48e-01 4.57e-01 1.92e-02
SHC-mediated cascade:FGFR2 14 5.28e-01 6.43e-01 0.15500 1.18e-01 1.00e-01 4.43e-01 5.16e-01
Sphingolipid de novo biosynthesis 44 2.46e-01 3.92e-01 0.15400 -1.43e-01 5.67e-02 9.99e-02 5.15e-01
Signaling by Rho GTPases 370 1.31e-06 1.73e-05 0.15400 1.49e-03 1.54e-01 9.61e-01 3.86e-07
Cell-Cell communication 108 1.77e-02 5.62e-02 0.15400 2.95e-03 1.54e-01 9.58e-01 5.72e-03
EML4 and NUDC in mitotic spindle formation 94 2.35e-02 6.98e-02 0.15400 3.01e-02 1.51e-01 6.14e-01 1.16e-02
Plasma lipoprotein assembly 17 5.87e-01 6.88e-01 0.15300 1.42e-01 -5.90e-02 3.12e-01 6.74e-01
Activation of AMPK downstream of NMDARs 10 7.04e-01 7.85e-01 0.15300 1.52e-01 -1.63e-02 4.05e-01 9.29e-01
Ras activation upon Ca2+ influx through NMDA receptor 19 4.67e-01 5.95e-01 0.15300 1.49e-01 3.35e-02 2.60e-01 8.00e-01
Metabolism of proteins 1749 2.08e-21 7.29e-19 0.15300 -6.58e-02 1.38e-01 7.12e-06 4.61e-21
Synthesis of PIPs at the Golgi membrane 18 5.73e-01 6.77e-01 0.15300 -1.40e-01 5.98e-02 3.02e-01 6.61e-01
TCF dependent signaling in response to WNT 172 5.38e-03 2.16e-02 0.15300 -6.34e-02 1.39e-01 1.52e-01 1.71e-03
Regulation of PLK1 Activity at G2/M Transition 87 2.79e-02 8.09e-02 0.15300 5.02e-02 1.44e-01 4.19e-01 2.03e-02
Protein folding 93 4.56e-02 1.16e-01 0.15200 -3.09e-02 1.49e-01 6.07e-01 1.30e-02
CaM pathway 33 2.39e-01 3.82e-01 0.15200 8.37e-02 1.27e-01 4.05e-01 2.06e-01
Calmodulin induced events 33 2.39e-01 3.82e-01 0.15200 8.37e-02 1.27e-01 4.05e-01 2.06e-01
Cobalamin (Cbl, vitamin B12) transport and metabolism 16 4.97e-01 6.17e-01 0.15200 -8.95e-02 -1.23e-01 5.35e-01 3.94e-01
Inflammasomes 20 5.05e-01 6.22e-01 0.15200 -1.51e-01 2.14e-02 2.44e-01 8.68e-01
cGMP effects 15 5.20e-01 6.34e-01 0.15200 1.22e-01 9.02e-02 4.12e-01 5.45e-01
Transferrin endocytosis and recycling 30 2.95e-01 4.45e-01 0.15100 5.05e-02 1.43e-01 6.32e-01 1.76e-01
Processing of Capped Intron-Containing Pre-mRNA 231 1.67e-03 8.27e-03 0.15000 -9.55e-02 1.16e-01 1.26e-02 2.42e-03
NS1 Mediated Effects on Host Pathways 38 2.09e-01 3.47e-01 0.15000 6.61e-02 1.35e-01 4.81e-01 1.51e-01
Sodium/Calcium exchangers 10 7.49e-01 8.23e-01 0.15000 1.32e-01 -7.05e-02 4.70e-01 7.00e-01
M Phase 348 6.40e-06 6.69e-05 0.14900 1.48e-03 1.49e-01 9.62e-01 1.85e-06
Diseases associated with glycosaminoglycan metabolism 38 2.16e-01 3.55e-01 0.14900 6.20e-02 1.35e-01 5.09e-01 1.49e-01
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants 57 1.74e-01 3.08e-01 0.14900 -4.20e-02 1.43e-01 5.84e-01 6.25e-02
Constitutive Signaling by NOTCH1 PEST Domain Mutants 57 1.74e-01 3.08e-01 0.14900 -4.20e-02 1.43e-01 5.84e-01 6.25e-02
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer 57 1.74e-01 3.08e-01 0.14900 -4.20e-02 1.43e-01 5.84e-01 6.25e-02
Signaling by NOTCH1 PEST Domain Mutants in Cancer 57 1.74e-01 3.08e-01 0.14900 -4.20e-02 1.43e-01 5.84e-01 6.25e-02
Signaling by NOTCH1 in Cancer 57 1.74e-01 3.08e-01 0.14900 -4.20e-02 1.43e-01 5.84e-01 6.25e-02
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) 30 3.19e-01 4.62e-01 0.14900 1.45e-01 3.51e-02 1.71e-01 7.39e-01
Regulation of Glucokinase by Glucokinase Regulatory Protein 30 3.19e-01 4.62e-01 0.14900 1.45e-01 3.51e-02 1.71e-01 7.39e-01
Signaling by Receptor Tyrosine Kinases 451 1.49e-06 1.94e-05 0.14900 -4.34e-02 1.42e-01 1.16e-01 2.51e-07
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling 27 3.41e-01 4.85e-01 0.14800 6.02e-02 1.35e-01 5.88e-01 2.24e-01
Energy dependent regulation of mTOR by LKB1-AMPK 29 4.53e-01 5.87e-01 0.14800 1.18e-01 -9.01e-02 2.73e-01 4.01e-01
Mitotic G2-G2/M phases 183 3.32e-03 1.51e-02 0.14800 -2.84e-02 1.45e-01 5.08e-01 7.30e-04
Pre-NOTCH Transcription and Translation 41 1.95e-01 3.32e-01 0.14800 1.33e-01 6.51e-02 1.42e-01 4.71e-01
G2/M Transition 181 3.65e-03 1.62e-02 0.14800 -2.93e-02 1.45e-01 4.97e-01 8.06e-04
Constitutive Signaling by Aberrant PI3K in Cancer 60 1.92e-01 3.29e-01 0.14700 -1.25e-01 7.82e-02 9.46e-02 2.95e-01
GABA receptor activation 48 2.21e-01 3.58e-01 0.14700 -2.59e-02 1.45e-01 7.56e-01 8.23e-02
Sphingolipid metabolism 81 8.14e-02 1.79e-01 0.14700 -1.44e-01 3.04e-02 2.51e-02 6.36e-01
Cellular Senescence 136 6.70e-03 2.57e-02 0.14700 1.43e-01 3.28e-02 3.92e-03 5.10e-01
Downstream signaling of activated FGFR4 19 5.88e-01 6.88e-01 0.14700 -1.30e-01 6.87e-02 3.27e-01 6.04e-01
MAP3K8 (TPL2)-dependent MAPK1/3 activation 16 5.93e-01 6.93e-01 0.14700 -1.21e-02 1.46e-01 9.33e-01 3.11e-01
Cell Cycle, Mitotic 488 2.55e-08 6.75e-07 0.14700 3.31e-02 1.43e-01 2.13e-01 7.29e-08
Immune System 1784 4.99e-20 1.40e-17 0.14600 -6.31e-02 1.32e-01 1.37e-05 9.46e-20
LDL clearance 19 5.68e-01 6.74e-01 0.14600 -4.03e-02 1.41e-01 7.61e-01 2.89e-01
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 32 3.63e-01 5.06e-01 0.14600 -1.87e-02 1.45e-01 8.55e-01 1.56e-01
Developmental Biology 770 5.30e-12 5.20e-10 0.14600 1.98e-02 1.45e-01 3.52e-01 1.16e-11
FGFR1 mutant receptor activation 24 4.70e-01 5.96e-01 0.14500 -1.71e-02 1.44e-01 8.85e-01 2.21e-01
Interleukin-17 signaling 66 9.49e-02 1.99e-01 0.14500 2.79e-02 1.43e-01 6.96e-01 4.52e-02
RHO GTPases Activate Formins 117 2.20e-02 6.61e-02 0.14500 -2.90e-03 1.45e-01 9.57e-01 6.71e-03
Mitotic Prophase 89 2.95e-02 8.38e-02 0.14500 8.73e-02 1.16e-01 1.55e-01 5.90e-02
Acyl chain remodelling of PE 20 5.48e-01 6.59e-01 0.14500 1.42e-01 -3.04e-02 2.73e-01 8.14e-01
Neddylation 224 3.22e-03 1.48e-02 0.14500 -1.08e-01 9.62e-02 5.36e-03 1.33e-02
Regulation of TP53 Activity through Association with Co-factors 13 6.02e-01 7.00e-01 0.14500 1.24e-01 7.41e-02 4.38e-01 6.44e-01
PI3K events in ERBB2 signaling 14 6.03e-01 7.00e-01 0.14500 -1.40e-01 -3.60e-02 3.64e-01 8.15e-01
PI Metabolism 82 9.13e-02 1.94e-01 0.14500 -3.75e-02 1.40e-01 5.58e-01 2.89e-02
Formation of the Early Elongation Complex 33 2.90e-01 4.40e-01 0.14400 5.60e-02 1.33e-01 5.78e-01 1.87e-01
Formation of the HIV-1 Early Elongation Complex 33 2.90e-01 4.40e-01 0.14400 5.60e-02 1.33e-01 5.78e-01 1.87e-01
Glycosphingolipid metabolism 37 2.99e-01 4.49e-01 0.14400 -1.44e-01 -9.74e-04 1.30e-01 9.92e-01
Mitotic Prometaphase 184 9.93e-04 5.20e-03 0.14400 6.29e-02 1.30e-01 1.42e-01 2.47e-03
Defects in cobalamin (B12) metabolism 13 6.09e-01 7.04e-01 0.14400 -1.28e-01 -6.66e-02 4.26e-01 6.78e-01
Disease 1333 8.84e-17 1.38e-14 0.14300 -2.17e-02 1.42e-01 1.89e-01 9.26e-18
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal 90 4.24e-02 1.10e-01 0.14300 3.28e-02 1.40e-01 5.91e-01 2.23e-02
Amplification of signal from the kinetochores 90 4.24e-02 1.10e-01 0.14300 3.28e-02 1.40e-01 5.91e-01 2.23e-02
Activation of Matrix Metalloproteinases 22 5.58e-01 6.67e-01 0.14300 -1.27e-01 6.54e-02 3.02e-01 5.95e-01
Signaling by FGFR2 in disease 34 2.77e-01 4.23e-01 0.14300 7.36e-02 1.22e-01 4.58e-01 2.18e-01
Estrogen-dependent gene expression 97 4.88e-02 1.22e-01 0.14200 -5.73e-03 1.42e-01 9.22e-01 1.55e-02
Regulation of insulin secretion 69 7.16e-02 1.64e-01 0.14200 1.05e-01 9.52e-02 1.30e-01 1.72e-01
GRB2 events in ERBB2 signaling 14 7.03e-01 7.85e-01 0.14200 -8.43e-02 1.14e-01 5.85e-01 4.60e-01
Cell recruitment (pro-inflammatory response) 22 4.51e-01 5.87e-01 0.14100 5.51e-02 1.30e-01 6.55e-01 2.90e-01
Purinergic signaling in leishmaniasis infection 22 4.51e-01 5.87e-01 0.14100 5.51e-02 1.30e-01 6.55e-01 2.90e-01
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 16 6.08e-01 7.04e-01 0.14100 -1.32e-03 1.41e-01 9.93e-01 3.29e-01
Metabolism of cofactors 19 6.02e-01 7.00e-01 0.14100 -1.32e-01 4.86e-02 3.20e-01 7.14e-01
L1CAM interactions 92 3.80e-02 1.00e-01 0.14000 5.67e-02 1.28e-01 3.48e-01 3.35e-02
Muscle contraction 144 5.60e-03 2.22e-02 0.14000 6.60e-02 1.24e-01 1.72e-01 1.04e-02
DAG and IP3 signaling 39 2.36e-01 3.81e-01 0.14000 8.19e-02 1.14e-01 3.76e-01 2.19e-01
Mitochondrial protein import 61 1.09e-01 2.22e-01 0.14000 1.23e-01 6.78e-02 9.76e-02 3.60e-01
Cytokine Signaling in Immune system 736 1.47e-08 4.37e-07 0.14000 -6.04e-02 1.26e-01 5.56e-03 6.86e-09
Glycerophospholipid biosynthesis 114 5.46e-02 1.31e-01 0.14000 1.27e-01 -5.97e-02 1.98e-02 2.72e-01
Fatty acid metabolism 150 9.37e-03 3.35e-02 0.13900 1.07e-02 1.39e-01 8.21e-01 3.38e-03
Gamma carboxylation, hypusine formation and arylsulfatase activation 34 3.20e-01 4.63e-01 0.13900 -3.66e-02 -1.34e-01 7.12e-01 1.77e-01
Mitochondrial biogenesis 89 4.18e-02 1.09e-01 0.13900 7.35e-02 1.17e-01 2.31e-01 5.57e-02
Regulation of beta-cell development 29 3.50e-01 4.94e-01 0.13800 1.10e-01 8.38e-02 3.04e-01 4.35e-01
Mitotic Spindle Checkpoint 106 3.00e-02 8.41e-02 0.13800 3.78e-02 1.33e-01 5.02e-01 1.83e-02
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 48 3.11e-01 4.59e-01 0.13800 -7.00e-02 1.19e-01 4.02e-01 1.54e-01
PKA activation in glucagon signalling 16 5.69e-01 6.74e-01 0.13800 1.20e-01 6.82e-02 4.07e-01 6.37e-01
SLC transporter disorders 90 1.21e-01 2.38e-01 0.13800 8.80e-02 -1.06e-01 1.49e-01 8.25e-02
Transcriptional Regulation by VENTX 35 4.41e-01 5.78e-01 0.13800 9.95e-02 -9.52e-02 3.09e-01 3.30e-01
Presynaptic function of Kainate receptors 19 5.84e-01 6.87e-01 0.13700 -1.29e-02 1.36e-01 9.22e-01 3.03e-01
Transcriptional Regulation by TP53 340 2.37e-05 2.12e-04 0.13700 2.81e-02 1.34e-01 3.75e-01 2.26e-05
Negative regulation of NMDA receptor-mediated neuronal transmission 20 6.21e-01 7.15e-01 0.13700 7.29e-02 -1.16e-01 5.73e-01 3.69e-01
MicroRNA (miRNA) biogenesis 24 5.58e-01 6.67e-01 0.13600 1.23e-01 -5.99e-02 2.98e-01 6.12e-01
MHC class II antigen presentation 95 9.87e-02 2.04e-01 0.13600 -5.69e-02 1.24e-01 3.38e-01 3.69e-02
RIPK1-mediated regulated necrosis 26 5.02e-01 6.21e-01 0.13600 -2.98e-02 1.33e-01 7.92e-01 2.40e-01
Regulated Necrosis 26 5.02e-01 6.21e-01 0.13600 -2.98e-02 1.33e-01 7.92e-01 2.40e-01
Regulation of necroptotic cell death 26 5.02e-01 6.21e-01 0.13600 -2.98e-02 1.33e-01 7.92e-01 2.40e-01
PI3K/AKT Signaling in Cancer 87 1.37e-01 2.60e-01 0.13600 -1.02e-01 9.07e-02 1.02e-01 1.44e-01
Vpr-mediated nuclear import of PICs 34 3.11e-01 4.59e-01 0.13600 1.17e-01 6.86e-02 2.36e-01 4.89e-01
RNA Polymerase III Transcription Initiation From Type 3 Promoter 26 4.68e-01 5.95e-01 0.13600 1.36e-01 2.83e-03 2.31e-01 9.80e-01
SUMOylation of DNA replication proteins 46 2.05e-01 3.44e-01 0.13600 7.52e-02 1.13e-01 3.78e-01 1.85e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function 43 3.51e-01 4.94e-01 0.13600 1.25e-01 -5.35e-02 1.57e-01 5.44e-01
Sulfur amino acid metabolism 26 5.50e-01 6.61e-01 0.13500 7.64e-02 -1.12e-01 5.00e-01 3.25e-01
Heme biosynthesis 13 7.17e-01 7.97e-01 0.13500 -1.30e-01 3.48e-02 4.16e-01 8.28e-01
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein 72 1.31e-01 2.51e-01 0.13500 -1.35e-01 2.97e-03 4.79e-02 9.65e-01
Transcriptional regulation by RUNX1 174 2.09e-02 6.38e-02 0.13500 -9.35e-02 9.70e-02 3.36e-02 2.76e-02
RNA Polymerase I Transcription Initiation 44 3.49e-01 4.94e-01 0.13500 -1.23e-01 5.47e-02 1.58e-01 5.30e-01
RNA Polymerase III Abortive And Retractive Initiation 39 3.68e-01 5.11e-01 0.13400 1.31e-01 -3.11e-02 1.58e-01 7.37e-01
RNA Polymerase III Transcription 39 3.68e-01 5.11e-01 0.13400 1.31e-01 -3.11e-02 1.58e-01 7.37e-01
Synthesis of IP3 and IP4 in the cytosol 25 5.07e-01 6.22e-01 0.13400 -1.30e-02 1.34e-01 9.11e-01 2.47e-01
Synthesis of PA 32 4.91e-01 6.12e-01 0.13400 9.78e-02 -9.19e-02 3.39e-01 3.69e-01
Phosphorylation of the APC/C 19 5.37e-01 6.49e-01 0.13400 1.21e-01 5.70e-02 3.61e-01 6.67e-01
Signaling by NTRKs 125 2.79e-02 8.09e-02 0.13400 8.54e-03 1.33e-01 8.69e-01 1.00e-02
Deadenylation-dependent mRNA decay 52 3.14e-01 4.59e-01 0.13300 -7.86e-02 1.08e-01 3.27e-01 1.79e-01
Maturation of nucleoprotein 10 7.92e-01 8.56e-01 0.13300 -5.78e-02 1.20e-01 7.52e-01 5.11e-01
Collagen formation 75 1.35e-01 2.58e-01 0.13300 -1.07e-02 1.33e-01 8.73e-01 4.73e-02
Regulation of gene expression in beta cells 13 6.73e-01 7.59e-01 0.13300 1.28e-01 3.38e-02 4.24e-01 8.33e-01
Signaling by NTRK2 (TRKB) 25 5.69e-01 6.74e-01 0.13200 -6.37e-02 1.16e-01 5.81e-01 3.15e-01
Postmitotic nuclear pore complex (NPC) reformation 27 4.90e-01 6.12e-01 0.13200 -1.18e-02 1.32e-01 9.15e-01 2.36e-01
Transport of Ribonucleoproteins into the Host Nucleus 32 3.47e-01 4.92e-01 0.13200 1.03e-01 8.33e-02 3.15e-01 4.15e-01
Collagen chain trimerization 34 4.81e-01 6.05e-01 0.13200 -9.96e-02 8.64e-02 3.15e-01 3.83e-01
Post-translational protein modification 1238 1.16e-11 8.56e-10 0.13200 -6.85e-02 1.12e-01 6.11e-05 4.99e-11
Gene Silencing by RNA 79 1.40e-01 2.64e-01 0.13100 1.29e-01 -2.36e-02 4.75e-02 7.17e-01
Synthesis of PC 27 4.92e-01 6.12e-01 0.13100 -5.33e-03 1.30e-01 9.62e-01 2.41e-01
Signaling by NOTCH3 47 3.35e-01 4.79e-01 0.13000 -3.95e-02 1.24e-01 6.40e-01 1.41e-01
Cell junction organization 76 9.71e-02 2.02e-01 0.13000 5.43e-02 1.18e-01 4.14e-01 7.51e-02
Netrin-1 signaling 46 3.20e-01 4.63e-01 0.13000 -1.97e-02 1.28e-01 8.17e-01 1.32e-01
Intraflagellar transport 40 3.13e-01 4.59e-01 0.13000 -1.25e-01 -3.26e-02 1.70e-01 7.21e-01
SUMOylation of DNA damage response and repair proteins 75 9.84e-02 2.04e-01 0.12900 6.65e-02 1.11e-01 3.19e-01 9.80e-02
Tight junction interactions 24 6.04e-01 7.00e-01 0.12900 6.97e-02 -1.09e-01 5.55e-01 3.58e-01
Fanconi Anemia Pathway 35 4.46e-01 5.83e-01 0.12900 1.24e-01 -3.52e-02 2.05e-01 7.19e-01
Inactivation of APC/C via direct inhibition of the APC/C complex 20 5.53e-01 6.62e-01 0.12800 1.18e-01 4.89e-02 3.59e-01 7.05e-01
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components 20 5.53e-01 6.62e-01 0.12800 1.18e-01 4.89e-02 3.59e-01 7.05e-01
Growth hormone receptor signaling 20 5.63e-01 6.72e-01 0.12800 1.23e-01 3.67e-02 3.43e-01 7.76e-01
SHC-mediated cascade:FGFR3 12 6.92e-01 7.76e-01 0.12800 1.08e-01 6.90e-02 5.18e-01 6.79e-01
RNA Polymerase III Transcription Initiation 34 4.67e-01 5.95e-01 0.12800 1.22e-01 -3.78e-02 2.19e-01 7.03e-01
Regulation of TP53 Activity through Methylation 17 7.02e-01 7.84e-01 0.12800 6.36e-02 -1.11e-01 6.50e-01 4.30e-01
G2/M DNA damage checkpoint 61 1.89e-01 3.27e-01 0.12700 2.23e-02 1.26e-01 7.63e-01 9.02e-02
Kinesins 40 4.50e-01 5.87e-01 0.12700 8.56e-02 -9.40e-02 3.49e-01 3.04e-01
RNA Polymerase III Transcription Initiation From Type 2 Promoter 25 5.87e-01 6.88e-01 0.12700 1.16e-01 -5.09e-02 3.15e-01 6.60e-01
Interleukin-6 family signaling 21 5.67e-01 6.74e-01 0.12700 2.20e-02 1.25e-01 8.61e-01 3.23e-01
HCMV Early Events 67 1.32e-01 2.52e-01 0.12600 9.04e-02 8.84e-02 2.01e-01 2.11e-01
SUMOylation of DNA methylation proteins 16 6.27e-01 7.19e-01 0.12600 -5.63e-02 -1.13e-01 6.97e-01 4.35e-01
Antimicrobial peptides 23 6.38e-01 7.27e-01 0.12600 -9.05e-02 8.74e-02 4.53e-01 4.68e-01
Meiosis 60 1.70e-01 3.05e-01 0.12600 1.05e-01 6.95e-02 1.61e-01 3.52e-01
RNA Polymerase III Transcription Initiation From Type 1 Promoter 26 5.86e-01 6.88e-01 0.12500 1.13e-01 -5.31e-02 3.18e-01 6.39e-01
Metabolism of carbohydrates 264 6.33e-04 3.50e-03 0.12500 1.14e-01 5.02e-02 1.40e-03 1.61e-01
Regulation of TP53 Activity 152 1.76e-02 5.61e-02 0.12500 2.83e-02 1.22e-01 5.47e-01 9.68e-03
Glucagon signaling in metabolic regulation 28 4.42e-01 5.79e-01 0.12500 6.70e-02 1.05e-01 5.40e-01 3.34e-01
Transport of bile salts and organic acids, metal ions and amine compounds 76 1.58e-01 2.89e-01 0.12400 -2.99e-03 -1.24e-01 9.64e-01 6.19e-02
Phase I - Functionalization of compounds 85 8.68e-02 1.88e-01 0.12400 7.07e-02 1.02e-01 2.60e-01 1.05e-01
SUMOylation of transcription factors 17 6.18e-01 7.13e-01 0.12300 6.09e-02 1.07e-01 6.64e-01 4.43e-01
NOTCH3 Activation and Transmission of Signal to the Nucleus 24 6.32e-01 7.23e-01 0.12300 -1.02e-01 6.90e-02 3.87e-01 5.59e-01
Heparan sulfate/heparin (HS-GAG) metabolism 51 2.38e-01 3.81e-01 0.12300 -6.50e-02 -1.04e-01 4.22e-01 1.97e-01
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 26 5.58e-01 6.67e-01 0.12300 1.22e-01 -1.46e-02 2.82e-01 8.97e-01
ERBB2 Regulates Cell Motility 13 7.82e-01 8.49e-01 0.12300 -1.01e-01 6.99e-02 5.29e-01 6.63e-01
Antigen processing: Ubiquitination & Proteasome degradation 288 5.23e-03 2.11e-02 0.12300 -8.45e-02 8.87e-02 1.38e-02 9.79e-03
Abacavir transport and metabolism 10 7.61e-01 8.33e-01 0.12200 5.19e-02 1.11e-01 7.76e-01 5.44e-01
Adenylate cyclase inhibitory pathway 13 7.30e-01 8.07e-01 0.12200 9.21e-03 1.22e-01 9.54e-01 4.47e-01
RET signaling 40 4.05e-01 5.45e-01 0.12200 -1.21e-01 6.82e-03 1.84e-01 9.41e-01
Nonhomologous End-Joining (NHEJ) 35 4.84e-01 6.06e-01 0.12100 -1.18e-01 2.79e-02 2.28e-01 7.75e-01
Cardiac conduction 95 7.35e-02 1.67e-01 0.12100 9.69e-02 7.24e-02 1.03e-01 2.23e-01
Cell Cycle 607 2.46e-07 4.42e-06 0.12100 4.11e-02 1.14e-01 8.59e-02 1.95e-06
Interleukin-7 signaling 22 6.14e-01 7.10e-01 0.12000 1.20e-01 -7.40e-03 3.29e-01 9.52e-01
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 17 6.46e-01 7.33e-01 0.12000 4.18e-02 1.13e-01 7.65e-01 4.22e-01
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase 19 6.25e-01 7.18e-01 0.11900 1.14e-01 3.38e-02 3.90e-01 7.99e-01
Post NMDA receptor activation events 60 2.07e-01 3.46e-01 0.11900 1.02e-01 6.15e-02 1.73e-01 4.10e-01
Adenylate cyclase activating pathway 10 8.40e-01 8.92e-01 0.11900 7.50e-02 -9.19e-02 6.82e-01 6.15e-01
Signaling by Insulin receptor 65 2.92e-01 4.41e-01 0.11800 -4.02e-02 1.11e-01 5.76e-01 1.21e-01
G alpha (12/13) signalling events 76 2.09e-01 3.47e-01 0.11800 -1.42e-02 1.17e-01 8.31e-01 7.81e-02
B-WICH complex positively regulates rRNA expression 37 4.53e-01 5.87e-01 0.11800 -4.38e-03 1.18e-01 9.63e-01 2.15e-01
RNA Polymerase I Promoter Clearance 56 3.72e-01 5.14e-01 0.11800 -5.97e-02 1.01e-01 4.40e-01 1.89e-01
RNA Polymerase I Transcription 56 3.72e-01 5.14e-01 0.11800 -5.97e-02 1.01e-01 4.40e-01 1.89e-01
APC/C:Cdc20 mediated degradation of Cyclin B 23 5.48e-01 6.59e-01 0.11700 8.90e-02 7.66e-02 4.60e-01 5.25e-01
G1/S-Specific Transcription 28 5.31e-01 6.46e-01 0.11700 1.54e-02 1.16e-01 8.88e-01 2.89e-01
The canonical retinoid cycle in rods (twilight vision) 17 6.45e-01 7.33e-01 0.11700 -6.88e-02 -9.45e-02 6.23e-01 5.00e-01
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 12 7.63e-01 8.33e-01 0.11700 1.16e-01 1.56e-02 4.88e-01 9.25e-01
Diseases of hemostasis 12 7.63e-01 8.33e-01 0.11700 1.16e-01 1.56e-02 4.88e-01 9.25e-01
Pre-NOTCH Expression and Processing 57 2.38e-01 3.81e-01 0.11700 5.84e-02 1.01e-01 4.46e-01 1.87e-01
G alpha (q) signalling events 159 4.50e-02 1.14e-01 0.11600 -1.95e-02 1.15e-01 6.72e-01 1.28e-02
Telomere Extension By Telomerase 22 6.88e-01 7.71e-01 0.11600 9.68e-02 -6.41e-02 4.32e-01 6.03e-01
Regulation of TP53 Activity through Phosphorylation 90 1.06e-01 2.15e-01 0.11600 6.25e-02 9.75e-02 3.06e-01 1.10e-01
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 16 6.75e-01 7.60e-01 0.11600 5.13e-02 1.04e-01 7.22e-01 4.72e-01
Nicotinamide salvaging 18 6.33e-01 7.24e-01 0.11600 7.66e-02 8.66e-02 5.74e-01 5.25e-01
Deactivation of the beta-catenin transactivating complex 39 4.80e-01 6.05e-01 0.11500 -1.12e-01 2.48e-02 2.26e-01 7.89e-01
Transcriptional Regulation by MECP2 52 4.26e-01 5.66e-01 0.11500 -6.62e-02 9.34e-02 4.09e-01 2.44e-01
Acyl chain remodelling of PS 16 7.08e-01 7.88e-01 0.11400 1.13e-01 1.44e-02 4.32e-01 9.21e-01
Packaging Of Telomere Ends 13 7.84e-01 8.50e-01 0.11400 1.12e-01 -2.34e-02 4.85e-01 8.84e-01
Peroxisomal protein import 61 3.76e-01 5.19e-01 0.11400 -8.67e-02 7.37e-02 2.42e-01 3.20e-01
HDR through Homologous Recombination (HRR) 65 2.15e-01 3.54e-01 0.11300 1.00e-01 5.34e-02 1.63e-01 4.56e-01
Peptide ligand-binding receptors 110 1.42e-01 2.67e-01 0.11300 -3.10e-02 1.09e-01 5.75e-01 4.90e-02
Inhibition of replication initiation of damaged DNA by RB1/E2F1 13 7.30e-01 8.07e-01 0.11300 8.26e-02 7.70e-02 6.06e-01 6.31e-01
Collagen degradation 30 6.24e-01 7.18e-01 0.11300 -7.29e-02 8.58e-02 4.89e-01 4.16e-01
Regulation of cholesterol biosynthesis by SREBP (SREBF) 55 4.19e-01 5.59e-01 0.11200 -9.18e-02 6.48e-02 2.39e-01 4.06e-01
Nucleotide-like (purinergic) receptors 15 7.20e-01 7.99e-01 0.11200 -3.11e-02 -1.08e-01 8.35e-01 4.70e-01
COPI-dependent Golgi-to-ER retrograde traffic 79 2.68e-01 4.13e-01 0.11200 -1.04e-01 4.13e-02 1.11e-01 5.26e-01
Regulation of PTEN gene transcription 60 3.92e-01 5.36e-01 0.11200 -6.41e-02 9.15e-02 3.91e-01 2.21e-01
Epigenetic regulation of gene expression 93 2.05e-01 3.45e-01 0.11200 -3.41e-02 1.06e-01 5.71e-01 7.69e-02
SHC-mediated cascade:FGFR1 13 7.92e-01 8.56e-01 0.11100 -1.89e-02 1.09e-01 9.06e-01 4.95e-01
Vitamin B5 (pantothenate) metabolism 16 7.43e-01 8.17e-01 0.11100 -1.10e-01 8.58e-03 4.45e-01 9.53e-01
Acyl chain remodelling of PG 12 8.28e-01 8.84e-01 0.11000 -9.73e-02 5.23e-02 5.60e-01 7.54e-01
Metabolism of fat-soluble vitamins 43 4.39e-01 5.77e-01 0.11000 5.47e-04 1.10e-01 9.95e-01 2.11e-01
Signaling by ERBB2 TMD/JMD mutants 20 7.29e-01 8.07e-01 0.11000 -4.92e-02 9.85e-02 7.03e-01 4.46e-01
GPCR downstream signalling 710 1.85e-07 3.45e-06 0.11000 -7.53e-02 -7.96e-02 6.84e-04 3.30e-04
Glutamate binding, activation of AMPA receptors and synaptic plasticity 28 6.07e-01 7.03e-01 0.10900 1.09e-01 -1.15e-02 3.20e-01 9.16e-01
Trafficking of AMPA receptors 28 6.07e-01 7.03e-01 0.10900 1.09e-01 -1.15e-02 3.20e-01 9.16e-01
Gap junction assembly 13 7.99e-01 8.60e-01 0.10900 1.07e-01 -1.98e-02 5.03e-01 9.02e-01
Diseases associated with glycosylation precursor biosynthesis 18 6.82e-01 7.66e-01 0.10900 -4.14e-02 -1.00e-01 7.61e-01 4.61e-01
Metabolism of nucleotides 93 1.96e-01 3.33e-01 0.10800 1.08e-01 -1.16e-02 7.28e-02 8.46e-01
mTORC1-mediated signalling 24 6.69e-01 7.55e-01 0.10800 -1.06e-01 2.36e-02 3.70e-01 8.41e-01
FRS-mediated FGFR2 signaling 16 7.37e-01 8.12e-01 0.10800 1.22e-02 1.07e-01 9.33e-01 4.59e-01
Retinoid metabolism and transport 39 4.39e-01 5.77e-01 0.10700 4.70e-02 9.66e-02 6.12e-01 2.97e-01
Defective B3GALT6 causes EDSP2 and SEMDJL1 20 6.65e-01 7.52e-01 0.10700 3.48e-02 1.02e-01 7.88e-01 4.32e-01
Acyl chain remodelling of PI 11 8.38e-01 8.91e-01 0.10700 1.04e-01 -2.71e-02 5.52e-01 8.76e-01
NEP/NS2 Interacts with the Cellular Export Machinery 32 5.04e-01 6.22e-01 0.10700 8.81e-02 6.03e-02 3.88e-01 5.55e-01
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism 12 8.45e-01 8.96e-01 0.10600 6.83e-02 -8.14e-02 6.82e-01 6.25e-01
alpha-linolenic acid (ALA) metabolism 12 8.45e-01 8.96e-01 0.10600 6.83e-02 -8.14e-02 6.82e-01 6.25e-01
Death Receptor Signalling 135 1.19e-01 2.36e-01 0.10600 -2.62e-02 1.03e-01 5.99e-01 3.93e-02
Signaling by FGFR in disease 54 3.17e-01 4.62e-01 0.10600 6.75e-02 8.17e-02 3.91e-01 2.99e-01
p75 NTR receptor-mediated signalling 95 2.41e-01 3.85e-01 0.10600 -3.66e-02 9.90e-02 5.38e-01 9.57e-02
Rab regulation of trafficking 117 1.66e-01 3.00e-01 0.10500 -2.60e-02 1.01e-01 6.28e-01 5.82e-02
Collagen biosynthesis and modifying enzymes 56 4.65e-01 5.95e-01 0.10500 -6.21e-02 8.43e-02 4.22e-01 2.75e-01
Signaling by FGFR2 63 3.55e-01 4.99e-01 0.10500 -9.48e-03 1.04e-01 8.96e-01 1.53e-01
Integration of energy metabolism 98 1.36e-01 2.59e-01 0.10400 8.53e-02 5.99e-02 1.45e-01 3.06e-01
Metabolism of porphyrins 23 6.96e-01 7.79e-01 0.10400 -1.84e-02 1.02e-01 8.79e-01 3.95e-01
Synthesis of substrates in N-glycan biosythesis 58 4.12e-01 5.52e-01 0.10300 -1.01e-01 2.19e-02 1.83e-01 7.73e-01
TBC/RABGAPs 43 4.30e-01 5.68e-01 0.10300 8.96e-02 5.07e-02 3.09e-01 5.65e-01
Signaling by Retinoic Acid 38 5.67e-01 6.74e-01 0.10300 -2.40e-02 9.99e-02 7.98e-01 2.87e-01
Interferon alpha/beta signaling 59 3.27e-01 4.69e-01 0.10300 -3.99e-02 -9.45e-02 5.96e-01 2.10e-01
RHO GTPases activate KTN1 11 8.67e-01 9.09e-01 0.10200 -7.32e-02 7.17e-02 6.74e-01 6.81e-01
Stimuli-sensing channels 82 3.44e-01 4.88e-01 0.10200 8.33e-02 -5.90e-02 1.92e-01 3.56e-01
Regulation of MECP2 expression and activity 29 6.56e-01 7.44e-01 0.10200 -9.82e-02 2.72e-02 3.60e-01 8.00e-01
Signaling by Non-Receptor Tyrosine Kinases 52 3.97e-01 5.38e-01 0.10100 2.54e-02 9.83e-02 7.51e-01 2.21e-01
Signaling by PTK6 52 3.97e-01 5.38e-01 0.10100 2.54e-02 9.83e-02 7.51e-01 2.21e-01
Degradation of the extracellular matrix 86 1.99e-01 3.36e-01 0.10100 4.66e-02 8.98e-02 4.55e-01 1.50e-01
Neurexins and neuroligins 52 4.76e-01 6.02e-01 0.10100 2.41e-02 -9.76e-02 7.64e-01 2.24e-01
Export of Viral Ribonucleoproteins from Nucleus 33 5.41e-01 6.53e-01 0.09960 5.54e-02 8.28e-02 5.82e-01 4.11e-01
Activation of kainate receptors upon glutamate binding 27 6.03e-01 7.00e-01 0.09930 6.61e-02 7.42e-02 5.53e-01 5.05e-01
WNT ligand biogenesis and trafficking 19 7.78e-01 8.45e-01 0.09910 -3.54e-02 9.26e-02 7.90e-01 4.85e-01
Meiotic synapsis 34 5.38e-01 6.50e-01 0.09870 5.28e-02 8.34e-02 5.94e-01 4.00e-01
Transcriptional activation of mitochondrial biogenesis 52 5.35e-01 6.48e-01 0.09870 -7.31e-02 6.63e-02 3.62e-01 4.09e-01
Signaling by GPCR 758 1.82e-06 2.22e-05 0.09810 -6.56e-02 -7.30e-02 2.27e-03 6.87e-04
Class B/2 (Secretin family receptors) 61 4.06e-01 5.46e-01 0.09810 -4.46e-03 9.80e-02 9.52e-01 1.86e-01
Nuclear signaling by ERBB4 28 6.61e-01 7.49e-01 0.09810 -4.60e-03 9.80e-02 9.66e-01 3.70e-01
Trafficking of GluR2-containing AMPA receptors 17 7.96e-01 8.58e-01 0.09770 9.47e-02 -2.42e-02 4.99e-01 8.63e-01
Interferon Signaling 168 1.44e-01 2.69e-01 0.09700 -6.95e-02 6.77e-02 1.21e-01 1.31e-01
Nucleobase catabolism 36 6.20e-01 7.14e-01 0.09700 9.42e-02 -2.31e-02 3.28e-01 8.11e-01
Regulation of TNFR1 signaling 35 6.66e-01 7.53e-01 0.09640 -7.74e-02 5.75e-02 4.29e-01 5.56e-01
Reproduction 75 3.36e-01 4.80e-01 0.09610 9.61e-02 1.49e-03 1.50e-01 9.82e-01
SUMOylation 165 1.43e-01 2.67e-01 0.09600 -4.58e-02 8.44e-02 3.11e-01 6.17e-02
Rho GTPase cycle 134 1.74e-01 3.08e-01 0.09560 -1.95e-02 9.36e-02 6.97e-01 6.17e-02
Transcriptional regulation of white adipocyte differentiation 80 3.92e-01 5.36e-01 0.09520 -4.41e-02 8.44e-02 4.96e-01 1.92e-01
Nuclear Receptor transcription pathway 50 4.59e-01 5.92e-01 0.09500 -9.21e-02 -2.33e-02 2.60e-01 7.76e-01
Nuclear import of Rev protein 33 5.95e-01 6.94e-01 0.09490 9.09e-02 2.73e-02 3.66e-01 7.86e-01
Cell death signalling via NRAGE, NRIF and NADE 74 4.03e-01 5.42e-01 0.09480 -2.97e-02 9.01e-02 6.59e-01 1.81e-01
Effects of PIP2 hydrolysis 25 6.75e-01 7.60e-01 0.09480 -2.67e-02 -9.10e-02 8.17e-01 4.31e-01
N-Glycan antennae elongation 14 8.48e-01 8.99e-01 0.09420 8.65e-02 -3.74e-02 5.75e-01 8.08e-01
SUMO E3 ligases SUMOylate target proteins 159 1.68e-01 3.02e-01 0.09370 -4.44e-02 8.24e-02 3.34e-01 7.32e-02
Activation of NMDA receptors and postsynaptic events 73 3.18e-01 4.62e-01 0.09340 8.61e-02 3.63e-02 2.04e-01 5.92e-01
IRS-related events triggered by IGF1R 40 6.42e-01 7.31e-01 0.09320 -8.00e-02 4.77e-02 3.81e-01 6.02e-01
SHC-mediated cascade:FGFR4 12 8.65e-01 9.09e-01 0.09310 -2.57e-02 8.95e-02 8.77e-01 5.92e-01
Neuronal System 328 3.20e-02 8.73e-02 0.09290 5.96e-02 -7.12e-02 6.42e-02 2.71e-02
Phase II - Conjugation of compounds 85 4.10e-01 5.50e-01 0.09220 5.98e-02 -7.02e-02 3.41e-01 2.64e-01
IGF1R signaling cascade 41 6.44e-01 7.32e-01 0.09220 -7.78e-02 4.95e-02 3.89e-01 5.84e-01
Defective B4GALT7 causes EDS, progeroid type 20 7.24e-01 8.04e-01 0.09210 6.93e-02 6.08e-02 5.92e-01 6.38e-01
Pexophagy 11 8.51e-01 8.99e-01 0.09210 8.89e-02 2.38e-02 6.10e-01 8.91e-01
Negative epigenetic regulation of rRNA expression 55 4.69e-01 5.95e-01 0.09190 9.16e-03 9.14e-02 9.07e-01 2.41e-01
Uptake and actions of bacterial toxins 25 7.75e-01 8.43e-01 0.09000 5.10e-02 -7.42e-02 6.59e-01 5.21e-01
RNA Polymerase II Transcription 1047 3.78e-05 3.14e-04 0.08960 -4.11e-02 7.96e-02 2.59e-02 1.65e-05
ATF4 activates genes in response to endoplasmic reticulum stress 25 7.35e-01 8.11e-01 0.08930 -3.35e-03 8.92e-02 9.77e-01 4.40e-01
SUMOylation of chromatin organization proteins 56 5.07e-01 6.22e-01 0.08920 -5.40e-03 8.91e-02 9.44e-01 2.49e-01
Transport of Mature Transcript to Cytoplasm 80 4.54e-01 5.87e-01 0.08900 -7.20e-02 5.23e-02 2.66e-01 4.19e-01
Insulin receptor signalling cascade 42 6.65e-01 7.52e-01 0.08870 -6.26e-02 6.28e-02 4.83e-01 4.81e-01
Constitutive Signaling by AKT1 E17K in Cancer 26 7.50e-01 8.23e-01 0.08840 -2.06e-02 8.60e-02 8.56e-01 4.48e-01
CS/DS degradation 14 8.15e-01 8.75e-01 0.08800 5.21e-02 7.10e-02 7.36e-01 6.46e-01
Potassium Channels 83 3.80e-01 5.23e-01 0.08790 7.15e-03 -8.76e-02 9.10e-01 1.68e-01
Metabolism of amino acids and derivatives 308 1.42e-02 4.73e-02 0.08780 3.75e-02 7.94e-02 2.59e-01 1.69e-02
SUMOylation of RNA binding proteins 47 5.15e-01 6.29e-01 0.08780 3.99e-02 7.82e-02 6.36e-01 3.54e-01
NCAM signaling for neurite out-growth 53 4.70e-01 5.96e-01 0.08770 4.38e-02 7.60e-02 5.82e-01 3.39e-01
APC-Cdc20 mediated degradation of Nek2A 25 6.95e-01 7.78e-01 0.08770 6.76e-02 5.58e-02 5.58e-01 6.29e-01
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 42 6.74e-01 7.59e-01 0.08700 -6.77e-02 5.47e-02 4.48e-01 5.40e-01
Signaling by FGFR 74 4.92e-01 6.12e-01 0.08700 -4.58e-02 7.39e-02 4.96e-01 2.72e-01
Phenylalanine and tyrosine metabolism 10 8.96e-01 9.26e-01 0.08620 -1.27e-02 8.53e-02 9.44e-01 6.41e-01
Selective autophagy 57 5.35e-01 6.48e-01 0.08590 -1.04e-02 8.53e-02 8.92e-01 2.66e-01
Peptide hormone metabolism 64 5.61e-01 6.70e-01 0.08420 -4.27e-02 7.25e-02 5.55e-01 3.16e-01
Metabolism 1871 2.52e-10 1.41e-08 0.08410 6.64e-02 5.16e-02 2.99e-06 2.85e-04
Striated Muscle Contraction 24 7.37e-01 8.12e-01 0.08350 3.60e-02 7.53e-02 7.60e-01 5.23e-01
Long-term potentiation 22 8.25e-01 8.82e-01 0.08340 4.72e-02 -6.88e-02 7.02e-01 5.77e-01
Reversible hydration of carbon dioxide 10 9.11e-01 9.35e-01 0.08290 2.73e-02 -7.83e-02 8.81e-01 6.68e-01
Regulation of PTEN mRNA translation 11 8.73e-01 9.13e-01 0.08250 -3.35e-02 -7.53e-02 8.47e-01 6.65e-01
FRS-mediated FGFR3 signaling 14 8.70e-01 9.10e-01 0.08220 -1.21e-02 8.13e-02 9.37e-01 5.99e-01
Negative regulation of TCF-dependent signaling by WNT ligand antagonists 14 8.89e-01 9.22e-01 0.08190 4.99e-02 -6.50e-02 7.47e-01 6.74e-01
PI-3K cascade:FGFR3 12 8.81e-01 9.18e-01 0.08190 -8.19e-02 -1.12e-03 6.23e-01 9.95e-01
PRC2 methylates histones and DNA 22 7.66e-01 8.35e-01 0.08180 3.26e-02 7.50e-02 7.92e-01 5.42e-01
Downstream signaling of activated FGFR2 21 8.25e-01 8.82e-01 0.08140 -2.39e-02 7.79e-02 8.50e-01 5.37e-01
Diseases of carbohydrate metabolism 32 7.05e-01 7.86e-01 0.08060 -7.94e-02 -1.39e-02 4.37e-01 8.92e-01
Acyl chain remodelling of PC 21 7.72e-01 8.41e-01 0.08060 -6.23e-02 -5.12e-02 6.21e-01 6.85e-01
Synthesis of IP2, IP, and Ins in the cytosol 14 8.93e-01 9.24e-01 0.08030 4.67e-02 -6.54e-02 7.62e-01 6.72e-01
Platelet Aggregation (Plug Formation) 36 6.50e-01 7.38e-01 0.08030 4.01e-02 6.96e-02 6.77e-01 4.70e-01
Xenobiotics 13 8.73e-01 9.13e-01 0.08020 8.00e-02 5.76e-03 6.17e-01 9.71e-01
Gene expression (Transcription) 1171 1.05e-04 7.50e-04 0.08010 -3.35e-02 7.27e-02 5.62e-02 3.36e-05
Disorders of transmembrane transporters 163 2.01e-01 3.39e-01 0.07950 -7.95e-02 -6.95e-04 8.04e-02 9.88e-01
Lysine catabolism 12 8.82e-01 9.18e-01 0.07940 -7.86e-02 -1.16e-02 6.37e-01 9.45e-01
P2Y receptors 11 9.04e-01 9.30e-01 0.07920 1.37e-02 -7.80e-02 9.37e-01 6.54e-01
Metabolic disorders of biological oxidation enzymes 29 7.98e-01 8.60e-01 0.07910 6.11e-02 -5.02e-02 5.69e-01 6.40e-01
A tetrasaccharide linker sequence is required for GAG synthesis 26 7.74e-01 8.43e-01 0.07900 -1.16e-03 -7.90e-02 9.92e-01 4.86e-01
tRNA processing in the nucleus 59 5.28e-01 6.43e-01 0.07800 2.65e-02 7.34e-02 7.25e-01 3.30e-01
Ion channel transport 149 1.92e-01 3.29e-01 0.07710 4.40e-02 6.33e-02 3.55e-01 1.83e-01
Post-translational modification: synthesis of GPI-anchored proteins 76 5.70e-01 6.74e-01 0.07670 4.26e-02 -6.38e-02 5.21e-01 3.37e-01
Generic Transcription Pathway 932 8.57e-04 4.57e-03 0.07650 -2.36e-02 7.28e-02 2.27e-01 1.89e-04
IL-6-type cytokine receptor ligand interactions 15 8.61e-01 9.08e-01 0.07590 7.35e-02 1.91e-02 6.22e-01 8.98e-01
Transport of Mature mRNA derived from an Intron-Containing Transcript 72 5.98e-01 6.97e-01 0.07580 -5.97e-02 4.67e-02 3.81e-01 4.93e-01
TNF signaling 44 7.33e-01 8.09e-01 0.07530 -4.61e-02 5.95e-02 5.97e-01 4.95e-01
NoRC negatively regulates rRNA expression 52 6.30e-01 7.21e-01 0.07510 1.15e-03 7.51e-02 9.89e-01 3.49e-01
Prolactin receptor signaling 11 9.27e-01 9.47e-01 0.07450 -5.10e-02 5.43e-02 7.70e-01 7.55e-01
Recycling of bile acids and salts 12 9.04e-01 9.30e-01 0.07430 -5.58e-03 7.40e-02 9.73e-01 6.57e-01
Anchoring of the basal body to the plasma membrane 96 3.71e-01 5.14e-01 0.07410 5.89e-02 4.50e-02 3.19e-01 4.47e-01
Neurotransmitter release cycle 40 7.38e-01 8.12e-01 0.07360 1.84e-02 -7.13e-02 8.40e-01 4.36e-01
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) 94 4.14e-01 5.54e-01 0.07270 6.83e-02 2.49e-02 2.53e-01 6.77e-01
N-glycan antennae elongation in the medial/trans-Golgi 22 8.58e-01 9.05e-01 0.07250 -2.91e-02 6.64e-02 8.13e-01 5.90e-01
Protein localization 157 2.62e-01 4.08e-01 0.07210 9.33e-03 7.15e-02 8.40e-01 1.23e-01
Downstream signaling of activated FGFR3 19 8.85e-01 9.19e-01 0.07210 -4.56e-02 5.58e-02 7.31e-01 6.74e-01
PPARA activates gene expression 114 4.87e-01 6.09e-01 0.07150 -4.65e-02 5.44e-02 3.92e-01 3.17e-01
DNA Repair 280 8.88e-02 1.90e-01 0.07140 6.92e-02 1.74e-02 4.68e-02 6.16e-01
Hyaluronan uptake and degradation 12 9.18e-01 9.42e-01 0.07140 6.91e-02 -1.78e-02 6.79e-01 9.15e-01
O-linked glycosylation 97 4.57e-01 5.89e-01 0.07120 7.11e-02 3.35e-03 2.26e-01 9.55e-01
Formation of the beta-catenin:TCF transactivating complex 40 7.10e-01 7.90e-01 0.07120 -7.00e-02 -1.31e-02 4.44e-01 8.86e-01
Signal Transduction 2201 6.59e-06 6.84e-05 0.07110 -4.34e-02 5.63e-02 1.07e-03 2.25e-05
TNFR1-induced proapoptotic signaling 13 9.24e-01 9.47e-01 0.07000 -4.43e-02 5.41e-02 7.82e-01 7.35e-01
Signaling by NOTCH2 32 8.24e-01 8.82e-01 0.06990 -4.48e-02 5.37e-02 6.61e-01 5.99e-01
Defective B3GAT3 causes JDSSDHD 20 8.34e-01 8.88e-01 0.06990 3.56e-02 6.02e-02 7.83e-01 6.41e-01
Processing of DNA double-strand break ends 62 5.70e-01 6.74e-01 0.06930 4.32e-02 5.42e-02 5.56e-01 4.61e-01
Signaling by FGFR3 in disease 16 8.86e-01 9.20e-01 0.06850 4.24e-03 6.84e-02 9.77e-01 6.36e-01
Signaling by FGFR3 point mutants in cancer 16 8.86e-01 9.20e-01 0.06850 4.24e-03 6.84e-02 9.77e-01 6.36e-01
Interactions of Rev with host cellular proteins 36 7.31e-01 8.08e-01 0.06770 4.48e-02 5.08e-02 6.42e-01 5.98e-01
RNA Polymerase I Promoter Escape 37 7.26e-01 8.05e-01 0.06750 4.57e-02 4.97e-02 6.31e-01 6.01e-01
Regulated proteolysis of p75NTR 11 9.25e-01 9.47e-01 0.06720 8.96e-04 6.72e-02 9.96e-01 7.00e-01
Chromatin modifying enzymes 211 3.07e-01 4.55e-01 0.06690 -5.62e-02 3.64e-02 1.60e-01 3.63e-01
Chromatin organization 211 3.07e-01 4.55e-01 0.06690 -5.62e-02 3.64e-02 1.60e-01 3.63e-01
DNA Double Strand Break Response 43 7.85e-01 8.52e-01 0.06680 -3.73e-02 5.55e-02 6.73e-01 5.29e-01
Inositol phosphate metabolism 46 6.95e-01 7.78e-01 0.06680 2.21e-02 6.30e-02 7.96e-01 4.60e-01
DDX58/IFIH1-mediated induction of interferon-alpha/beta 71 6.76e-01 7.60e-01 0.06660 -4.03e-02 5.30e-02 5.57e-01 4.40e-01
PI3K Cascade 33 7.62e-01 8.33e-01 0.06590 -5.03e-02 -4.25e-02 6.17e-01 6.72e-01
Deposition of new CENPA-containing nucleosomes at the centromere 32 7.88e-01 8.53e-01 0.06570 6.37e-02 1.61e-02 5.33e-01 8.75e-01
Nucleosome assembly 32 7.88e-01 8.53e-01 0.06570 6.37e-02 1.61e-02 5.33e-01 8.75e-01
IRS-mediated signalling 37 8.14e-01 8.75e-01 0.06560 -5.81e-02 3.05e-02 5.41e-01 7.48e-01
Homology Directed Repair 100 4.67e-01 5.95e-01 0.06550 6.14e-02 2.29e-02 2.89e-01 6.93e-01
SUMOylation of intracellular receptors 29 8.32e-01 8.87e-01 0.06520 -6.48e-02 7.42e-03 5.46e-01 9.45e-01
Purine catabolism 18 9.01e-01 9.30e-01 0.06470 -1.94e-02 6.17e-02 8.87e-01 6.50e-01
Rev-mediated nuclear export of HIV RNA 35 7.65e-01 8.35e-01 0.06410 5.39e-02 3.47e-02 5.81e-01 7.23e-01
Peroxisomal lipid metabolism 28 8.69e-01 9.10e-01 0.06370 -4.59e-02 4.42e-02 6.74e-01 6.86e-01
tRNA processing 121 4.10e-01 5.50e-01 0.06370 2.82e-02 5.71e-02 5.93e-01 2.79e-01
TNFR1-induced NFkappaB signaling pathway 26 8.30e-01 8.85e-01 0.06330 2.26e-02 5.91e-02 8.42e-01 6.02e-01
Surfactant metabolism 20 8.78e-01 9.16e-01 0.06320 -6.30e-02 -5.36e-03 6.26e-01 9.67e-01
Phospholipid metabolism 195 2.57e-01 4.04e-01 0.06320 6.00e-02 1.97e-02 1.49e-01 6.35e-01
Activation of gene expression by SREBF (SREBP) 42 8.03e-01 8.64e-01 0.06290 -5.74e-02 2.56e-02 5.20e-01 7.74e-01
Diseases of glycosylation 129 3.86e-01 5.29e-01 0.06280 5.06e-02 3.71e-02 3.21e-01 4.67e-01
Regulation of lipid metabolism by PPARalpha 116 5.64e-01 6.72e-01 0.06260 -3.39e-02 5.26e-02 5.29e-01 3.28e-01
The phototransduction cascade 30 8.24e-01 8.82e-01 0.06260 -7.73e-03 -6.21e-02 9.42e-01 5.56e-01
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) 10 9.51e-01 9.62e-01 0.06260 5.31e-02 -3.30e-02 7.71e-01 8.56e-01
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 26 8.39e-01 8.92e-01 0.06220 1.73e-02 5.97e-02 8.79e-01 5.98e-01
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks 42 8.22e-01 8.82e-01 0.06140 -4.35e-02 4.33e-02 6.25e-01 6.27e-01
Plasma lipoprotein clearance 32 8.67e-01 9.09e-01 0.05990 -4.62e-02 3.80e-02 6.51e-01 7.10e-01
PI-3K cascade:FGFR2 14 9.40e-01 9.55e-01 0.05960 -4.41e-02 4.00e-02 7.75e-01 7.95e-01
GABA synthesis, release, reuptake and degradation 13 9.43e-01 9.57e-01 0.05930 3.00e-02 -5.12e-02 8.51e-01 7.49e-01
Tryptophan catabolism 14 9.41e-01 9.55e-01 0.05930 -3.85e-02 4.51e-02 8.03e-01 7.70e-01
Metabolism of non-coding RNA 52 7.54e-01 8.26e-01 0.05920 -1.31e-03 5.92e-02 9.87e-01 4.60e-01
snRNP Assembly 52 7.54e-01 8.26e-01 0.05920 -1.31e-03 5.92e-02 9.87e-01 4.60e-01
Biological oxidations 175 3.65e-01 5.08e-01 0.05910 5.85e-02 8.51e-03 1.83e-01 8.46e-01
Nucleotide salvage 21 8.91e-01 9.23e-01 0.05890 5.89e-02 8.91e-04 6.40e-01 9.94e-01
NCAM1 interactions 33 8.49e-01 8.99e-01 0.05770 6.63e-03 -5.73e-02 9.47e-01 5.69e-01
Transmission across Chemical Synapses 212 4.24e-01 5.64e-01 0.05640 4.96e-02 -2.69e-02 2.14e-01 5.01e-01
G alpha (i) signalling events 281 1.90e-01 3.27e-01 0.05630 3.80e-02 4.15e-02 2.75e-01 2.32e-01
DNA Double-Strand Break Repair 128 4.82e-01 6.06e-01 0.05590 4.97e-02 2.55e-02 3.32e-01 6.19e-01
FGFR2 alternative splicing 26 8.63e-01 9.08e-01 0.05520 4.74e-02 2.83e-02 6.76e-01 8.03e-01
Chondroitin sulfate/dermatan sulfate metabolism 50 8.17e-01 8.77e-01 0.05500 -5.11e-02 2.03e-02 5.32e-01 8.04e-01
O-linked glycosylation of mucins 50 7.66e-01 8.35e-01 0.05470 -1.87e-02 -5.15e-02 8.19e-01 5.29e-01
Other interleukin signaling 19 9.03e-01 9.30e-01 0.05390 2.62e-02 4.72e-02 8.43e-01 7.22e-01
Nicotinate metabolism 30 8.51e-01 8.99e-01 0.05330 3.61e-02 3.92e-02 7.32e-01 7.10e-01
Interleukin-15 signaling 14 9.48e-01 9.60e-01 0.05290 -5.02e-02 1.67e-02 7.45e-01 9.14e-01
RNA Polymerase I Transcription Termination 27 8.67e-01 9.09e-01 0.05290 -3.44e-02 -4.01e-02 7.57e-01 7.18e-01
Resolution of D-Loop Structures 33 8.95e-01 9.25e-01 0.05220 3.75e-02 -3.63e-02 7.09e-01 7.18e-01
Oxidative Stress Induced Senescence 71 7.08e-01 7.88e-01 0.05210 4.83e-02 1.96e-02 4.82e-01 7.76e-01
Interleukin-37 signaling 19 9.44e-01 9.57e-01 0.04940 -3.54e-02 3.45e-02 7.89e-01 7.95e-01
Transport of the SLBP Dependant Mature mRNA 36 8.54e-01 9.02e-01 0.04890 2.18e-02 4.38e-02 8.21e-01 6.50e-01
Factors involved in megakaryocyte development and platelet production 126 5.89e-01 6.88e-01 0.04820 2.05e-02 4.36e-02 6.91e-01 3.99e-01
Transport of the SLBP independent Mature mRNA 35 8.62e-01 9.08e-01 0.04810 2.18e-02 4.29e-02 8.23e-01 6.61e-01
Autophagy 119 6.87e-01 7.71e-01 0.04630 -6.32e-03 4.59e-02 9.05e-01 3.88e-01
Carboxyterminal post-translational modifications of tubulin 28 9.28e-01 9.47e-01 0.04600 -3.92e-02 2.39e-02 7.19e-01 8.27e-01
Plasma lipoprotein assembly, remodeling, and clearance 64 8.33e-01 8.87e-01 0.04560 4.36e-02 -1.34e-02 5.47e-01 8.53e-01
NR1H2 and NR1H3-mediated signaling 44 8.82e-01 9.19e-01 0.04530 1.31e-02 -4.34e-02 8.80e-01 6.19e-01
HATs acetylate histones 87 7.89e-01 8.53e-01 0.04530 -1.74e-02 4.19e-02 7.80e-01 5.00e-01
Protein methylation 14 9.49e-01 9.61e-01 0.04500 1.96e-02 4.05e-02 8.99e-01 7.93e-01
KSRP (KHSRP) binds and destabilizes mRNA 16 9.41e-01 9.55e-01 0.04480 2.96e-02 3.36e-02 8.38e-01 8.16e-01
Chondroitin sulfate biosynthesis 20 9.51e-01 9.62e-01 0.04470 -3.48e-02 2.81e-02 7.88e-01 8.28e-01
Association of TriC/CCT with target proteins during biosynthesis 39 8.70e-01 9.10e-01 0.04430 -4.01e-02 -1.88e-02 6.65e-01 8.39e-01
Organelle biogenesis and maintenance 271 4.51e-01 5.87e-01 0.04430 -3.14e-03 4.42e-02 9.29e-01 2.12e-01
MTOR signalling 41 8.75e-01 9.13e-01 0.04410 4.34e-02 7.75e-03 6.31e-01 9.32e-01
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux 35 9.09e-01 9.35e-01 0.04390 1.08e-02 -4.25e-02 9.12e-01 6.63e-01
Metabolism of lipids 660 1.36e-01 2.59e-01 0.04390 4.39e-03 4.37e-02 8.48e-01 5.72e-02
NRAGE signals death through JNK 57 8.65e-01 9.09e-01 0.04330 -1.43e-02 4.09e-02 8.52e-01 5.93e-01
Transport of small molecules 634 1.85e-01 3.21e-01 0.04180 4.18e-02 1.05e-03 7.43e-02 9.64e-01
Neurotransmitter receptors and postsynaptic signal transmission 160 6.17e-01 7.12e-01 0.04160 3.97e-02 1.25e-02 3.87e-01 7.85e-01
Cilium Assembly 182 6.38e-01 7.27e-01 0.04150 -4.08e-02 7.66e-03 3.43e-01 8.59e-01
HS-GAG biosynthesis 28 9.36e-01 9.54e-01 0.04010 -5.94e-03 3.96e-02 9.57e-01 7.17e-01
RMTs methylate histone arginines 36 9.01e-01 9.30e-01 0.03990 3.62e-02 1.68e-02 7.07e-01 8.62e-01
Regulation of gene expression by Hypoxia-inducible Factor 11 9.79e-01 9.86e-01 0.03900 -2.90e-02 2.62e-02 8.68e-01 8.80e-01
Inactivation, recovery and regulation of the phototransduction cascade 29 9.25e-01 9.47e-01 0.03860 -1.58e-02 -3.52e-02 8.83e-01 7.43e-01
Amino acids regulate mTORC1 51 8.84e-01 9.19e-01 0.03830 3.81e-02 4.59e-03 6.38e-01 9.55e-01
PKMTs methylate histone lysines 44 9.25e-01 9.47e-01 0.03750 -3.04e-02 2.20e-02 7.27e-01 8.01e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release 18 9.69e-01 9.78e-01 0.03650 -1.61e-02 3.28e-02 9.06e-01 8.10e-01
Cell-cell junction organization 51 8.90e-01 9.23e-01 0.03500 1.84e-02 2.97e-02 8.20e-01 7.14e-01
mRNA Splicing - Minor Pathway 50 9.32e-01 9.51e-01 0.03370 2.19e-02 -2.57e-02 7.89e-01 7.54e-01
Metabolism of water-soluble vitamins and cofactors 114 8.23e-01 8.82e-01 0.03290 -1.08e-03 -3.29e-02 9.84e-01 5.45e-01
Transport of Mature mRNAs Derived from Intronless Transcripts 42 9.34e-01 9.52e-01 0.03250 -1.24e-03 3.25e-02 9.89e-01 7.16e-01
Transport of Mature mRNA Derived from an Intronless Transcript 41 9.40e-01 9.55e-01 0.03150 -1.78e-03 3.15e-02 9.84e-01 7.28e-01
Class A/1 (Rhodopsin-like receptors) 191 8.55e-01 9.03e-01 0.02580 -1.56e-02 2.05e-02 7.10e-01 6.26e-01
GPCR ligand binding 264 7.95e-01 8.58e-01 0.02510 -6.59e-03 2.43e-02 8.54e-01 4.98e-01
Eicosanoid ligand-binding receptors 11 9.88e-01 9.92e-01 0.02450 -1.23e-02 -2.11e-02 9.44e-01 9.03e-01
Resolution of D-loop Structures through Holliday Junction Intermediates 32 9.78e-01 9.85e-01 0.02380 1.83e-02 -1.51e-02 8.58e-01 8.82e-01
mRNA decay by 3' to 5' exoribonuclease 15 9.89e-01 9.92e-01 0.02340 2.24e-02 -6.54e-03 8.80e-01 9.65e-01
Visual phototransduction 83 9.27e-01 9.47e-01 0.02260 -8.41e-03 -2.09e-02 8.95e-01 7.42e-01
Metabolism of steroids 128 9.02e-01 9.30e-01 0.02090 1.01e-02 1.83e-02 8.43e-01 7.21e-01
Activation of HOX genes during differentiation 69 9.64e-01 9.73e-01 0.02060 -1.08e-02 1.76e-02 8.77e-01 8.01e-01
Activation of anterior HOX genes in hindbrain development during early embryogenesis 69 9.64e-01 9.73e-01 0.02060 -1.08e-02 1.76e-02 8.77e-01 8.01e-01
Macroautophagy 108 9.37e-01 9.54e-01 0.01850 6.19e-03 1.74e-02 9.12e-01 7.55e-01
Regulation of FOXO transcriptional activity by acetylation 10 9.95e-01 9.97e-01 0.01630 -6.64e-03 -1.49e-02 9.71e-01 9.35e-01
HDMs demethylate histones 23 9.94e-01 9.97e-01 0.01430 -6.97e-03 1.25e-02 9.54e-01 9.18e-01
Metabolism of vitamins and cofactors 175 9.70e-01 9.78e-01 0.01180 -9.57e-03 6.86e-03 8.27e-01 8.76e-01
Glycosaminoglycan metabolism 114 9.82e-01 9.88e-01 0.01110 9.52e-03 -5.73e-03 8.61e-01 9.16e-01
Repression of WNT target genes 14 9.98e-01 9.99e-01 0.00971 4.01e-03 8.84e-03 9.79e-01 9.54e-01
Glycogen storage diseases 15 9.99e-01 9.99e-01 0.00706 -6.92e-03 1.39e-03 9.63e-01 9.93e-01
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 10 9.99e-01 9.99e-01 0.00697 -6.96e-03 3.71e-04 9.70e-01 9.98e-01
Diseases of metabolism 217 9.86e-01 9.91e-01 0.00596 2.54e-03 5.40e-03 9.49e-01 8.91e-01


Detailed Gene set reports


Folding of actin by CCT/TriC

Folding of actin by CCT/TriC
metric value
setSize 10
pMANOVA 3.94e-05
p.adjustMANOVA 0.000325
s.dist 0.881
s.diabetes -0.791
s.mitoG 0.389
p.diabetes 1.49e-05
p.mitoG 0.0334




Top 20 genes
Gene diabetes mitoG
CCT6A -6594 8781
TCP1 -6476 7694
CCT5 -6746 6513
ACTB -4152 7953
CCT7 -4755 5328
CCT2 -5508 4188
CCT8 -6214 2208
CCT4 -4722 2145

Click HERE to show all gene set members

All member genes
diabetes mitoG
ACTB -4152 7953
CCT2 -5508 4188
CCT3 -6871 -215
CCT4 -4722 2145
CCT5 -6746 6513
CCT6A -6594 8781
CCT6B -5158 -3943
CCT7 -4755 5328
CCT8 -6214 2208
TCP1 -6476 7694



Establishment of Sister Chromatid Cohesion

Establishment of Sister Chromatid Cohesion
metric value
setSize 11
pMANOVA 6.11e-05
p.adjustMANOVA 0.000468
s.dist 0.838
s.diabetes -0.488
s.mitoG 0.681
p.diabetes 0.00503
p.mitoG 9.08e-05




Top 20 genes
Gene diabetes mitoG
WAPL -5506 8690
PDS5A -5431 8725
SMC3 -4007 8640
STAG2 -3857 8559
STAG1 -4924 6068
ESCO1 -3108 7987
SMC1A -2764 6742
RAD21 -2278 8063
PDS5B -4646 3792
ESCO2 -1964 3305

Click HERE to show all gene set members

All member genes
diabetes mitoG
CDCA5 1553 -680
ESCO1 -3108 7987
ESCO2 -1964 3305
PDS5A -5431 8725
PDS5B -4646 3792
RAD21 -2278 8063
SMC1A -2764 6742
SMC3 -4007 8640
STAG1 -4924 6068
STAG2 -3857 8559
WAPL -5506 8690



Cohesin Loading onto Chromatin

Cohesin Loading onto Chromatin
metric value
setSize 10
pMANOVA 0.000173
p.adjustMANOVA 0.00113
s.dist 0.832
s.diabetes -0.5
s.mitoG 0.665
p.diabetes 0.00614
p.mitoG 0.00027




Top 20 genes
Gene diabetes mitoG
WAPL -5506 8690
PDS5A -5431 8725
NIPBL -5366 8173
SMC3 -4007 8640
STAG2 -3857 8559
STAG1 -4924 6068
SMC1A -2764 6742
RAD21 -2278 8063
PDS5B -4646 3792

Click HERE to show all gene set members

All member genes
diabetes mitoG
MAU2 4263 -5182
NIPBL -5366 8173
PDS5A -5431 8725
PDS5B -4646 3792
RAD21 -2278 8063
SMC1A -2764 6742
SMC3 -4007 8640
STAG1 -4924 6068
STAG2 -3857 8559
WAPL -5506 8690



tRNA processing in the mitochondrion

tRNA processing in the mitochondrion
metric value
setSize 18
pMANOVA 1.74e-07
p.adjustMANOVA 3.29e-06
s.dist 0.718
s.diabetes 0.116
s.mitoG 0.709
p.diabetes 0.395
p.mitoG 1.91e-07




Top 20 genes
Gene diabetes mitoG
MT-ND5 6025 8007
MT-ND1 5618 7323
MT-ND6 5059 8045
MT-CO1 6781 5983
MT-CYB 3577 8110
MT-ND4L 2829 8068
HSD17B10 3539 5976
MT-ATP8 3277 6153
MT-ND3 1835 8689
MT-CO3 2273 6269
MT-ND4 1752 7883
ELAC2 3639 1857

Click HERE to show all gene set members

All member genes
diabetes mitoG
ELAC2 3639.0 1857.0
HSD17B10 3539.0 5976.0
MT-ATP6 -5818.0 8744.0
MT-ATP8 3277.0 6153.0
MT-CO1 6781.0 5983.0
MT-CO2 293.0 -1711.0
MT-CO3 2273.0 6269.0
MT-CYB 3577.0 8110.0
MT-ND1 5618.0 7323.0
MT-ND2 -1693.0 8626.0
MT-ND3 1835.0 8689.0
MT-ND4 1752.0 7883.0
MT-ND4L 2829.0 8068.0
MT-ND5 6025.0 8007.0
MT-ND6 5059.0 8045.0
PRORP -4253.5 5249.5
TRMT10C -5437.0 8416.0
TRNT1 -4756.0 6488.0



ATF6 (ATF6-alpha) activates chaperone genes

ATF6 (ATF6-alpha) activates chaperone genes
metric value
setSize 10
pMANOVA 0.00304
p.adjustMANOVA 0.0141
s.dist 0.677
s.diabetes -0.566
s.mitoG 0.372
p.diabetes 0.00195
p.mitoG 0.0416




Top 20 genes
Gene diabetes mitoG
HSP90B1 -7279 8368
HSPA5 -7309 7589
ATF6 -6191 8479
XBP1 -7174 6737
ATF4 -6143 7857
CALR -7105 5809
NFYA -6056 1269

Click HERE to show all gene set members

All member genes
diabetes mitoG
ATF4 -6143 7857
ATF6 -6191 8479
CALR -7105 5809
DDIT3 -2070 -609
HSP90B1 -7279 8368
HSPA5 -7309 7589
NFYA -6056 1269
NFYB 4475 -1375
NFYC 5234 -4754
XBP1 -7174 6737



Attenuation phase

Attenuation phase
metric value
setSize 22
pMANOVA 2.93e-06
p.adjustMANOVA 3.39e-05
s.dist 0.673
s.diabetes -0.58
s.mitoG 0.341
p.diabetes 2.45e-06
p.mitoG 0.00565




Top 20 genes
Gene diabetes mitoG
HSP90AA1 -7286.0 8742.0
PTGES3 -7067.0 8733.0
HSPA8 -7307.0 8180.0
UBB -7104.0 8341.0
HSPA1A -7272.5 7293.5
HSPA1B -7272.5 7293.5
DNAJB6 -6088.0 7159.0
HSP90AB1 -7306.0 5626.0
HSPH1 -7334.0 5252.0
SERPINH1 -7218.0 4296.0
CREBBP -6181.0 3954.0
DNAJB1 -7114.0 1852.0
MRPL18 -4156.0 1438.0
COL4A6 -3205.0 1099.0
EP300 -2449.0 1336.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
COL4A6 -3205.0 1099.0
CREBBP -6181.0 3954.0
DEDD2 242.0 -4343.0
DNAJB1 -7114.0 1852.0
DNAJB6 -6088.0 7159.0
EP300 -2449.0 1336.0
FKBP4 -7096.0 -111.0
HSF1 -1770.0 -3977.0
HSP90AA1 -7286.0 8742.0
HSP90AB1 -7306.0 5626.0
HSPA1A -7272.5 7293.5
HSPA1B -7272.5 7293.5
HSPA1L -3778.0 -133.0
HSPA2 7012.0 5387.0
HSPA8 -7307.0 8180.0
HSPH1 -7334.0 5252.0
MRPL18 -4156.0 1438.0
PTGES3 -7067.0 8733.0
RLN1 2347.5 469.5
SERPINH1 -7218.0 4296.0
TNFRSF21 7819.0 3310.0
UBB -7104.0 8341.0



MyD88 deficiency (TLR2/4)

MyD88 deficiency (TLR2/4)
metric value
setSize 10
pMANOVA 0.00385
p.adjustMANOVA 0.0169
s.dist 0.669
s.diabetes -0.432
s.mitoG 0.511
p.diabetes 0.0179
p.mitoG 0.00518




Top 20 genes
Gene diabetes mitoG
CD36 -7328 6006
TLR4 -4128 8470
TLR6 -4778 7142
BTK -5279 5486
MYD88 -5933 3612
TIRAP -3143 6369
TLR1 -3224 560
LY96 -4879 364

Click HERE to show all gene set members

All member genes
diabetes mitoG
BTK -5279 5486
CD14 4081 6994
CD36 -7328 6006
LY96 -4879 364
MYD88 -5933 3612
TIRAP -3143 6369
TLR1 -3224 560
TLR2 5407 5188
TLR4 -4128 8470
TLR6 -4778 7142



Classical antibody-mediated complement activation

Classical antibody-mediated complement activation
metric value
setSize 22
pMANOVA 3.07e-06
p.adjustMANOVA 3.53e-05
s.dist 0.644
s.diabetes -0.177
s.mitoG 0.619
p.diabetes 0.15
p.mitoG 5.07e-07




Top 20 genes
Gene diabetes mitoG
IGHV1-69 -7353.5 8845.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
C1QA -4412.0 7389.0
IGKC -2925.0 7318.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
C1QB -2143.0 5685.0
CRP -3243.0 1012.0
C1QC -1561.0 780.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
C1QA -4412.0 7389.0
C1QB -2143.0 5685.0
C1QC -1561.0 780.0
C1R 1107.0 6557.0
C1S 644.0 7556.0
CRP -3243.0 1012.0
IGHV1-69 -7353.5 8845.5
IGHV2-5 4395.0 4965.0
IGHV2-70 4395.0 4965.0
IGHV7-81 517.5 7570.5
IGKC -2925.0 7318.0
IGKV1-12 2052.5 4944.5
IGKV1-17 2052.5 4944.5
IGKV1-39 2052.5 4944.5
IGKV1D-12 2052.5 4944.5
IGKV1D-39 2052.5 4944.5
IGKV2-30 101.5 8396.5
IGKV2D-30 101.5 8396.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5



Formation of tubulin folding intermediates by CCT/TriC

Formation of tubulin folding intermediates by CCT/TriC
metric value
setSize 20
pMANOVA 3.45e-05
p.adjustMANOVA 0.000291
s.dist 0.642
s.diabetes -0.509
s.mitoG 0.39
p.diabetes 8.09e-05
p.mitoG 0.0025




Top 20 genes
Gene diabetes mitoG
CCT6A -6594 8781
TCP1 -6476 7694
TUBB4B -5222 8679
CCT5 -6746 6513
TUBA4A -5187 7242
TUBA1C -3546 8104
CCT7 -4755 5328
CCT2 -5508 4188
TUBA1B -2891 7211
TUBA1A -1927 8153
CCT8 -6214 2208
CCT4 -4722 2145
TUBB1 -954 3430

Click HERE to show all gene set members

All member genes
diabetes mitoG
CCT2 -5508 4188
CCT3 -6871 -215
CCT4 -4722 2145
CCT5 -6746 6513
CCT6A -6594 8781
CCT6B -5158 -3943
CCT7 -4755 5328
CCT8 -6214 2208
TCP1 -6476 7694
TUBA1A -1927 8153
TUBA1B -2891 7211
TUBA1C -3546 8104
TUBA4A -5187 7242
TUBA8 2488 -2512
TUBB1 -954 3430
TUBB2A 1093 8351
TUBB2B 3491 6524
TUBB4A -797 -1288
TUBB4B -5222 8679
TUBB6 -3844 -5018



Prefoldin mediated transfer of substrate to CCT/TriC

Prefoldin mediated transfer of substrate to CCT/TriC
metric value
setSize 25
pMANOVA 3.93e-06
p.adjustMANOVA 4.34e-05
s.dist 0.634
s.diabetes -0.467
s.mitoG 0.43
p.diabetes 5.37e-05
p.mitoG 2e-04




Top 20 genes
Gene diabetes mitoG
CCT6A -6594 8781
TCP1 -6476 7694
TUBB4B -5222 8679
CCT5 -6746 6513
VBP1 -5361 8016
TUBA4A -5187 7242
ACTB -4152 7953
TUBA1C -3546 8104
CCT7 -4755 5328
CCT2 -5508 4188
TUBA1A -1927 8153
CCT8 -6214 2208
CCT4 -4722 2145
PFDN2 -1073 7198
TUBB1 -954 3430
PFDN1 -3515 485
PFDN4 -210 3562

Click HERE to show all gene set members

All member genes
diabetes mitoG
ACTB -4152 7953
CCT2 -5508 4188
CCT3 -6871 -215
CCT4 -4722 2145
CCT5 -6746 6513
CCT6A -6594 8781
CCT6B -5158 -3943
CCT7 -4755 5328
CCT8 -6214 2208
PFDN1 -3515 485
PFDN2 -1073 7198
PFDN4 -210 3562
PFDN5 2482 8089
PFDN6 2162 -2593
TCP1 -6476 7694
TUBA1A -1927 8153
TUBA1C -3546 8104
TUBA4A -5187 7242
TUBB1 -954 3430
TUBB2A 1093 8351
TUBB2B 3491 6524
TUBB4A -797 -1288
TUBB4B -5222 8679
TUBB6 -3844 -5018
VBP1 -5361 8016



IRAK4 deficiency (TLR2/4)

IRAK4 deficiency (TLR2/4)
metric value
setSize 11
pMANOVA 0.00439
p.adjustMANOVA 0.0187
s.dist 0.628
s.diabetes -0.371
s.mitoG 0.506
p.diabetes 0.033
p.mitoG 0.00365




Top 20 genes
Gene diabetes mitoG
CD36 -7328 6006
TLR4 -4128 8470
TLR6 -4778 7142
BTK -5279 5486
MYD88 -5933 3612
TIRAP -3143 6369
TLR1 -3224 560
LY96 -4879 364

Click HERE to show all gene set members

All member genes
diabetes mitoG
BTK -5279 5486
CD14 4081 6994
CD36 -7328 6006
IRAK4 2339 4636
LY96 -4879 364
MYD88 -5933 3612
TIRAP -3143 6369
TLR1 -3224 560
TLR2 5407 5188
TLR4 -4128 8470
TLR6 -4778 7142



Cytosolic iron-sulfur cluster assembly

Cytosolic iron-sulfur cluster assembly
metric value
setSize 13
pMANOVA 0.00197
p.adjustMANOVA 0.00967
s.dist 0.617
s.diabetes 0.507
s.mitoG -0.353
p.diabetes 0.00156
p.mitoG 0.0277




Top 20 genes
Gene diabetes mitoG
NDOR1 7585.0 -6564.0
MMS19 7591.0 -6460.0
ERCC2 6295.0 -6411.0
CIAO2B 5422.0 -6319.0
POLD1 4995.0 -5596.0
RTEL1 5543.5 -4539.5
NUBP1 6858.0 -1573.0
CIAO3 1942.0 -1857.0
CIAPIN1 6552.0 -65.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
ABCB7 -5950.0 8196.0
BRIP1 6470.0 3893.0
CIAO1 2402.0 4375.0
CIAO2B 5422.0 -6319.0
CIAO3 1942.0 -1857.0
CIAPIN1 6552.0 -65.0
ERCC2 6295.0 -6411.0
MMS19 7591.0 -6460.0
NDOR1 7585.0 -6564.0
NUBP1 6858.0 -1573.0
NUBP2 1692.0 509.0
POLD1 4995.0 -5596.0
RTEL1 5543.5 -4539.5



Glucuronidation

Glucuronidation
metric value
setSize 16
pMANOVA 0.000647
p.adjustMANOVA 0.00353
s.dist 0.609
s.diabetes 0.448
s.mitoG -0.413
p.diabetes 0.00193
p.mitoG 0.00427




Top 20 genes
Gene diabetes mitoG
UGT1A10 8268.5 -6174.5
UGT1A7 8268.5 -6174.5
UGT1A8 8268.5 -6174.5
UGT1A9 8268.5 -6174.5
UGT1A3 8254.0 -5328.0
UGT1A4 8254.0 -5328.0
UGT1A5 8254.0 -5328.0
SLC35D1 7505.0 -5061.0
UGT1A1 8194.0 -551.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
ABHD10 149.0 3960.0
SLC35D1 7505.0 -5061.0
UGDH 7487.0 4096.0
UGP2 -6121.0 8636.0
UGT1A1 8194.0 -551.0
UGT1A10 8268.5 -6174.5
UGT1A3 8254.0 -5328.0
UGT1A4 8254.0 -5328.0
UGT1A5 8254.0 -5328.0
UGT1A6 -1567.0 -5689.0
UGT1A7 8268.5 -6174.5
UGT1A8 8268.5 -6174.5
UGT1A9 8268.5 -6174.5
UGT2A2 4001.0 290.0
UGT2A3 -6867.0 -5535.0
UGT3A2 -7338.0 5454.0



Regulation of TLR by endogenous ligand

Regulation of TLR by endogenous ligand
metric value
setSize 15
pMANOVA 0.000137
p.adjustMANOVA 0.000955
s.dist 0.605
s.diabetes 0.0464
s.mitoG 0.603
p.diabetes 0.756
p.mitoG 5.23e-05




Top 20 genes
Gene diabetes mitoG
APOB 7604 5782
LBP 4550 7403
FGG 5980 5427
CD14 4081 6994
TLR2 5407 5188
FGA 4508 5893
HMGB1 2876 8283
S100A1 1975 8367
FGB 3640 3338

Click HERE to show all gene set members

All member genes
diabetes mitoG
APOB 7604 5782
CD14 4081 6994
CD36 -7328 6006
FGA 4508 5893
FGB 3640 3338
FGG 5980 5427
HMGB1 2876 8283
LBP 4550 7403
LY96 -4879 364
S100A1 1975 8367
S100A8 -3981 6893
TLR1 -3224 560
TLR2 5407 5188
TLR4 -4128 8470
TLR6 -4778 7142



CD28 dependent Vav1 pathway

CD28 dependent Vav1 pathway
metric value
setSize 12
pMANOVA 0.00416
p.adjustMANOVA 0.0178
s.dist 0.602
s.diabetes -0.338
s.mitoG 0.498
p.diabetes 0.0427
p.mitoG 0.0028




Top 20 genes
Gene diabetes mitoG
CDC42 -5961 8129
PAK2 -4906 6708
CD28 -4408 5134
VAV1 -4395 5076
CD86 -2679 5554
FYN -2200 6221
LCK -2194 5687
CD80 -3453 3286
RAC1 -1258 4008
PAK1 -886 5458

Click HERE to show all gene set members

All member genes
diabetes mitoG
CD28 -4408 5134
CD80 -3453 3286
CD86 -2679 5554
CDC42 -5961 8129
FYN -2200 6221
GRB2 3285 1922
LCK -2194 5687
PAK1 -886 5458
PAK2 -4906 6708
PAK3 2878 1881
RAC1 -1258 4008
VAV1 -4395 5076



Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding

Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
metric value
setSize 27
pMANOVA 5.89e-06
p.adjustMANOVA 6.25e-05
s.dist 0.601
s.diabetes -0.438
s.mitoG 0.41
p.diabetes 8.05e-05
p.mitoG 0.000223




Top 20 genes
Gene diabetes mitoG
CCT6A -6594 8781
TCP1 -6476 7694
TUBB4B -5222 8679
CCT5 -6746 6513
VBP1 -5361 8016
TUBA4A -5187 7242
ACTB -4152 7953
TUBA1C -3546 8104
CCT7 -4755 5328
CCT2 -5508 4188
TUBA1B -2891 7211
TUBA1A -1927 8153
CCT8 -6214 2208
CCT4 -4722 2145
PFDN2 -1073 7198
TUBB1 -954 3430
PFDN1 -3515 485
PFDN4 -210 3562

Click HERE to show all gene set members

All member genes
diabetes mitoG
ACTB -4152 7953
CCT2 -5508 4188
CCT3 -6871 -215
CCT4 -4722 2145
CCT5 -6746 6513
CCT6A -6594 8781
CCT6B -5158 -3943
CCT7 -4755 5328
CCT8 -6214 2208
PFDN1 -3515 485
PFDN2 -1073 7198
PFDN4 -210 3562
PFDN5 2482 8089
PFDN6 2162 -2593
TCP1 -6476 7694
TUBA1A -1927 8153
TUBA1B -2891 7211
TUBA1C -3546 8104
TUBA4A -5187 7242
TUBA8 2488 -2512
TUBB1 -954 3430
TUBB2A 1093 8351
TUBB2B 3491 6524
TUBB4A -797 -1288
TUBB4B -5222 8679
TUBB6 -3844 -5018
VBP1 -5361 8016



Role of LAT2/NTAL/LAB on calcium mobilization

Role of LAT2/NTAL/LAB on calcium mobilization
metric value
setSize 29
pMANOVA 1.7e-06
p.adjustMANOVA 2.11e-05
s.dist 0.589
s.diabetes -0.244
s.mitoG 0.537
p.diabetes 0.023
p.mitoG 5.67e-07




Top 20 genes
Gene diabetes mitoG
IGHV1-69 -7353.5 8845.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
SOS1 -6566.0 7698.0
LYN -4685.0 8216.0
SYK -6921.0 4480.0
IGKC -2925.0 7318.0
PIK3CA -6347.0 2923.0
FYN -2200.0 6221.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
PDPK1 -4074.0 1936.0
PIK3R1 -839.0 8363.0
LAT2 -2578.0 2305.0
GAB2 -717.0 7438.0
PIK3CB -1756.0 1880.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
FYN -2200.0 6221.0
GAB2 -717.0 7438.0
GRB2 3285.0 1922.0
IGHV1-69 -7353.5 8845.5
IGHV2-5 4395.0 4965.0
IGHV2-70 4395.0 4965.0
IGHV7-81 517.5 7570.5
IGKC -2925.0 7318.0
IGKV1-12 2052.5 4944.5
IGKV1-17 2052.5 4944.5
IGKV1-39 2052.5 4944.5
IGKV1D-12 2052.5 4944.5
IGKV1D-39 2052.5 4944.5
IGKV2-30 101.5 8396.5
IGKV2D-30 101.5 8396.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
LAT2 -2578.0 2305.0
LYN -4685.0 8216.0
PDPK1 -4074.0 1936.0
PIK3CA -6347.0 2923.0
PIK3CB -1756.0 1880.0
PIK3R1 -839.0 8363.0
PIK3R2 1669.5 -3969.5
SHC1 568.0 1962.0
SOS1 -6566.0 7698.0
SYK -6921.0 4480.0



Signaling by Hippo

Signaling by Hippo
metric value
setSize 20
pMANOVA 0.000141
p.adjustMANOVA 0.000972
s.dist 0.584
s.diabetes -0.266
s.mitoG 0.52
p.diabetes 0.0392
p.mitoG 5.71e-05




Top 20 genes
Gene diabetes mitoG
SAV1 -7082.0 8274.0
LATS2 -6449.0 8602.0
AMOTL1 -5250.0 8552.0
YWHAB -4723.0 8579.0
STK4 -5141.0 6978.0
MOB1B -4923.0 7268.0
AMOT -7095.0 4659.0
MOB1A -3643.0 7867.0
TJP2 -3964.5 6046.5
STK3 -2985.0 7280.0
LATS1 -3300.0 5874.0
YWHAE -2079.0 7315.0
YAP1 -4463.0 1332.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
AMOT -7095.0 4659.0
AMOTL1 -5250.0 8552.0
AMOTL2 3350.0 2424.0
CASP3 4881.0 3606.0
DVL2 7754.0 -6212.0
LATS1 -3300.0 5874.0
LATS2 -6449.0 8602.0
MOB1A -3643.0 7867.0
MOB1B -4923.0 7268.0
NPHP4 2213.0 -3773.0
SAV1 -7082.0 8274.0
STK3 -2985.0 7280.0
STK4 -5141.0 6978.0
TJP1 4021.0 8531.0
TJP2 -3964.5 6046.5
WWC1 1462.0 81.0
WWTR1 4978.0 8485.0
YAP1 -4463.0 1332.0
YWHAB -4723.0 8579.0
YWHAE -2079.0 7315.0



ATF6 (ATF6-alpha) activates chaperones

ATF6 (ATF6-alpha) activates chaperones
metric value
setSize 12
pMANOVA 0.00554
p.adjustMANOVA 0.022
s.dist 0.583
s.diabetes -0.497
s.mitoG 0.304
p.diabetes 0.00285
p.mitoG 0.0679




Top 20 genes
Gene diabetes mitoG
HSP90B1 -7279 8368
HSPA5 -7309 7589
ATF6 -6191 8479
XBP1 -7174 6737
ATF4 -6143 7857
CALR -7105 5809
NFYA -6056 1269

Click HERE to show all gene set members

All member genes
diabetes mitoG
ATF4 -6143 7857
ATF6 -6191 8479
CALR -7105 5809
DDIT3 -2070 -609
HSP90B1 -7279 8368
HSPA5 -7309 7589
MBTPS1 -6525 -4354
MBTPS2 5009 5876
NFYA -6056 1269
NFYB 4475 -1375
NFYC 5234 -4754
XBP1 -7174 6737



Scavenging of heme from plasma

Scavenging of heme from plasma
metric value
setSize 29
pMANOVA 6.98e-07
p.adjustMANOVA 1.03e-05
s.dist 0.574
s.diabetes -0.0735
s.mitoG 0.569
p.diabetes 0.494
p.mitoG 1.12e-07




Top 20 genes
Gene diabetes mitoG
IGHV1-69 -7353.5 8845.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
IGHA1 -5036.5 7384.5
IGHA2 -5036.5 7384.5
IGKC -2925.0 7318.0
CD163 -2470.0 7418.0
APOL1 -5660.5 2701.5
JCHAIN -1963.0 6913.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
HP -1369.5 6104.5
HPR -1369.5 6104.5

Click HERE to show all gene set members

All member genes
diabetes mitoG
ALB 6253.0 -380.0
AMBP 4518.0 -3879.0
APOA1 3682.0 -305.0
APOL1 -5660.5 2701.5
CD163 -2470.0 7418.0
HBA1 5772.5 8630.5
HP -1369.5 6104.5
HPR -1369.5 6104.5
HPX 2769.0 2190.0
IGHA1 -5036.5 7384.5
IGHA2 -5036.5 7384.5
IGHV1-69 -7353.5 8845.5
IGHV2-5 4395.0 4965.0
IGHV2-70 4395.0 4965.0
IGHV7-81 517.5 7570.5
IGKC -2925.0 7318.0
IGKV1-12 2052.5 4944.5
IGKV1-17 2052.5 4944.5
IGKV1-39 2052.5 4944.5
IGKV1D-12 2052.5 4944.5
IGKV1D-39 2052.5 4944.5
IGKV2-30 101.5 8396.5
IGKV2D-30 101.5 8396.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
JCHAIN -1963.0 6913.0
LRP1 7344.0 8465.0



CD22 mediated BCR regulation

CD22 mediated BCR regulation
metric value
setSize 20
pMANOVA 0.000118
p.adjustMANOVA 0.000834
s.dist 0.57
s.diabetes -0.157
s.mitoG 0.548
p.diabetes 0.225
p.mitoG 2.22e-05




Top 20 genes
Gene diabetes mitoG
IGHV1-69 -7353.5 8845.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
LYN -4685.0 8216.0
IGKC -2925.0 7318.0
CD79A -4689.0 2648.0
CD79B -2701.0 2433.0
CD22 -4125.0 1554.0
PTPN6 -1098.0 2140.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
CD22 -4125.0 1554.0
CD79A -4689.0 2648.0
CD79B -2701.0 2433.0
IGHM 5659.0 -3544.0
IGHV1-69 -7353.5 8845.5
IGHV2-5 4395.0 4965.0
IGHV2-70 4395.0 4965.0
IGHV7-81 517.5 7570.5
IGKC -2925.0 7318.0
IGKV1-12 2052.5 4944.5
IGKV1-17 2052.5 4944.5
IGKV1-39 2052.5 4944.5
IGKV1D-12 2052.5 4944.5
IGKV1D-39 2052.5 4944.5
IGKV2-30 101.5 8396.5
IGKV2D-30 101.5 8396.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
LYN -4685.0 8216.0
PTPN6 -1098.0 2140.0



Pyrimidine salvage

Pyrimidine salvage
metric value
setSize 10
pMANOVA 0.0125
p.adjustMANOVA 0.0429
s.dist 0.57
s.diabetes 0.533
s.mitoG -0.2
p.diabetes 0.00349
p.mitoG 0.274




Top 20 genes
Gene diabetes mitoG
TYMP 5612 -6441
CDA 4457 -5554
UCKL1 3359 -5927
DCK 3738 -4745
TK2 7046 -155

Click HERE to show all gene set members

All member genes
diabetes mitoG
CDA 4457 -5554
DCK 3738 -4745
TK1 -494 -991
TK2 7046 -155
TYMP 5612 -6441
UCK1 4426 607
UCK2 4470 6711
UCKL1 3359 -5927
UPP1 5774 8231
UPP2 7868 2949



FCGR activation

FCGR activation
metric value
setSize 28
pMANOVA 1.93e-05
p.adjustMANOVA 0.000174
s.dist 0.554
s.diabetes -0.301
s.mitoG 0.465
p.diabetes 0.00585
p.mitoG 2.08e-05




Top 20 genes
Gene diabetes mitoG
IGHV1-69 -7353.5 8845.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
FCGR2A -7297.0 5966.0
LYN -4685.0 8216.0
FCGR3A -5407.5 6212.5
SYK -6921.0 4480.0
FCGR1A -5675.5 4265.5
IGKC -2925.0 7318.0
FYN -2200.0 6221.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
FGR -3144.0 378.0
YES1 -120.0 7265.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
CD247 1213.0 -5666.0
CD3G -1784.0 -3919.0
FCGR1A -5675.5 4265.5
FCGR2A -7297.0 5966.0
FCGR3A -5407.5 6212.5
FGR -3144.0 378.0
FYN -2200.0 6221.0
HCK -3484.0 -1326.0
IGHV1-69 -7353.5 8845.5
IGHV2-5 4395.0 4965.0
IGHV2-70 4395.0 4965.0
IGHV7-81 517.5 7570.5
IGKC -2925.0 7318.0
IGKV1-12 2052.5 4944.5
IGKV1-17 2052.5 4944.5
IGKV1-39 2052.5 4944.5
IGKV1D-12 2052.5 4944.5
IGKV1D-39 2052.5 4944.5
IGKV2-30 101.5 8396.5
IGKV2D-30 101.5 8396.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
LYN -4685.0 8216.0
SRC -2657.0 -1643.0
SYK -6921.0 4480.0
YES1 -120.0 7265.0



Elastic fibre formation

Elastic fibre formation
metric value
setSize 37
pMANOVA 1.43e-09
p.adjustMANOVA 6.91e-08
s.dist 0.549
s.diabetes 0.234
s.mitoG 0.497
p.diabetes 0.0137
p.mitoG 1.7e-07




Top 20 genes
Gene diabetes mitoG
LOX 7282.0 7922.0
LOXL1 6829.0 8361.0
FBN1 6578.0 8391.0
BMP4 6672.0 7143.0
EFEMP1 6611.0 6380.0
ITGA5 5929.0 6964.0
LOXL2 5024.0 8008.0
FBLN2 4810.0 7504.0
FBLN5 4332.0 8272.0
BMP2 4300.0 7938.0
LOXL3 4869.0 6408.0
TGFB2 4490.0 6652.0
ITGAV 8155.0 2693.0
EFEMP2 2292.0 7425.0
MFAP3 2866.0 4624.0
ITGB5 7359.0 1316.0
ITGB3 1530.5 4298.5
MFAP2 6000.0 930.0
MFAP5 479.0 5300.0
LTBP2 415.0 4760.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
BMP2 4300.0 7938.0
BMP4 6672.0 7143.0
BMP7 8109.0 -1080.0
EFEMP1 6611.0 6380.0
EFEMP2 2292.0 7425.0
ELN 3735.0 -4141.0
FBLN1 1746.0 16.0
FBLN2 4810.0 7504.0
FBLN5 4332.0 8272.0
FBN1 6578.0 8391.0
FBN2 -2413.0 6151.0
FURIN 3696.0 -3590.0
ITGA5 5929.0 6964.0
ITGA8 -802.0 4862.0
ITGAV 8155.0 2693.0
ITGB1 -6241.0 8758.0
ITGB3 1530.5 4298.5
ITGB5 7359.0 1316.0
ITGB6 -7094.0 613.0
ITGB8 -1078.0 2920.0
LOX 7282.0 7922.0
LOXL1 6829.0 8361.0
LOXL2 5024.0 8008.0
LOXL3 4869.0 6408.0
LOXL4 -1571.0 8483.0
LTBP1 -5412.0 7176.0
LTBP2 415.0 4760.0
LTBP3 8038.0 -540.0
LTBP4 -6699.0 5054.0
MFAP1 -1345.0 8624.0
MFAP2 6000.0 930.0
MFAP3 2866.0 4624.0
MFAP4 -1577.0 2378.0
MFAP5 479.0 5300.0
TGFB1 -1851.0 6152.0
TGFB2 4490.0 6652.0
TGFB3 -1546.0 8322.0



HSF1 activation

HSF1 activation
metric value
setSize 24
pMANOVA 0.000154
p.adjustMANOVA 0.00105
s.dist 0.542
s.diabetes -0.421
s.mitoG 0.342
p.diabetes 0.000356
p.mitoG 0.00374




Top 20 genes
Gene diabetes mitoG
HSP90AA1 -7286.0 8742.0
PTGES3 -7067.0 8733.0
UBB -7104.0 8341.0
HSPA1A -7272.5 7293.5
HSPA1B -7272.5 7293.5
DNAJB6 -6088.0 7159.0
HSP90AB1 -7306.0 5626.0
VCP -7069.0 5449.0
HSPH1 -7334.0 5252.0
SERPINH1 -7218.0 4296.0
YWHAE -2079.0 7315.0
DNAJB1 -7114.0 1852.0
MRPL18 -4156.0 1438.0
COL4A6 -3205.0 1099.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
COL4A6 -3205.0 1099.0
DEDD2 242.0 -4343.0
DNAJB1 -7114.0 1852.0
DNAJB6 -6088.0 7159.0
FKBP4 -7096.0 -111.0
HDAC6 7878.0 1757.0
HSF1 -1770.0 -3977.0
HSP90AA1 -7286.0 8742.0
HSP90AB1 -7306.0 5626.0
HSPA1A -7272.5 7293.5
HSPA1B -7272.5 7293.5
HSPA1L -3778.0 -133.0
HSPH1 -7334.0 5252.0
MRPL18 -4156.0 1438.0
PTGES3 -7067.0 8733.0
RLN1 2347.5 469.5
RPA1 4920.0 5750.0
RPA2 6082.0 4722.0
RPA3 3029.0 1440.0
SERPINH1 -7218.0 4296.0
TNFRSF21 7819.0 3310.0
UBB -7104.0 8341.0
VCP -7069.0 5449.0
YWHAE -2079.0 7315.0



Creation of C4 and C2 activators

Creation of C4 and C2 activators
metric value
setSize 26
pMANOVA 1.72e-05
p.adjustMANOVA 0.000162
s.dist 0.542
s.diabetes -0.112
s.mitoG 0.531
p.diabetes 0.324
p.mitoG 2.82e-06




Top 20 genes
Gene diabetes mitoG
IGHV1-69 -7353.5 8845.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
C1QA -4412.0 7389.0
IGKC -2925.0 7318.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
C1QB -2143.0 5685.0
CRP -3243.0 1012.0
C1QC -1561.0 780.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
C1QA -4412.0 7389.0
C1QB -2143.0 5685.0
C1QC -1561.0 780.0
C1R 1107.0 6557.0
C1S 644.0 7556.0
COLEC11 631.0 3003.0
CRP -3243.0 1012.0
IGHV1-69 -7353.5 8845.5
IGHV2-5 4395.0 4965.0
IGHV2-70 4395.0 4965.0
IGHV7-81 517.5 7570.5
IGKC -2925.0 7318.0
IGKV1-12 2052.5 4944.5
IGKV1-17 2052.5 4944.5
IGKV1-39 2052.5 4944.5
IGKV1D-12 2052.5 4944.5
IGKV1D-39 2052.5 4944.5
IGKV2-30 101.5 8396.5
IGKV2D-30 101.5 8396.5
IGKV4-1 -7301.0 8840.0
IGKV5-2 -5895.0 8671.0
IGLV4-60 -3537.5 3617.5
IGLV4-69 -3537.5 3617.5
MASP1 7705.0 8599.0
MASP2 -4240.0 -2143.0
MBL2 5539.0 -3910.0



eNOS activation

eNOS activation
metric value
setSize 11
pMANOVA 0.0127
p.adjustMANOVA 0.0432
s.dist 0.54
s.diabetes -0.176
s.mitoG 0.51
p.diabetes 0.313
p.mitoG 0.00339




Top 20 genes
Gene diabetes mitoG
HSP90AA1 -7286 8742
LYPLA1 -6790 7638
CALM1 -4401 8702
ZDHHC21 -4110 5505
DDAH1 -5433 2105

Click HERE to show all gene set members

All member genes
diabetes mitoG
AKT1 4859 7244
CALM1 -4401 8702
CAV1 875 7970
CYGB 7666 8450
DDAH1 -5433 2105
DDAH2 7098 2607
HSP90AA1 -7286 8742
LYPLA1 -6790 7638
NOS3 1400 2054
SPR -3932 -5850
ZDHHC21 -4110 5505



Activation of BAD and translocation to mitochondria

Activation of BAD and translocation to mitochondria
metric value
setSize 15
pMANOVA 0.00335
p.adjustMANOVA 0.0152
s.dist 0.536
s.diabetes -0.218
s.mitoG 0.49
p.diabetes 0.144
p.mitoG 0.00103




Top 20 genes
Gene diabetes mitoG
YWHAH -6051 7949
YWHAZ -5614 8512
YWHAB -4723 8579
AKT2 -4939 3281
YWHAE -2079 7315
YWHAG -5348 1700
AKT3 -375 7862

Click HERE to show all gene set members

All member genes
diabetes mitoG
AKT1 4859.0 7244.0
AKT2 -4939.0 3281.0
AKT3 -375.0 7862.0
BAD -2216.0 -4664.0
BCL2 -1449.0 -2113.0
BID -6112.0 -270.0
PPP3CC 5563.0 4840.0
PPP3R1 2835.5 8199.5
SFN 3916.0 5704.0
YWHAB -4723.0 8579.0
YWHAE -2079.0 7315.0
YWHAG -5348.0 1700.0
YWHAH -6051.0 7949.0
YWHAQ 3046.0 8675.0
YWHAZ -5614.0 8512.0



RHO GTPases activate IQGAPs

RHO GTPases activate IQGAPs
metric value
setSize 11
pMANOVA 0.00883
p.adjustMANOVA 0.0318
s.dist 0.535
s.diabetes -0.0558
s.mitoG 0.532
p.diabetes 0.749
p.mitoG 0.00223




Top 20 genes
Gene diabetes mitoG
CDC42 -5961 8129
CALM1 -4401 8702
CLIP1 -2374 7522
CTNNB1 -6022 2664
CDH1 -1038 5837
RAC1 -1258 4008

Click HERE to show all gene set members

All member genes
diabetes mitoG
CALM1 -4401 8702
CDC42 -5961 8129
CDH1 -1038 5837
CLIP1 -2374 7522
CTNNA1 2129 7795
CTNNB1 -6022 2664
IQGAP1 7427 8123
IQGAP2 8068 6890
IQGAP3 5270 -2082
MEN1 -1596 -513
RAC1 -1258 4008



Apoptosis induced DNA fragmentation

Apoptosis induced DNA fragmentation
metric value
setSize 13
pMANOVA 0.000897
p.adjustMANOVA 0.00474
s.dist 0.534
s.diabetes 0.414
s.mitoG 0.337
p.diabetes 0.00981
p.mitoG 0.0354




Top 20 genes
Gene diabetes mitoG
H1-4 7392 8249
H1-0 7817 6665
H1-2 7795 4082
H1-1 4222 7277
HMGB1 2876 8283
CASP3 4881 3606
HMGB2 6857 1304

Click HERE to show all gene set members

All member genes
diabetes mitoG
CASP3 4881 3606
DFFA 4899 -803
DFFB 6044 -6041
H1-0 7817 6665
H1-1 4222 7277
H1-2 7795 4082
H1-3 3925 -879
H1-4 7392 8249
H1-5 -1450 1228
HMGB1 2876 8283
HMGB2 6857 1304
KPNA1 -5632 8815
KPNB1 -1668 5829



Cellular hexose transport

Cellular hexose transport
metric value
setSize 16
pMANOVA 0.00277
p.adjustMANOVA 0.013
s.dist 0.533
s.diabetes 0.472
s.mitoG -0.247
p.diabetes 0.00108
p.mitoG 0.0873




Top 20 genes
Gene diabetes mitoG
SLC2A8 8092 -6699
SLC5A9 7137 -4112
SLC2A6 5023 -5218
SLC2A4 8055 -2624
SLC45A3 7307 -1341

Click HERE to show all gene set members

All member genes
diabetes mitoG
MFSD4B -7244 -3791
SLC2A1 6575 1160
SLC2A10 -2881 7772
SLC2A12 -2021 -721
SLC2A2 7902 2301
SLC2A4 8055 -2624
SLC2A6 5023 -5218
SLC2A8 8092 -6699
SLC2A9 8222 3166
SLC45A3 7307 -1341
SLC50A1 7423 1711
SLC5A1 7441 3409
SLC5A10 8243 1886
SLC5A2 -269 -5668
SLC5A4 -2676 -5608
SLC5A9 7137 -4112



Metabolism of nitric oxide: NOS3 activation and regulation

Metabolism of nitric oxide: NOS3 activation and regulation
metric value
setSize 15
pMANOVA 0.00351
p.adjustMANOVA 0.0157
s.dist 0.53
s.diabetes -0.197
s.mitoG 0.492
p.diabetes 0.187
p.mitoG 0.00096




Top 20 genes
Gene diabetes mitoG
HSP90AA1 -7286 8742
LYPLA1 -6790 7638
CALM1 -4401 8702
NOSTRIN -5504 6787
WASL -3989 7855
ZDHHC21 -4110 5505
DDAH1 -5433 2105
DNM2 -1598 5364

Click HERE to show all gene set members

All member genes
diabetes mitoG
AKT1 4859 7244
CALM1 -4401 8702
CAV1 875 7970
CYGB 7666 8450
DDAH1 -5433 2105
DDAH2 7098 2607
DNM2 -1598 5364
HSP90AA1 -7286 8742
LYPLA1 -6790 7638
NOS3 1400 2054
NOSIP 4944 -2035
NOSTRIN -5504 6787
SPR -3932 -5850
WASL -3989 7855
ZDHHC21 -4110 5505



Synthesis of active ubiquitin: roles of E1 and E2 enzymes

Synthesis of active ubiquitin: roles of E1 and E2 enzymes
metric value
setSize 30
pMANOVA 2.72e-05
p.adjustMANOVA 0.00024
s.dist 0.529
s.diabetes -0.313
s.mitoG 0.426
p.diabetes 0.00296
p.mitoG 5.29e-05




Top 20 genes
Gene diabetes mitoG
UBB -7104.0 8341.0
UBE2E1 -6831.0 8405.0
UBC -6013.0 8514.0
UCHL3 -5410.0 8491.0
USP9X -5668.0 7709.0
UBA6 -6905.0 6312.0
UBE2A -4551.0 7336.0
USP7 -4172.0 7828.0
UBE2B -4389.0 7152.0
UBE2G2 -6897.0 3570.0
UBE2K -3148.0 7485.0
UBE2L3 -4226.5 5465.5
UBA1 -3069.0 6814.0
UBE2R2 -4372.0 2763.0
UBE2W -2829.5 4199.5
OTULIN -2347.0 4384.0
UBE2H -2417.0 3799.0
UBE2D2 -935.0 6690.0
UBE2Q2 -701.0 7516.0
CDC34 -806.0 2346.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
CDC34 -806.0 2346.0
OTULIN -2347.0 4384.0
RPS27A -133.0 -1807.0
UBA1 -3069.0 6814.0
UBA52 7488.0 -4269.0
UBA6 -6905.0 6312.0
UBB -7104.0 8341.0
UBC -6013.0 8514.0
UBE2A -4551.0 7336.0
UBE2B -4389.0 7152.0
UBE2C 733.0 -1864.0
UBE2D1 5638.0 3025.0
UBE2D2 -935.0 6690.0
UBE2E1 -6831.0 8405.0
UBE2E3 441.0 4538.0
UBE2G1 6022.0 6179.0
UBE2G2 -6897.0 3570.0
UBE2H -2417.0 3799.0
UBE2K -3148.0 7485.0
UBE2L3 -4226.5 5465.5
UBE2Q2 -701.0 7516.0
UBE2R2 -4372.0 2763.0
UBE2S 4549.0 -1742.0
UBE2T -5289.0 -307.0
UBE2W -2829.5 4199.5
UBE2Z 1411.0 812.0
UCHL3 -5410.0 8491.0
USP5 2291.0 1038.0
USP7 -4172.0 7828.0
USP9X -5668.0 7709.0



Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)

Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
metric value
setSize 12
pMANOVA 0.00793
p.adjustMANOVA 0.0298
s.dist 0.528
s.diabetes 0.518
s.mitoG -0.0983
p.diabetes 0.00187
p.mitoG 0.556




Top 20 genes
Gene diabetes mitoG
MLH1 5288.0 -5779.0
MSH2 7784.0 -3657.0
POLD1 4995.0 -5596.0
POLD4 4693.5 -4991.5
MSH3 1132.0 -2806.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
EXO1 -2093.0 1780.0
LIG1 4884.0 892.0
MLH1 5288.0 -5779.0
MSH2 7784.0 -3657.0
MSH3 1132.0 -2806.0
PCNA 5956.0 8353.0
POLD1 4995.0 -5596.0
POLD2 7422.0 3041.0
POLD4 4693.5 -4991.5
RPA1 4920.0 5750.0
RPA2 6082.0 4722.0
RPA3 3029.0 1440.0



Cell-extracellular matrix interactions

Cell-extracellular matrix interactions
metric value
setSize 16
pMANOVA 8e-04
p.adjustMANOVA 0.00428
s.dist 0.526
s.diabetes 0.0313
s.mitoG 0.525
p.diabetes 0.829
p.mitoG 0.000274




Top 20 genes
Gene diabetes mitoG
FBLIM1 6708 8090
PARVA 5964 7822
FERMT2 5215 7566
ARHGEF6 6287 4232
FLNC 3035 7604
ILK 2044 6846

Click HERE to show all gene set members

All member genes
diabetes mitoG
ACTN1 -2202 6473
ARHGEF6 6287 4232
FBLIM1 6708 8090
FERMT2 5215 7566
FLNA -4704 7432
FLNC 3035 7604
ILK 2044 6846
ITGB1 -6241 8758
LIMS1 -2575 8409
LIMS2 3312 -2249
PARVA 5964 7822
PARVB -4468 7551
PXN 1455 -4084
RSU1 -2273 7295
TESK1 2247 -4119
VASP -2568 4503



HSP90 chaperone cycle for steroid hormone receptors (SHR)

HSP90 chaperone cycle for steroid hormone receptors (SHR)
metric value
setSize 37
pMANOVA 3.12e-06
p.adjustMANOVA 3.56e-05
s.dist 0.522
s.diabetes -0.296
s.mitoG 0.43
p.diabetes 0.00184
p.mitoG 6e-06




Top 20 genes
Gene diabetes mitoG
HSP90AA1 -7286.0 8742.0
PTGES3 -7067.0 8733.0
HSPA8 -7307.0 8180.0
CAPZA1 -6942.0 8474.0
STIP1 -7236.0 7449.0
DYNLL1 -6952.0 7645.0
HSPA1A -7272.5 7293.5
HSPA1B -7272.5 7293.5
DNAJA1 -7303.0 6518.0
DNAJA4 -7004.0 6662.0
HSP90AB1 -7306.0 5626.0
DCTN4 -4133.0 7527.0
DNAJA2 -3327.0 8515.0
PGR -4247.0 5891.0
DCTN5 -4033.0 5094.0
CAPZB -2513.0 7203.0
CAPZA2 -1687.0 8135.0
DNAJB1 -7114.0 1852.0
NR3C1 -2732.0 2240.0
DYNC1LI2 -1436.0 1861.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
ACTR10 268.0 6666.0
ACTR1A 965.0 5035.0
AR 2841.0 2349.0
CAPZA1 -6942.0 8474.0
CAPZA2 -1687.0 8135.0
CAPZB -2513.0 7203.0
DCTN1 7218.0 -3098.0
DCTN2 2623.0 -2017.0
DCTN3 -715.0 689.0
DCTN4 -4133.0 7527.0
DCTN5 -4033.0 5094.0
DCTN6 4374.0 7565.0
DNAJA1 -7303.0 6518.0
DNAJA2 -3327.0 8515.0
DNAJA4 -7004.0 6662.0
DNAJB1 -7114.0 1852.0
DYNC1H1 4822.0 2594.0
DYNC1I1 3045.0 -5230.0
DYNC1I2 -251.0 7398.0
DYNC1LI1 2249.0 7292.0
DYNC1LI2 -1436.0 1861.0
DYNLL1 -6952.0 7645.0
DYNLL2 4932.0 -5028.0
FKBP4 -7096.0 -111.0
FKBP5 6201.0 5807.0
HSP90AA1 -7286.0 8742.0
HSP90AB1 -7306.0 5626.0
HSPA1A -7272.5 7293.5
HSPA1B -7272.5 7293.5
HSPA1L -3778.0 -133.0
HSPA2 7012.0 5387.0
HSPA8 -7307.0 8180.0
NR3C1 -2732.0 2240.0
NR3C2 7008.0 -3900.0
PGR -4247.0 5891.0
PTGES3 -7067.0 8733.0
STIP1 -7236.0 7449.0



EPHB-mediated forward signaling

EPHB-mediated forward signaling
metric value
setSize 34
pMANOVA 4.22e-06
p.adjustMANOVA 4.59e-05
s.dist 0.52
s.diabetes -0.183
s.mitoG 0.486
p.diabetes 0.0646
p.mitoG 9.3e-07




Top 20 genes
Gene diabetes mitoG
SDC2 -6850 7623
ARPC3 -5747 8757
CDC42 -5961 8129
RASA1 -5274 8011
RHOA -5203 7671
ARPC2 -4512 8767
LYN -4685 8216
ACTR2 -5189 7356
ACTB -4152 7953
WASL -3989 7855
ACTR3 -3716 8206
ROCK1 -2765 8654
CFL1 -1720 8321
FYN -2200 6221
ROCK2 -1368 8738
ITSN1 -2643 3175
RAC1 -1258 4008
PAK1 -886 5458
ARHGEF28 -1889 2041
ACTG1 -1502 1482

Click HERE to show all gene set members

All member genes
diabetes mitoG
ACTB -4152 7953
ACTG1 -1502 1482
ACTR2 -5189 7356
ACTR3 -3716 8206
ARHGEF28 -1889 2041
ARPC1A -1009 -3070
ARPC1B 7126 2266
ARPC2 -4512 8767
ARPC3 -5747 8757
ARPC4 3077 1525
ARPC5 920 7514
CDC42 -5961 8129
CFL1 -1720 8321
FYN -2200 6221
GRIN1 3290 -5743
GRIN2B -40 2055
HRAS 1503 -318
ITSN1 -2643 3175
KALRN 8046 3199
LIMK1 3519 2264
LIMK2 7085 -848
LYN -4685 8216
PAK1 -886 5458
PTK2 2264 6997
RAC1 -1258 4008
RASA1 -5274 8011
RHOA -5203 7671
ROCK1 -2765 8654
ROCK2 -1368 8738
SDC2 -6850 7623
SRC -2657 -1643
TIAM1 5502 5849
WASL -3989 7855
YES1 -120 7265



Josephin domain DUBs

Josephin domain DUBs
metric value
setSize 11
pMANOVA 0.0166
p.adjustMANOVA 0.0535
s.dist 0.519
s.diabetes -0.496
s.mitoG 0.152
p.diabetes 0.00438
p.mitoG 0.384




Top 20 genes
Gene diabetes mitoG
UBB -7104 8341
RAD23B -6778 7740
UBC -6013 8514
VCP -7069 5449
JOSD1 -6550 274

Click HERE to show all gene set members

All member genes
diabetes mitoG
ATXN3 633.5 4150.5
ATXN3L 633.5 4150.5
JOSD1 -6550.0 274.0
JOSD2 -6887.0 -5777.0
RAD23A -5824.0 -2416.0
RAD23B -6778.0 7740.0
RPS27A -133.0 -1807.0
UBA52 7488.0 -4269.0
UBB -7104.0 8341.0
UBC -6013.0 8514.0
VCP -7069.0 5449.0



Mitotic Telophase/Cytokinesis

Mitotic Telophase/Cytokinesis
metric value
setSize 13
pMANOVA 0.0125
p.adjustMANOVA 0.0429
s.dist 0.517
s.diabetes -0.293
s.mitoG 0.427
p.diabetes 0.0676
p.mitoG 0.00775




Top 20 genes
Gene diabetes mitoG
WAPL -5506 8690
PDS5A -5431 8725
NIPBL -5366 8173
SMC3 -4007 8640
STAG2 -3857 8559
STAG1 -4924 6068
SMC1A -2764 6742
RAD21 -2278 8063
PDS5B -4646 3792

Click HERE to show all gene set members

All member genes
diabetes mitoG
KIF20A 3022 -1094
KIF23 6834 -2775
MAU2 4263 -5182
NIPBL -5366 8173
PDS5A -5431 8725
PDS5B -4646 3792
PLK1 884 -1699
RAD21 -2278 8063
SMC1A -2764 6742
SMC3 -4007 8640
STAG1 -4924 6068
STAG2 -3857 8559
WAPL -5506 8690



Sema3A PAK dependent Axon repulsion

Sema3A PAK dependent Axon repulsion
metric value
setSize 16
pMANOVA 0.005
p.adjustMANOVA 0.0204
s.dist 0.511
s.diabetes -0.276
s.mitoG 0.43
p.diabetes 0.056
p.mitoG 0.00288




Top 20 genes
Gene diabetes mitoG
HSP90AA1 -7286 8742
HSP90AB1 -7306 5626
NRP1 -6603 5497
PAK2 -4906 6708
PLXNA2 -4201 6548
CFL1 -1720 8321
FYN -2200 6221
FES -4869 2558
RAC1 -1258 4008
PAK1 -886 5458
SEMA3A -748 6343

Click HERE to show all gene set members

All member genes
diabetes mitoG
CFL1 -1720 8321
FES -4869 2558
FYN -2200 6221
HSP90AA1 -7286 8742
HSP90AB1 -7306 5626
LIMK1 3519 2264
NRP1 -6603 5497
PAK1 -886 5458
PAK2 -4906 6708
PAK3 2878 1881
PLXNA1 4653 -1180
PLXNA2 -4201 6548
PLXNA3 324 -181
PLXNA4 3459 1441
RAC1 -1258 4008
SEMA3A -748 6343



CTLA4 inhibitory signaling

CTLA4 inhibitory signaling
metric value
setSize 20
pMANOVA 5e-04
p.adjustMANOVA 0.00284
s.dist 0.511
s.diabetes -0.087
s.mitoG 0.503
p.diabetes 0.501
p.mitoG 9.78e-05




Top 20 genes
Gene diabetes mitoG
PPP2CA -5725 8237
LYN -4685 8216
PPP2R1B -6463 4855
PTPN11 -3946 6142
AKT2 -4939 3281
CD86 -2679 5554
FYN -2200 6221
LCK -2194 5687
CD80 -3453 3286
AKT3 -375 7862
YES1 -120 7265

Click HERE to show all gene set members

All member genes
diabetes mitoG
AKT1 4859 7244
AKT2 -4939 3281
AKT3 -375 7862
CD80 -3453 3286
CD86 -2679 5554
FYN -2200 6221
LCK -2194 5687
LYN -4685 8216
PPP2CA -5725 8237
PPP2CB 5588 159
PPP2R1A 6355 3115
PPP2R1B -6463 4855
PPP2R5A 7319 1089
PPP2R5B 627 5414
PPP2R5C 3181 8384
PPP2R5D 2088 5911
PPP2R5E 5001 2898
PTPN11 -3946 6142
SRC -2657 -1643
YES1 -120 7265



Defective CFTR causes cystic fibrosis

Defective CFTR causes cystic fibrosis
metric value
setSize 60
pMANOVA 2.63e-09
p.adjustMANOVA 1.05e-07
s.dist 0.51
s.diabetes -0.429
s.mitoG 0.276
p.diabetes 8.76e-09
p.mitoG 0.000221




Top 20 genes
Gene diabetes mitoG
PSMC6 -6851.0 8666.0
UBB -7104.0 8341.0
PSME4 -6830.0 8511.0
PSMD1 -6497.0 8619.0
SEL1L -7264.0 7670.0
PSMD12 -6149.0 8628.0
PSMD7 -6943.0 7625.0
PSMA1 -6705.0 7838.0
UBC -6013.0 8514.0
PSMC4 -6423.0 7920.0
PSMD14 -6080.0 8262.0
DERL2 -7153.0 6854.0
PSMD5 -6156.0 7150.0
PSMD6 -6385.0 6157.0
VCP -7069.0 5449.0
PSMD11 -6873.0 5201.0
ERLIN1 -7147.0 4833.0
CFTR -6902.0 4865.0
PSMA2 -5464.5 6058.5
ERLEC1 -3854.0 8504.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
CFTR -6902.0 4865.0
DERL1 -5101.0 3639.0
DERL2 -7153.0 6854.0
DERL3 -4530.0 -5374.0
ERLEC1 -3854.0 8504.0
ERLIN1 -7147.0 4833.0
ERLIN2 -5110.0 -648.0
OS9 -5615.0 3279.0
PSMA1 -6705.0 7838.0
PSMA2 -5464.5 6058.5
PSMA3 -3145.0 7801.0
PSMA4 -6074.0 4688.0
PSMA5 -6660.0 4497.0
PSMA6 -1954.0 8445.0
PSMA7 1612.0 7052.0
PSMA8 649.0 -4004.0
PSMB1 -5281.0 5936.0
PSMB10 3752.0 -908.0
PSMB11 1977.0 -5501.0
PSMB2 1472.0 -4144.0
PSMB3 -3388.0 5539.0
PSMB4 -4941.0 -5852.0
PSMB5 -1638.0 -2409.0
PSMB6 1806.0 -1845.0
PSMB7 -4628.0 -657.0
PSMB8 1080.0 -3793.0
PSMB9 5987.0 -4708.0
PSMC1 -1312.0 4327.0
PSMC2 -6765.0 4648.0
PSMC3 -4285.0 3386.0
PSMC4 -6423.0 7920.0
PSMC5 -4831.0 1120.0
PSMC6 -6851.0 8666.0
PSMD1 -6497.0 8619.0
PSMD10 -1613.0 2576.0
PSMD11 -6873.0 5201.0
PSMD12 -6149.0 8628.0
PSMD13 1898.0 5044.0
PSMD14 -6080.0 8262.0
PSMD2 -6702.0 -3836.0
PSMD3 -2532.0 -3242.0
PSMD4 -5648.0 4994.0
PSMD5 -6156.0 7150.0
PSMD6 -6385.0 6157.0
PSMD7 -6943.0 7625.0
PSMD8 1978.0 7546.0
PSMD9 7707.5 -894.5
PSME1 2907.0 5905.0
PSME2 1270.0 -4595.0
PSME3 752.0 7366.0
PSME4 -6830.0 8511.0
PSMF1 5087.0 4771.0
RNF185 2705.0 5366.0
RNF5 -1555.0 -4449.0
RPS27A -133.0 -1807.0
SEL1L -7264.0 7670.0
UBA52 7488.0 -4269.0
UBB -7104.0 8341.0
UBC -6013.0 8514.0
VCP -7069.0 5449.0



Formation of the ternary complex, and subsequently, the 43S complex

Formation of the ternary complex, and subsequently, the 43S complex
metric value
setSize 36
pMANOVA 4.74e-08
p.adjustMANOVA 1.17e-06
s.dist 0.51
s.diabetes 0.196
s.mitoG 0.47
p.diabetes 0.042
p.mitoG 1.04e-06




Top 20 genes
Gene diabetes mitoG
FAU 6809.0 7710.0
RPS15 7253.0 6174.0
RPS17 5667.0 7685.0
RPS25 4261.0 8455.0
RPS2 7322.0 4216.0
RPS8 3874.0 7646.0
RPS5 3848.0 7515.0
EIF3K 4728.0 6062.0
EIF3L 5174.0 4824.0
EIF3C 4964.5 4995.5
RPS4X 2522.0 7391.0
RPS14 4070.0 4443.0
EIF3I 5694.0 2343.0
RPS3 2340.0 4381.0
RPS16 6244.0 1119.0
EIF3F 2793.0 1790.0
EIF3D 511.0 8172.0
RPS13 7174.0 315.0
EIF3G 836.0 1475.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
EIF2S1 -4830.0 8741.0
EIF2S2 -3307.0 8799.0
EIF2S3 -2819.5 4900.5
EIF3A -4951.0 8381.0
EIF3B -286.0 3875.0
EIF3C 4964.5 4995.5
EIF3D 511.0 8172.0
EIF3E -4677.0 8580.0
EIF3F 2793.0 1790.0
EIF3G 836.0 1475.0
EIF3H -4343.0 8629.0
EIF3I 5694.0 2343.0
EIF3J -4890.0 8838.0
EIF3K 4728.0 6062.0
EIF3L 5174.0 4824.0
EIF3M -2954.0 7258.0
FAU 6809.0 7710.0
RPS13 7174.0 315.0
RPS14 4070.0 4443.0
RPS15 7253.0 6174.0
RPS16 6244.0 1119.0
RPS17 5667.0 7685.0
RPS18 4253.0 -526.0
RPS19 6565.0 -1215.0
RPS2 7322.0 4216.0
RPS21 7111.0 -6494.0
RPS25 4261.0 8455.0
RPS27A -133.0 -1807.0
RPS28 7208.0 -396.0
RPS3 2340.0 4381.0
RPS3A -3115.0 8824.0
RPS4X 2522.0 7391.0
RPS5 3848.0 7515.0
RPS6 -1700.0 8603.0
RPS8 3874.0 7646.0
RPS9 -1719.0 -2555.0



Hh mutants that don't undergo autocatalytic processing are degraded by ERAD

Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
metric value
setSize 55
pMANOVA 1.92e-08
p.adjustMANOVA 5.61e-07
s.dist 0.506
s.diabetes -0.424
s.mitoG 0.275
p.diabetes 5.17e-08
p.mitoG 0.000426




Top 20 genes
Gene diabetes mitoG
PSMC6 -6851.0 8666.0
UBB -7104.0 8341.0
PSME4 -6830.0 8511.0
PSMD1 -6497.0 8619.0
SEL1L -7264.0 7670.0
PSMD12 -6149.0 8628.0
PSMD7 -6943.0 7625.0
PSMA1 -6705.0 7838.0
UBC -6013.0 8514.0
PSMC4 -6423.0 7920.0
PSMD14 -6080.0 8262.0
DERL2 -7153.0 6854.0
PSMD5 -6156.0 7150.0
PSMD6 -6385.0 6157.0
VCP -7069.0 5449.0
PSMD11 -6873.0 5201.0
PSMA2 -5464.5 6058.5
ERLEC1 -3854.0 8504.0
PSMC2 -6765.0 4648.0
PSMB1 -5281.0 5936.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
DERL2 -7153.0 6854.0
ERLEC1 -3854.0 8504.0
OS9 -5615.0 3279.0
PSMA1 -6705.0 7838.0
PSMA2 -5464.5 6058.5
PSMA3 -3145.0 7801.0
PSMA4 -6074.0 4688.0
PSMA5 -6660.0 4497.0
PSMA6 -1954.0 8445.0
PSMA7 1612.0 7052.0
PSMA8 649.0 -4004.0
PSMB1 -5281.0 5936.0
PSMB10 3752.0 -908.0
PSMB11 1977.0 -5501.0
PSMB2 1472.0 -4144.0
PSMB3 -3388.0 5539.0
PSMB4 -4941.0 -5852.0
PSMB5 -1638.0 -2409.0
PSMB6 1806.0 -1845.0
PSMB7 -4628.0 -657.0
PSMB8 1080.0 -3793.0
PSMB9 5987.0 -4708.0
PSMC1 -1312.0 4327.0
PSMC2 -6765.0 4648.0
PSMC3 -4285.0 3386.0
PSMC4 -6423.0 7920.0
PSMC5 -4831.0 1120.0
PSMC6 -6851.0 8666.0
PSMD1 -6497.0 8619.0
PSMD10 -1613.0 2576.0
PSMD11 -6873.0 5201.0
PSMD12 -6149.0 8628.0
PSMD13 1898.0 5044.0
PSMD14 -6080.0 8262.0
PSMD2 -6702.0 -3836.0
PSMD3 -2532.0 -3242.0
PSMD4 -5648.0 4994.0
PSMD5 -6156.0 7150.0
PSMD6 -6385.0 6157.0
PSMD7 -6943.0 7625.0
PSMD8 1978.0 7546.0
PSMD9 7707.5 -894.5
PSME1 2907.0 5905.0
PSME2 1270.0 -4595.0
PSME3 752.0 7366.0
PSME4 -6830.0 8511.0
PSMF1 5087.0 4771.0
RPS27A -133.0 -1807.0
SEL1L -7264.0 7670.0
SHH -4143.0 -5003.0
SYVN1 -7005.0 -3045.0
UBA52 7488.0 -4269.0
UBB -7104.0 8341.0
UBC -6013.0 8514.0
VCP -7069.0 5449.0



Response of EIF2AK1 (HRI) to heme deficiency

Response of EIF2AK1 (HRI) to heme deficiency
metric value
setSize 15
pMANOVA 0.00713
p.adjustMANOVA 0.0271
s.dist 0.503
s.diabetes -0.228
s.mitoG 0.449
p.diabetes 0.126
p.mitoG 0.00262




Top 20 genes
Gene diabetes mitoG
ATF4 -6143.0 7857.0
EIF2S1 -4830.0 8741.0
EIF2S2 -3307.0 8799.0
EIF2AK1 -3590.0 6471.0
CHAC1 -5498.0 4031.0
CEBPG -3135.0 6916.0
GRB10 -6904.0 2705.0
EIF2S3 -2819.5 4900.5
ATF3 -845.0 6400.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
ASNS 419.0 3160.0
ATF3 -845.0 6400.0
ATF4 -6143.0 7857.0
ATF5 342.0 3756.0
CEBPB 7403.0 754.0
CEBPG -3135.0 6916.0
CHAC1 -5498.0 4031.0
DDIT3 -2070.0 -609.0
EIF2AK1 -3590.0 6471.0
EIF2S1 -4830.0 8741.0
EIF2S2 -3307.0 8799.0
EIF2S3 -2819.5 4900.5
GRB10 -6904.0 2705.0
PPP1R15A 7471.0 4761.0
TRIB3 3661.0 -614.0



Molecules associated with elastic fibres

Molecules associated with elastic fibres
metric value
setSize 27
pMANOVA 6.32e-06
p.adjustMANOVA 6.67e-05
s.dist 0.502
s.diabetes 0.153
s.mitoG 0.478
p.diabetes 0.169
p.mitoG 1.73e-05




Top 20 genes
Gene diabetes mitoG
BMP4 6672.0 7143.0
EFEMP1 6611.0 6380.0
FBLN2 4810.0 7504.0
FBLN5 4332.0 8272.0
BMP2 4300.0 7938.0
TGFB2 4490.0 6652.0
ITGAV 8155.0 2693.0
EFEMP2 2292.0 7425.0
MFAP3 2866.0 4624.0
ITGB5 7359.0 1316.0
ITGB3 1530.5 4298.5
MFAP2 6000.0 930.0
MFAP5 479.0 5300.0
LTBP2 415.0 4760.0
FBLN1 1746.0 16.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
BMP2 4300.0 7938.0
BMP4 6672.0 7143.0
BMP7 8109.0 -1080.0
EFEMP1 6611.0 6380.0
EFEMP2 2292.0 7425.0
FBLN1 1746.0 16.0
FBLN2 4810.0 7504.0
FBLN5 4332.0 8272.0
ITGA8 -802.0 4862.0
ITGAV 8155.0 2693.0
ITGB1 -6241.0 8758.0
ITGB3 1530.5 4298.5
ITGB5 7359.0 1316.0
ITGB6 -7094.0 613.0
ITGB8 -1078.0 2920.0
LTBP1 -5412.0 7176.0
LTBP2 415.0 4760.0
LTBP3 8038.0 -540.0
LTBP4 -6699.0 5054.0
MFAP1 -1345.0 8624.0
MFAP2 6000.0 930.0
MFAP3 2866.0 4624.0
MFAP4 -1577.0 2378.0
MFAP5 479.0 5300.0
TGFB1 -1851.0 6152.0
TGFB2 4490.0 6652.0
TGFB3 -1546.0 8322.0



CDC6 association with the ORC:origin complex

CDC6 association with the ORC:origin complex
metric value
setSize 11
pMANOVA 0.00879
p.adjustMANOVA 0.0318
s.dist 0.501
s.diabetes 0.109
s.mitoG 0.489
p.diabetes 0.53
p.mitoG 0.00494




Top 20 genes
Gene diabetes mitoG
ORC5 4792.0 7601.0
ORC6 3477.0 6198.0
MCM8 7081.5 2390.5
ORC2 1857.0 8109.0
ORC1 5204.0 611.0
CDC6 65.0 3210.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
CDC6 65.0 3210.0
E2F1 4935.0 -488.0
E2F2 -2674.0 6447.0
E2F3 -3234.0 5297.0
MCM8 7081.5 2390.5
ORC1 5204.0 611.0
ORC2 1857.0 8109.0
ORC3 -5759.0 5941.0
ORC4 -1313.0 8070.0
ORC5 4792.0 7601.0
ORC6 3477.0 6198.0



Acetylcholine binding and downstream events

Acetylcholine binding and downstream events
metric value
setSize 11
pMANOVA 0.00708
p.adjustMANOVA 0.027
s.dist 0.499
s.diabetes -0.196
s.mitoG -0.459
p.diabetes 0.262
p.mitoG 0.00843




Top 20 genes
Gene diabetes mitoG
CHRNA4 -6731 -4461
CHRNA2 -4707 -5479
CHRNA1 -4214 -3240
CHRNB3 -3054 -779
CHRNG -902 -1730
CHRNB4 -377 -3200

Click HERE to show all gene set members

All member genes
diabetes mitoG
CHRNA1 -4214 -3240
CHRNA2 -4707 -5479
CHRNA4 -6731 -4461
CHRNA5 1576 -4557
CHRNA7 -6439 2976
CHRNA9 3644 -3688
CHRNB2 6212 -1716
CHRNB3 -3054 -779
CHRNB4 -377 -3200
CHRNE 3227 -2218
CHRNG -902 -1730



Postsynaptic nicotinic acetylcholine receptors

Postsynaptic nicotinic acetylcholine receptors
metric value
setSize 11
pMANOVA 0.00708
p.adjustMANOVA 0.027
s.dist 0.499
s.diabetes -0.196
s.mitoG -0.459
p.diabetes 0.262
p.mitoG 0.00843




Top 20 genes
Gene diabetes mitoG
CHRNA4 -6731 -4461
CHRNA2 -4707 -5479
CHRNA1 -4214 -3240
CHRNB3 -3054 -779
CHRNG -902 -1730
CHRNB4 -377 -3200

Click HERE to show all gene set members

All member genes
diabetes mitoG
CHRNA1 -4214 -3240
CHRNA2 -4707 -5479
CHRNA4 -6731 -4461
CHRNA5 1576 -4557
CHRNA7 -6439 2976
CHRNA9 3644 -3688
CHRNB2 6212 -1716
CHRNB3 -3054 -779
CHRNB4 -377 -3200
CHRNE 3227 -2218
CHRNG -902 -1730



AUF1 (hnRNP D0) binds and destabilizes mRNA

AUF1 (hnRNP D0) binds and destabilizes mRNA
metric value
setSize 54
pMANOVA 7.27e-08
p.adjustMANOVA 1.59e-06
s.dist 0.495
s.diabetes -0.383
s.mitoG 0.314
p.diabetes 1.12e-06
p.mitoG 6.62e-05




Top 20 genes
Gene diabetes mitoG
HSPA8 -7307.0 8180.0
PSMC6 -6851.0 8666.0
UBB -7104.0 8341.0
PSME4 -6830.0 8511.0
PSMD1 -6497.0 8619.0
HSPB1 -6918.0 7890.0
PSMD12 -6149.0 8628.0
HSPA1A -7272.5 7293.5
PSMD7 -6943.0 7625.0
PSMA1 -6705.0 7838.0
UBC -6013.0 8514.0
PSMC4 -6423.0 7920.0
PSMD14 -6080.0 8262.0
PSMD5 -6156.0 7150.0
PSMD6 -6385.0 6157.0
PSMD11 -6873.0 5201.0
EIF4G1 -5996.0 5731.0
PSMA2 -5464.5 6058.5
PSMC2 -6765.0 4648.0
PSMB1 -5281.0 5936.0

Click HERE to show all gene set members

All member genes
diabetes mitoG
EIF4G1 -5996.0 5731.0
HNRNPD 6599.0 1068.0
HSPA1A -7272.5 7293.5
HSPA8 -7307.0 8180.0
HSPB1 -6918.0 7890.0
PABPC1 -949.0 6861.0
PSMA1 -6705.0 7838.0
PSMA2 -5464.5 6058.5
PSMA3 -3145.0 7801.0
PSMA4 -6074.0 4688.0
PSMA5 -6660.0 4497.0
PSMA6 -1954.0 8445.0
PSMA7 1612.0 7052.0
PSMA8 649.0 -4004.0
PSMB1 -5281.0 5936.0
PSMB10 3752.0 -908.0
PSMB11 1977.0 -5501.0
PSMB2 1472.0 -4144.0
PSMB3 -3388.0 5539.0
PSMB4 -4941.0 -5852.0
PSMB5 -1638.0 -2409.0
PSMB6 1806.0 -1845.0
PSMB7 -4628.0 -657.0
PSMB8 1080.0 -3793.0
PSMB9 5987.0 -4708.0
PSMC1 -1312.0 4327.0
PSMC2 -6765.0 4648.0
PSMC3 -4285.0 3386.0
PSMC4 -6423.0 7920.0
PSMC5 -4831.0 1120.0
PSMC6 -6851.0 8666.0
PSMD1 -6497.0 8619.0
PSMD10 -1613.0 2576.0
PSMD11 -6873.0 5201.0
PSMD12 -6149.0 8628.0
PSMD13 1898.0 5044.0
PSMD14 -6080.0 8262.0
PSMD2 -6702.0 -3836.0
PSMD3 -2532.0 -3242.0
PSMD4 -5648.0 4994.0
PSMD5 -6156.0 7150.0
PSMD6 -6385.0 6157.0
PSMD7 -6943.0 7625.0
PSMD8 1978.0 7546.0
PSMD9 7707.5 -894.5
PSME1 2907.0 5905.0
PSME2 1270.0 -4595.0
PSME3 752.0 7366.0
PSME4 -6830.0 8511.0
PSMF1 5087.0 4771.0
RPS27A -133.0 -1807.0
UBA52 7488.0 -4269.0
UBB -7104.0 8341.0
UBC -6013.0 8514.0



Here is the session info with all the versions of packages used.

sessionInfo()
## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.5 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## attached base packages:
## [1] parallel  stats4    stats     graphics  grDevices utils     datasets 
## [8] methods   base     
## 
## other attached packages:
##  [1] pkgload_1.1.0               GGally_2.0.0               
##  [3] beeswarm_0.2.3              gtools_3.8.2               
##  [5] echarts4r_0.3.2             biomaRt_2.44.1             
##  [7] R.utils_2.10.1              R.oo_1.24.0                
##  [9] R.methodsS3_1.8.1           mitch_1.0.8                
## [11] eulerr_6.1.0                gplots_3.1.0               
## [13] DESeq2_1.28.1               SummarizedExperiment_1.18.2
## [15] DelayedArray_0.14.1         matrixStats_0.57.0         
## [17] Biobase_2.48.0              GenomicRanges_1.40.0       
## [19] GenomeInfoDb_1.24.2         IRanges_2.22.2             
## [21] S4Vectors_0.26.1            BiocGenerics_0.34.0        
## [23] reshape2_1.4.4              forcats_0.5.0              
## [25] stringr_1.4.0               dplyr_1.0.2                
## [27] purrr_0.3.4                 readr_1.4.0                
## [29] tidyr_1.1.2                 tibble_3.0.3               
## [31] ggplot2_3.3.2               tidyverse_1.3.0            
## 
## loaded via a namespace (and not attached):
##   [1] colorspace_1.4-1       ellipsis_0.3.1         rprojroot_1.3-2       
##   [4] XVector_0.28.0         fs_1.5.0               rstudioapi_0.11       
##   [7] farver_2.0.3           bit64_4.0.5            AnnotationDbi_1.50.3  
##  [10] fansi_0.4.1            lubridate_1.7.9        xml2_1.3.2            
##  [13] splines_4.0.2          geneplotter_1.66.0     knitr_1.30            
##  [16] polyclip_1.10-0        jsonlite_1.7.1         broom_0.7.1           
##  [19] annotate_1.66.0        dbplyr_1.4.4           shiny_1.5.0           
##  [22] compiler_4.0.2         httr_1.4.2             backports_1.1.10      
##  [25] assertthat_0.2.1       Matrix_1.2-18          fastmap_1.0.1         
##  [28] cli_2.0.2              later_1.1.0.1          prettyunits_1.1.1     
##  [31] htmltools_0.5.0        tools_4.0.2            gtable_0.3.0          
##  [34] glue_1.4.2             GenomeInfoDbData_1.2.3 rappdirs_0.3.1        
##  [37] Rcpp_1.0.5             cellranger_1.1.0       vctrs_0.3.4           
##  [40] polylabelr_0.2.0       xfun_0.18              testthat_2.3.2        
##  [43] rvest_0.3.6            mime_0.9               lifecycle_0.2.0       
##  [46] XML_3.99-0.5           zlibbioc_1.34.0        MASS_7.3-53           
##  [49] scales_1.1.1           hms_0.5.3              promises_1.1.1        
##  [52] RColorBrewer_1.1-2     curl_4.3               yaml_2.2.1            
##  [55] memoise_1.1.0          gridExtra_2.3          reshape_0.8.8         
##  [58] stringi_1.5.3          RSQLite_2.2.1          highr_0.8             
##  [61] genefilter_1.70.0      desc_1.2.0             caTools_1.18.0        
##  [64] BiocParallel_1.22.0    rlang_0.4.7            pkgconfig_2.0.3       
##  [67] bitops_1.0-6           evaluate_0.14          lattice_0.20-41       
##  [70] labeling_0.3           htmlwidgets_1.5.2      bit_4.0.4             
##  [73] tidyselect_1.1.0       plyr_1.8.6             magrittr_1.5          
##  [76] R6_2.4.1               generics_0.0.2         DBI_1.1.0             
##  [79] pillar_1.4.6           haven_2.3.1            withr_2.3.0           
##  [82] survival_3.2-7         RCurl_1.98-1.2         modelr_0.1.8          
##  [85] crayon_1.3.4           KernSmooth_2.23-17     BiocFileCache_1.12.1  
##  [88] rmarkdown_2.4          progress_1.2.2         locfit_1.5-9.4        
##  [91] grid_4.0.2             readxl_1.3.1           blob_1.2.1            
##  [94] reprex_0.3.0           digest_0.6.25          pbmcapply_1.5.0       
##  [97] xtable_1.8-4           httpuv_1.5.4           openssl_1.4.3         
## [100] munsell_0.5.0          askpass_1.1

END of report